
<html lang="en"     class="pb-page"  data-request-id="5faa7aa2-dd42-4109-a25d-18db12bb1c07"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00633;issue:issue:10.1021/jmcmar.2018.61.issue-15;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain" /></meta><meta name="dc.Creator" content="Sharan K.  Bagal" /></meta><meta name="dc.Creator" content="Mark  Andrews" /></meta><meta name="dc.Creator" content="Bruce M.  Bechle" /></meta><meta name="dc.Creator" content="Jianwei  Bian" /></meta><meta name="dc.Creator" content="James  Bilsland" /></meta><meta name="dc.Creator" content="David C.  Blakemore" /></meta><meta name="dc.Creator" content="John F.  Braganza" /></meta><meta name="dc.Creator" content="Peter J.  Bungay" /></meta><meta name="dc.Creator" content="Matthew S.  Corbett" /></meta><meta name="dc.Creator" content="Ciaran N.  Cronin" /></meta><meta name="dc.Creator" content="Jingrong Jean  Cui" /></meta><meta name="dc.Creator" content="Rebecca  Dias" /></meta><meta name="dc.Creator" content="Neil J.  Flanagan" /></meta><meta name="dc.Creator" content="Samantha E.  Greasley" /></meta><meta name="dc.Creator" content="Rachel  Grimley" /></meta><meta name="dc.Creator" content="Kim  James" /></meta><meta name="dc.Creator" content="Eric  Johnson" /></meta><meta name="dc.Creator" content="Linda  Kitching" /></meta><meta name="dc.Creator" content="Michelle L.  Kraus" /></meta><meta name="dc.Creator" content="Indrawan  McAlpine" /></meta><meta name="dc.Creator" content="Asako  Nagata" /></meta><meta name="dc.Creator" content="Sacha  Ninkovic" /></meta><meta name="dc.Creator" content="Kiyoyuki  Omoto" /></meta><meta name="dc.Creator" content="Stephanie  Scales" /></meta><meta name="dc.Creator" content="Sarah E.  Skerratt" /></meta><meta name="dc.Creator" content="Jianmin  Sun" /></meta><meta name="dc.Creator" content="Michelle  Tran-Dubé" /></meta><meta name="dc.Creator" content="Gareth J.  Waldron" /></meta><meta name="dc.Creator" content="Fen  Wang" /></meta><meta name="dc.Creator" content="Joseph S.  Warmus" /></meta><meta name="dc.Description" content="Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomy..." /></meta><meta name="Description" content="Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomy..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 26, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00633" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00633" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00633" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00633" /></link>
        
    
    

<title>Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00633" /></meta><meta property="og:title" content="Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0030.jpeg" /></meta><meta property="og:description" content="Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC). Moreover, inhibition of the TrkA kinase pathway in pain has been clinically validated by the NGF antibody tanezumab, leading to significant interest in the development of small molecule inhibitors of TrkA. Furthermore, Trk inhibitors having an acceptable safety profile will require minimal brain availability. Herein, we discuss the discovery of two potent, selective, peripherally restricted, efficacious, and well-tolerated series of pan-Trk inhibitors which successfully delivered three candidate quality compounds 10b, 13b, and 19. All three compounds are predicted to possess low metabolic clearance in human that does not proceed via aldehyde oxidase-catalyzed reactions, thus addressing the potential clearance prediction liability associated with our current pan-Trk development candidate PF-06273340." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00633"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00633">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00633&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00633&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00633&amp;href=/doi/10.1021/acs.jmedchem.8b00633" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6779-6800</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00632" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00678" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sharan K. Bagal</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharan K. Bagal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#deadb6bfacbfb0f0bcbfb9bfb29eb1abaab2b1b1b5f0bdb1b3"><span class="__cf_email__" data-cfemail="bdced5dccfdcd393dfdcdadcd1fdd2c8c9d1d2d2d693ded2d0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharan+K.++Bagal">Sharan K. Bagal</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0955-271X" title="Orcid link">http://orcid.org/0000-0003-0955-271X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Andrews</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Andrews</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., Sandwich, Kent CT13 9NJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Andrews">Mark Andrews</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bruce M. Bechle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruce M. Bechle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+M.++Bechle">Bruce M. Bechle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianwei Bian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianwei Bian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianwei++Bian">Jianwei Bian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Bilsland</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Bilsland</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Bilsland">James Bilsland</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David C. Blakemore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David C. Blakemore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Blakemore">David C. Blakemore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John F. Braganza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John F. Braganza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+F.++Braganza">John F. Braganza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter J. Bungay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter J. Bungay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacokinetics, Dynamics & Metabolism, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Bungay">Peter J. Bungay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew S. Corbett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew S. Corbett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+S.++Corbett">Matthew S. Corbett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ciaran N. Cronin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ciaran N. Cronin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ciaran+N.++Cronin">Ciaran N. Cronin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingrong Jean Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingrong Jean Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingrong+Jean++Cui">Jingrong Jean Cui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca Dias</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca Dias</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca++Dias">Rebecca Dias</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil J. Flanagan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil J. Flanagan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+J.++Flanagan">Neil J. Flanagan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samantha E. Greasley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha E. Greasley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha+E.++Greasley">Samantha E. Greasley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel Grimley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel Grimley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Grimley">Rachel Grimley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim James</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim James</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Peakdale Molecular, Discovery Park House, Ramsgate Road, Sandwich CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim++James">Kim James</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Johnson">Eric Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda Kitching</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda Kitching</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda++Kitching">Linda Kitching</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle L. Kraus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle L. Kraus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+L.++Kraus">Michelle L. Kraus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Indrawan McAlpine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Indrawan McAlpine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Indrawan++McAlpine">Indrawan McAlpine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Asako Nagata</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Asako Nagata</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Asako++Nagata">Asako Nagata</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sacha Ninkovic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sacha Ninkovic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sacha++Ninkovic">Sacha Ninkovic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kiyoyuki Omoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kiyoyuki Omoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kiyoyuki++Omoto">Kiyoyuki Omoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephanie Scales</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephanie Scales</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephanie++Scales">Stephanie Scales</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah E. Skerratt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah E. Skerratt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+E.++Skerratt">Sarah E. Skerratt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianmin Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianmin Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianmin++Sun">Jianmin Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Tran-Dubé</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Tran-Dubé</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Tran-Dub%C3%A9">Michelle Tran-Dubé</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gareth J. Waldron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gareth J. Waldron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gareth+J.++Waldron">Gareth J. Waldron</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fen++Wang">Fen Wang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joseph S. Warmus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph S. Warmus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+S.++Warmus">Joseph S. Warmus</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00633&amp;href=/doi/10.1021%2Facs.jmedchem.8b00633" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6779–6800</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 26, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 April 2018</li><li><span class="item_label"><b>Published</b> online</span>26 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 August 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00633</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6779%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSharan%2BK.%2BBagal%252C%2BMark%2BAndrews%252C%2BBruce%2BM.%2BBechle%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D15%26contentID%3Dacs.jmedchem.8b00633%26title%3DDiscovery%2Bof%2BPotent%252C%2BSelective%252C%2Band%2BPeripherally%2BRestricted%2BPan-Trk%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BPain%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6800%26publicationDate%3DAugust%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00633"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3385</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00633" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sharan&quot;,&quot;last_name&quot;:&quot;K. Bagal&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Andrews&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;M. Bechle&quot;},{&quot;first_name&quot;:&quot;Jianwei&quot;,&quot;last_name&quot;:&quot;Bian&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Bilsland&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Blakemore&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;F. Braganza&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Bungay&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;S. Corbett&quot;},{&quot;first_name&quot;:&quot;Ciaran&quot;,&quot;last_name&quot;:&quot;N. Cronin&quot;},{&quot;first_name&quot;:&quot;Jingrong&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;Dias&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;J. Flanagan&quot;},{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;E. Greasley&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Grimley&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Kitching&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;L. Kraus&quot;},{&quot;first_name&quot;:&quot;Indrawan&quot;,&quot;last_name&quot;:&quot;McAlpine&quot;},{&quot;first_name&quot;:&quot;Asako&quot;,&quot;last_name&quot;:&quot;Nagata&quot;},{&quot;first_name&quot;:&quot;Sacha&quot;,&quot;last_name&quot;:&quot;Ninkovic&quot;},{&quot;first_name&quot;:&quot;Kiyoyuki&quot;,&quot;last_name&quot;:&quot;Omoto&quot;},{&quot;first_name&quot;:&quot;Stephanie&quot;,&quot;last_name&quot;:&quot;Scales&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;E. Skerratt&quot;},{&quot;first_name&quot;:&quot;Jianmin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Tran-Dubé&quot;},{&quot;first_name&quot;:&quot;Gareth&quot;,&quot;last_name&quot;:&quot;J. Waldron&quot;},{&quot;first_name&quot;:&quot;Fen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;S. Warmus&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;6779-6800&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00633&quot;},&quot;abstract&quot;:&quot;Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC). Moreover, inhibition of the TrkA kinase pathway in pain has been clinically validated by the NGF antibody tanezumab, leading to significant interest in the development of small molecule inhibitors of TrkA. Furthermore, Trk inhibitors having an acceptable safety profile will require minimal brain availability. Herein, we discuss the discovery of two potent, selective, peripherally restricted, efficacious, and well-tolerated series of pan-Trk inhibitors which successfully delivered three candidate quality compounds 10b, 13b, and 19. All three compounds are predicted to possess low metabolic clearance in human that does not proceed via aldehyde oxidase-catalyzed reactions, thus addressing the potential clearance prediction liability associated with our current pan-Trk devel&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00633&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00633" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00633&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00633" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00633&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00633" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00633&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00633&amp;href=/doi/10.1021/acs.jmedchem.8b00633" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00633" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00633" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00633%26sid%3Dliteratum%253Aachs%26pmid%3D29944371%26genre%3Darticle%26aulast%3DBagal%26date%3D2018%26atitle%3DDiscovery%2Bof%2BPotent%252C%2BSelective%252C%2Band%2BPeripherally%2BRestricted%2BPan-Trk%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BPain%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D15%26spage%3D6779%26epage%3D6800%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292200" title="Layers">Layers</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/jmcmar.2018.61.issue-15/20180809/jmcmar.2018.61.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC). Moreover, inhibition of the TrkA kinase pathway in pain has been clinically validated by the NGF antibody tanezumab, leading to significant interest in the development of small molecule inhibitors of TrkA. Furthermore, Trk inhibitors having an acceptable safety profile will require minimal brain availability. Herein, we discuss the discovery of two potent, selective, peripherally restricted, efficacious, and well-tolerated series of pan-Trk inhibitors which successfully delivered three candidate quality compounds <b>10b</b>, <b>13b</b>, and <b>19</b>. All three compounds are predicted to possess low metabolic clearance in human that does not proceed via aldehyde oxidase-catalyzed reactions, thus addressing the potential clearance prediction liability associated with our current pan-Trk development candidate PF-06273340.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In particular, NGF has been shown to have a key role in the pathogenesis of inflammatory pain in preclinical studies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Moreover, clinical studies in osteoarthritis, chronic low back pain, and interstitial cystitis have demonstrated that NGF neutralizing antibodies such as tanezumab demonstrate robust efficacy.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> Because the NGF pathway involves NGF binding to the TrkA kinase receptor, inhibition of TrkA has been clinically validated as a target for pain, leading to increased interest in the development of small molecule inhibitors of TrkA.</div><div class="NLM_p">The majority of small molecule kinase inhibitors tend to be ATP competitive Type I or Type II binders, based on the conformation of the highly conserved aspartate-phenylalanine-glycine (DFG) residues in the beginning of the activation loop in the kinase domain.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Type I and Type II binders of TrkA generally exhibit pan-Trk (TrkA/B/C) inhibition rather than subtype selectivity because TrkA, TrkB, and TrkC kinases have no residue differences in the ATP binding site.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Furthermore, pan-Trk inhibitors require restriction to the peripheral compartment to avoid undesirable side effects associated with Trk inhibition in the central nervous system (CNS). TrkA is highly expressed in cholinergic neurons of the CNS, with ablation of the TrkA gene in preclinical species leading to dysfunction in cholinergic circuitry.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> TrkB is expressed throughout the body and is involved in excitatory signaling, long-term potentiation and feeding behavior.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a> Moreover, human genetic data has associated TrkB with obesity and development.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> TrkC is widely expressed in neural and non-neural tissues and plays a role in the development and survival of the sympathetic nervous system.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Finally, clinical studies on the CNS penetrant pan-Trk/Tie2 kinase inhibitor CE-245677 (advanced by Pfizer as an oncology agent) produced CNS side-effects, leading to the termination of Phase I multiple dose trials. The reported adverse events fully resolved upon cessation of dosing and included cognitive problems, personality changes, and sleep disturbances.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Given that the safety and toleration risks are associated with CNS Trk receptor occupancy and efficacy of Trk kinase inhibitors is expected to be driven by target engagement in peripheral neurons, we can address the safety risks by restricting Trk inhibitors to the peripheral compartment. This profile would require small molecule TrkA inhibitors that possess acceptable oral bioavailability but which are also peripherally restricted.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21−25)</a> These properties can be designed by operating within physicochemical space appropriate for absorption across the gastrointestinal (GI) epithelium (e.g. molecular weight (MW) < 500, polar surface area (PSA) < 140, < 10 rotatable bonds)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> while combining activity as substrates for the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) that are expressed at the blood-brain barrier (BBB).<a onclick="showRef(event, 'ref21 ref22 ref23 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref27">(21−23,27)</a> However, targeting P-gp and BCRP, which are also present in the apical membrane of intestinal epithelial cells, introduces the risk of restricting transport across the intestinal epithelium, resulting in low and variable oral bioavailability. This risk, however, is low because adequately soluble oral drugs at commonly prescribed doses are expected to saturate efflux transporters, given that substrates of P-gp typically possess Km values in the range 1–100 μM. In addition, the high concentration gradient across the intestinal epithelium will lead to a significant driving force for flux of compound, particularly for drugs with high intrinsic permeability.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">We have previously reported the discovery of our pan-Trk development candidate PF-06273340 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref9 ref29'); return false;" href="javascript:void(0);" class="ref ref9 ref29">(9,29)</a> The profile of metabolism of this compound involved a component that was mediated by aldehyde oxidase (AO), reducing the confidence with which human metabolic clearance (CL) could be predicted.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Hence, contingency pan-Trk candidates were sought, whereby AO-mediated metabolism was avoided to mitigate human pharmacokinetic (PK) risk associated with PF-06273340. This work describes the discovery of three candidate quality pan-Trk compounds that have high confidence in human PK prediction.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0001.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pfizer Pan-Trk development candidate PF-06273340 and hit molecule <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Identification and Optimization</h3><div class="NLM_p">To find novel pan-Trk chemical matter, the Pfizer kinase selectivity data set was analyzed. This data set is a collection of compounds that has been assessed for off-target kinase selectivity at Invitrogen by screening in a kinase selectivity panel. The Pfizer kinase selectivity panel included a TrkA assay in a Z′-LYTE biochemical assay format, whereby benzamide hit <b>1</b> was identified as having 98% inhibition of TrkA at 1 μM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Furthermore, <b>1</b> was found to be a potent pan-Trk inhibitor in cell-based assays with TrkA cell IC<sub>50</sub> 23 nM and TrkB/C cell IC<sub>50</sub> < 30 nM.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Benzamide hit <b>1</b> exhibited a ligand efficiency (LE) 0.3 and lipophilic efficiency (LipE) 3.9 (LipE = −log(TrkA cell IC<sub>50</sub>) – log <i>d</i>) both of which were considered acceptable start points for optimization. Moreover, <b>1</b> had low metabolic turnover in human liver microsomes (HLM) and human hepatocytes (hHep) (intrinsic clearance (CL<sub>int</sub>) in HLM 14 μL/min/mg protein, hHep < 6 μL/min/million cells), suggesting that this benzamide series was capable of delivering compounds with low predicted human CL. To achieve restriction from the CNS to the periphery and avoid unwanted CNS side effects, P-gp and BCRP efflux transporter substrates are required. P-gp and BCRP substrates are determined as having an efflux ratio (ER) > 2.5 in the current assay format to assess P-gp and BCRP efflux. Hit molecule <b>1</b> was a P-gp substrate with an efflux ratio (ER) of 4 (BCRP not determined), indicating this benzamide series had potential for the desired restriction to the peripheral compartment. The combination of potency, LE, LipE, metabolic stability, and P-gp efflux suggested that <b>1</b> was an exciting hit that warranted further investment.</div><div class="NLM_p">The human Ether-à-go-go-Related Gene (hERG) fluorescence polarization (FP) competition assay and patch express assay (PX) have been shown to be predictive of compound QT prolongation effects via hERG blockade.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The hERG FP assay can also be run in a high throughput 384-well plate manner.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Hit molecule <b>1</b> was shown to inhibit hERG in the hERG FP assay (hERG FP IC<sub>50</sub> 3.8 μM), indicating there was some cardiovascular risk, which may have been associated with the relatively high log <i>d</i> of <b>1</b> (log <i>d</i> 3.7).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Modification of urea <b>1</b> to an amide <b>2</b> improved potency and lowered log <i>d</i> moderately (TrkA cell IC<sub>50</sub> 8.7 nM, log <i>d</i> 3.5) such that LipE improved by 0.7 units to 4.6, although hERG FP IC<sub>50</sub> did not improve significantly (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Additional improvements in LipE were made by changing the <i>N</i>-methyl pyrazole into the isomeric <i>N</i>-methyl imidazole <b>3</b> (LipE 5.3) through decreasing log <i>d</i> further (log <i>d</i> 2.9) while maintaining potency (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Furthermore, the reduction in log <i>d</i> led to a concomitant decline in hERG liability (hERG FP IC<sub>50</sub> 18 μM). Ligand <b>3</b> was also assessed in the hERG PX assay, which suggested <b>3</b> was >1300-fold selective for TrkA in cell-based assays over hERG inhibition (TrkA cell IC<sub>50</sub> 7.0 nM, hERG PX IC<sub>50</sub> 9500 nM), making it an excellent lead molecule. Ligand <b>3</b> exhibited low turnover in HLM and hHep (CL<sub>int</sub> HLM < 8 μL/min/mg protein; hHep 8 μL/min/million cells). Moreover, metabolite identification studies suggested the major metabolism pathways involved only phase I oxidative pathways catalyzed by cytochrome P450 (CYP) (data not shown). Thus, the absence in <b>3</b> of metabolism catalyzed by AO would lend higher confidence to predictions made from in vitro metabolic CL when compared with PF-06273340 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The passive permeability of <b>3</b> was measured in the RRCK transcellular flux assay (RRCK P<sub>app</sub>10 × 10<sup>–6</sup>cms<sup>–1</sup>) and was consistent with good absorption.<a onclick="showRef(event, 'ref31 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref35">(31,34,35)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Discovery of benzamide lead molecule <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lead molecule <b>3</b> was progressed to oral and i.v. pharmacokinetic (PK) studies in rats and demonstrated moderate systemic CL (plasma CL 38 mL/min/kg) and moderate oral bioavailability (45%), consistent with complete absorption. The ability of <b>3</b> to act as a substrate for P-gp and BCRP was also assessed, and <b>3</b> was found to be a substrate for both these transporters (P-gp ER 18, BCRP ER 2.5). Ligand <b>3</b> was progressed to CNS penetration studies in rat to understand the level of restriction from the CNS achievable, and was found to be peripherally restricted with <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> of 0.0065. These data provided evidence that restriction from the CNS combined with acceptable oral absorption was indeed achievable in this chemical series. The binding mode of <b>3</b> was determined via X-ray crystallography with a 2.91 Å cocrystal structure of <b>3</b> with TrkA protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Ligand <b>3</b> was a Type II inhibitor which binds to the DFG-out conformation of TrkA formed by the movement of the activation loop to an inactive conformation. The movement of the activation loop involves relocation of the DFG motif which creates an unoccupied back pocket.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> In the case of ligand <b>3</b>, the back pocket is occupied by the p-OCF<sub>3</sub> aryl group. The primary carboxamide of <b>3</b> interacts with the kinase hinge through hydrogen bonds between the ligand C═O and backbone NH of Met592 and ligand NH with the backbone C═O of Glu590. Ligand <b>3</b> extends into TrkA, passing the gatekeeper Phe589 and DFG Phe669, and these phenylalanine residues sandwich the piperidine linker with the central amide carbonyl of <b>3</b> forming a hydrogen bond with the backbone NH of Asp668. The p-OCF<sub>3</sub> aryl group occupied the back pocket, and there was a CH-π interaction between this aryl unit and the backbone CH of Gly667. The <i>N</i>-methyl imidazole had a vector toward the solvent exposed kinase exit, which suggested that the structure–activity relationship (SAR) in this region will be relatively tolerant which, for example, explained the similar TrkA cellular potencies of inhibitors <b>2</b> and <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Variation of the p-OCF<sub>3</sub> aryl group revealed a number of potential replacements although, because the back pocket was formed by hydrophobic residues such as Leu564, Leu567, Phe646, and Ile666, the active back pocket substituents identified were relatively lipophilic (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Substitution of the benzylic carbon was tolerated by TrkA as exemplified by <b>4</b> and <b>5</b>, although one enantiomer was over 60-fold more potent than the other (TrkA cell IC<sub>50</sub><b>4:</b> 0.011 μM and <b>5:</b> 0.72 μM), presumably due to a clash between the benzylic methyl substituent and Phe589 in <b>5</b>. Substitution of the p-OCF<sub>3</sub> aryl group by 3-F in <b>6</b> was tolerated by TrkA but did not offer any advantages when compared with the unsubstituted analogue <b>3</b>. The p-OCF<sub>3</sub> substituent was successfully replaced by a cyclopropyl ether as demonstrated by ligand <b>7</b>, and this modification improved hERG liability considerably (hERG FP IC<sub>50</sub> > 40 μM). However, the cyclopropyl ether unit underwent greater metabolic CL in HLM (HLM 23 μL/min/mg protein) when compared with lead molecule <b>3</b> (HLM < 8 μL/min/mg protein). At this stage in the program, the p-OCF<sub>3</sub> phenyl group in <b>3</b> was favored as a back pocket substituent based on TrkA cell potency, LipE and metabolic CL. The benzamide in <b>3</b> could be successfully replaced by a nicotinamide as demonstrated by <b>8</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Nicotinamide <b>8</b> exhibited a similar TrkA potency to <b>3</b> but had a lower log <i>d</i> (<b>8:</b> log <i>d</i> 2.4, <b>3:</b> log <i>d</i> 2.9) and hence a greater LipE than <b>3</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Co-crystal structure of lead molecule <b>3</b> bound to TrkA protein in a DFG-out conformation highlighting key protein–ligand interactions with black dashed lines. (B) Co-crystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting binding site surface with brown representing hydrophobic regions, green neutral polarity regions, and blue polar regions. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKW">6DKW</a> for compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Back Pocket SAR and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0022.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0023.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">log <i>d</i> measured at pH 7.4.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">LipE = −log(TrkA cell IC<sub>50</sub>) – log <i>d</i>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in mL/min/mg protein.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Apparent permeability (× 10<sup>–6</sup> cms<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Data for log <i>d</i>, HLM, hHep, RRCK, and P-gp were results from at least two replicate determinations.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">hERG FP assay data with at least two tests on two different assay runs.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> ND denotes not determined.</p></div></div><div></div></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B shows the binding site surface of ligand <b>3</b> when bound to TrkA protein. The binding site surface suggests that the piperidine linker can be further substituted to occupy more of the binding site. Moreover, piperidine substitution may enhance interactions with Phe589 and Phe669 through increased van der Waals interactions and potential CH-π interactions if the piperidine is substituted by an electron withdrawing group. To this end, 3-fluoropiperidine derivatives of the most LipE efficient compound <b>8</b> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were prepared (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Both enantiomers of the cis and trans diastereomers were synthesized and gave up to a 3-fold enhancement in TrkA potency and improved LipE by up to 0.4 units when compared with lead molecule <b>3</b> (ligand <b>10b,</b> LipE 5.7). All compounds were pan-Trk inhibitors with similar potencies at TrkA/B/C (within 3-fold), P-gp and BCRP efflux substrates, and exhibited moderate apparent permeability. Ligand <b>10b</b> offered the best balance of TrkA potency (TrkA cell IC<sub>50</sub> 1.9 nM, TrkB cell IC<sub>50</sub> 2.6 nM, TrkC cell IC<sub>50</sub> 1.1 nM), LipE, metabolic stability as measured by hHep CLint, and hERG liability as measured by hERG FP (Ligand <b>10b</b> hERG FP IC<sub>50</sub> 14 μM). The binding mode of <b>10b</b> was established via X-ray crystallography with a 2.68 Å cocrystal structure with TrkA protein (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Ligand <b>10b</b> made similar interactions with TrkA protein to ligand <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), but had additional van der Waals interactions between F and Phe589. There were also CH-π interactions introduced between the piperidine and Phe589/Phe669. Compound <b>10b</b> was screened in 41 biochemical kinase assays (including TrkA) at a concentration of 1 μM at Invitrogen for kinase selectivity (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>). Gratifyingly, <b>10b</b> exhibited superb Trk selectivity with >95% inhibition of TrkA and >40% inhibition of only 1 other kinase VEGFR2 (cell-based assay follow-up at Caliper Lifesciences indicated VEGFR2 IC<sub>50</sub> > 5 μM). Furthermore, wide ligand profiling of <b>10b</b> at a concentration of 10 μM in 84 targets to assess off-target liabilities indicated a clean profile (1 hit with % inhibition >50% at 10 μM, which gave follow-up alpha1a antagonist IC<sub>50</sub> 8 μM). The exciting in vitro profile of <b>10b</b> led to the progression of this compound to in vivo studies.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Piperidine Linker SAR and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0024.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0025.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">log <i>d</i> measured at pH 7.4.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">LipE = −log(TrkA cell IC<sub>50</sub>) – log <i>d</i>.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in mL/min/mg protein.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Apparent permeability (× 10<sup>–6</sup> cms<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Data for log <i>d</i>, HLM, hHep, RRCK, P-gp, and BCRP were results from at least two replicate determinations.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">hERG FP assay data with at least two tests on two different assay runs.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> ND denotes not determined.</p></div></div><div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0004.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structure of ligand <b>10b</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>10b</b> is shown in magenta, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKB">6DKB</a> for compound <b>10b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Design of Benzamide Alcohols As Pan-Trk Inhibitors</h3><div class="NLM_p">The cocrystal structure of PF-06273340 with TrkA protein was published recently by our group.<a onclick="showRef(event, 'ref9 ref29'); return false;" href="javascript:void(0);" class="ref ref9 ref29">(9,29)</a> PF-06273340 and <b>10b</b> have different hinge binders with the aminopyrimidine of PF-06273340 interacting with the backbone NH and C═O of Met592, while the amide in <b>10b</b> interacts with the backbone NH of Met592 and backbone C═O of Glu590. Despite this difference, an overlay of the ligand bound conformation with TrkA of PF-06273340 and compound <b>10b</b> revealed an opportunity to remove the imidazole group in <b>10b</b> and append an alcohol moiety heading into the ribose pocket (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Keeping both the imidazole and alcohol groups would result in high strain and high molecular weight. To this end, the hybrid ether linked compounds shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> were prepared.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Gratifyingly, the alcohols <b>12</b>–<b>14</b> were active in TrkA cell-based assays and also demonstrated a lower hERG liability when compared with the benzamides in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The cis diastereomers <b>13a/13b</b> were 5–50 fold more active than the corresponding trans diastereomers <b>12a/12b</b>. The primary alcohol isomer <b>14</b> was also active in TrkA cell-based assays but showed significantly higher metabolic CL in hHeps, possibly due to enhanced metabolism involving the primary alcohol when compared with a tertiary alcohol.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0005.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of the bound ligand conformation in TrkA protein of DFG-out binders PF-06273340 (gray) and compound <b>10b</b> (magenta).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Benzamide Alcohols and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0026.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0027.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">log <i>d</i> measured at pH 7.4.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">LipE = −log(TrkA cell IC<sub>50</sub>) – log <i>d</i>.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in mL/min/mg protein.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Apparent permeability (× 10<sup>–6</sup> cms<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Data for log <i>d</i>, HLM, hHep, RRCK, P-gp, and BCRP were results from at least two replicate determinations.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">hERG FP assay data with at least two tests on two different assay runs.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> ND denotes not determined.</p></div></div><div></div></div><div class="NLM_p">Benzamide alcohol <b>13b</b> offered the best balance of TrkA potency (TrkA cell IC<sub>50</sub> 7.7 nM, TrkB cell IC<sub>50</sub> 15 nM, TrkC cell IC<sub>50</sub> 3.9 nM), LipE, and metabolic stability as determined in hHep (CL<sub>int</sub> = 2 μL/min/million cells). The binding mode of <b>13b</b> was established via X-ray crystallography with a 2.53 Å cocrystal structure with TrkA protein (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Ligand <b>13b</b> made similar interactions with TrkA to ligand <b>10b</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>); however <b>13b</b>, had additional van der Waals interactions between the gem dimethyl groups and Phe669 and interactions between the alcohol and water molecules toward the kinase exit. Compound <b>13b</b> was screened in 42 biochemical kinase assays (including TrkA) at a concentration of 1 μM at Invitrogen for kinase selectivity (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>). Gratifyingly, <b>13b</b> exhibited superb Trk selectivity with >95% inhibition of TrkA with no other kinase being inhibited by >40% at 1 μM. Furthermore, wide ligand profiling at a concentration of 10 μM at 82 targets to assess off-target liabilities showed a clean profile with no hits having >50% inhibition at 10 μM. The exciting in vitro profile of <b>13b</b> led to the progression of this compound to in vivo studies.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0006.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Co-crystal structure of ligand <b>13b</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>13b</b> is shown in orange, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKG">6DKG</a> for compound <b>13b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Design of Aminopyridine Pan-Trk Inhibitors</h3><div class="NLM_p">Aminopyridines have been described as efficient kinase hinge binding motifs, and this concept led to an additional hybrid design wherein the benzamide hinge binder in molecules <b>2</b>–<b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was changed to an aminopyridine.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> This hypothesis led to the synthesis of the aminopyridines shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The aminopyridine in <b>15</b> replaces the benzamide hinge binder in ligands <b>2</b>–<b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> displays an overlay of benzamide <b>3</b> when bound to TrkA protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) with aminopyridine <b>15</b> docked into TrkA protein. The methyl pyrazole substitution in <b>15</b> was thought to be optimal based on the overlay in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. Aminopyridine <b>15</b> was a potent Trk inhibitor in cell-based assays; however, replacement of the piperidine ring linker with a pyrrolidine ring during SAR exploration improved TrkA cellular potency by 2–3-fold and LipE by 1 unit in the case of the more active pyrrolidine enantiomer <b>16b</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, TrkA cell IC<sub>50</sub> 7.7 nM, LipE 5.5). Aminopyridines having a pyrrolidine linker were an exciting prospect, and further optimization was conducted on this motif. Based on the learnings with ligand <b>3</b> thus far (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), the <i>N</i>-methyl pyrazole unit was replaced by an <i>N</i>-methyl imidazole, and fluorinated pyrrolidine derivatives were prepared (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0007.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Generation of aminopyridine pan-Trk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Aminopyridine Amides and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0028.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0029.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">log <i>d</i> measured at pH 7.4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">LipE = −log(TrkA cell IC<sub>50</sub>) – log <i>d</i>.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in mL/min/mg protein.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Apparent permeability (× 10<sup>–6</sup> cms<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Data for log <i>d</i>, HLM, hHep, RRCK, P-gp, and BCRP were results from at least two replicate determinations.</p></div><div class="footnote" id="t4fn7"><sup><sup>g</sup></sup><p class="last">hERG FP assay data with at least two tests on two different assay runs.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> ND denotes not determined.</p></div></div><div></div></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0008.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Overlay of the bound ligand conformation in TrkA protein of lead molecule <b>3</b> (blue, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and aminopyridine <b>15</b> (green) docked into TrkA protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mono- and difluorinated pyrrolidines (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) were potent TrkA inhibitors with 100–1000-fold preference of TrkA for the more potent enantiomers (<b>17b</b> and <b>18b</b>) over the weaker enantiomers (<b>17a</b> and <b>18a</b>). Cis monofluorinated derivatives proved more challenging to synthesize than the corresponding trans monofluorinated isomers. Difluorinated pyrrolidine <b>18b</b> was 8-fold more active when compared with the monofluorinated derivative <b>17b</b>, possibly due to enhanced van der Waals interactions. Moreover, <b>18b</b> exhibited greater metabolic stability than <b>17b</b> as measured by hHep Cl<sub>int</sub> (<b>17b</b> and <b>18b</b> hHep CL<sub>int</sub> = 17 and 9.1 μL/min/10<sup>6</sup> cells respectively) conceivably due to blocking of oxidative metabolism by the additional F in <b>18b</b>. Metabolite identification studies in hHeps with <b>16b</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, data not shown) indicated the major metabolism pathways involved N-demethylation, pyrrolidine unit oxidation, and glucuronidation on the amino moiety. Ligand <b>18b</b> was active in the hERG FP and PX assay (hERG FP IC<sub>50</sub> 11 μM, hERG PX IC<sub>50</sub> 7.7 μM), although <b>18b</b> had a good therapeutic index (TI) for TrkA over hERG due to its nanomolar potency at TrkA. Based on the SAR developed to date, the imidazole substituent in <b>18b</b> could be replaced, as demonstrated by the benzamide alcohols in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Moreover, amides are well established bioisosteres for heterocycles, and hence an amide substituent was introduced in place of the imidazole moiety in <b>18b</b> to give amides <b>19</b> and <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Methyl amide <b>19</b> was a potent and LipE efficient TrkA inhibitor (TrkA cell IC<sub>50</sub> 8.4 nM, LipE 5.6) with low metabolic turnover in human in vitro assays (HLM < 8 μL/min/mg protein, hHep 1.4 μL/min/million cells). Moreover, <b>19</b> demonstrated excellent selectivity over hERG in the hERG FP assay (IC<sub>50</sub> 79 μM) and hERG PX assay (IC<sub>50</sub> 88 μM). Ethyl amide <b>20</b> was also a potent TrkA inhibitor (TrkA cell IC<sub>50</sub> 10 nM, LipE 5.2), although it offered no advantage over <b>19</b> and had a LipE that was ∼0.4 units lower than that of <b>19</b>. This relatively flat SAR was consistent with the terminal amide occupying a region of TrkA that exits the kinase toward solvent, much like the imidazole group in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Ligand <b>19</b> seemed to offer the best balance of TrkA potency, LipE, metabolic stability, and hERG liability when compared with <b>18b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) and was chosen for further progression. The binding mode of <b>19</b> was determined via X-ray crystallography with a 2.11 Å cocrystal structure with TrkA protein (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The aminopyridine group did indeed act as a hinge binder with the amino unit NH interacting with the main chain C═O of Glu590 and the pyridyl N interacting with the main chain Met592 NH. The terminal amide had a vector toward the solvent exposed kinase exit and appeared to interact with water. The pyrrolidine linker exhibited van der Waals interactions with the surrounding residues such as Phe669, Phe589, and Val524 along with potential CH-π interactions with Phe589 and Phe669. Consistent with the previous TrkA cocrystal structures discussed (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), the central amide carbonyl of <b>19</b> formed a hydrogen bond with the main chain NH of Asp668, and the p-OCF<sub>3</sub> phenyl group occupied the back pocket.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0009.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of aminopyridine amide <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0010.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Co-crystal structure of aminopyridine <b>19</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>19</b> is shown in yellow, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKI">6DKI</a> for compound <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>19</b> was screened at 44 biochemical kinase assays (including TrkA) at a concentration of 1 μM at Invitrogen for kinase selectivity (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>). Ligand <b>19</b> exhibited outstanding Trk selectivity with >95% inhibition of TrkA with no other kinase being inhibited by >40% at 1 μM. Furthermore, wide ligand profiling to assess off-target liabilities at a concentration of 10 μM in 82 targets indicated a clean profile with no hits having >50% inhibition at 10 μM. The exciting in vitro profile of <b>19</b> led to the progression of this compound to in vivo studies.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Surface Plasmon Resonance Data for Pan-Trk Ligands <b>10b</b>, <b>13b</b>, and <b>19</b></h3><div class="NLM_p last">Ligands <b>10b, 13b</b>, and <b>19</b> were evaluated using surface plasmon resonance with immobilized TrkA protein (residues 441–796). With nonactivated unphosphorylated TrkA protein, ligands <b>10b, 13b</b>, and <b>19</b> demonstrated relatively slow association and dissociation kinetics,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> with measured <i>K</i><sub>D</sub> values consistent with TrkA cellular potencies <b>10b</b>: <i>K</i><sub>a</sub> 6.9 × 10<sup>5</sup> M<sup>–1</sup> s<sup>–1</sup>, <i>K</i><sub>d</sub> 4.7 × 10<sup>–4</sup> s<sup>–1</sup>, <i>K</i><sub>D</sub> 0.7 nM; <b>13b</b>: <i>K</i><sub>a</sub> 4.4 × 10<sup>4</sup> M<sup>–1</sup> s<sup>–1</sup>, <i>K</i><sub>d</sub> 1.1 × 10<sup>–4</sup> s<sup>–1</sup>, <i>K</i><sub>D</sub> 2.6 nM; <b>19</b>: <i>K</i><sub>a</sub> 5.7 × 10<sup>4</sup> M<sup>–1</sup>s<sup>–1,</sup>, <i>K</i><sub>d</sub> 1.3 × 10<sup>–4</sup> s<sup>–1</sup>, <i>K</i><sub>D</sub> 2.3 nM.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo Rat PK data for Pan-Trk Ligands <b>10b</b>, <b>13b</b>, and <b>19</b></h3><div class="NLM_p">The optimized pan-Trk ligands <b>10b, 13b</b>, and <b>19</b> were examined in oral and i.v. PK studies in rats, where they demonstrated low systemic CL and moderate oral bioavailability that was consistent with good absorption (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These compounds were also found to be peripherally restricted with <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> of <0.05 in all cases in CNS penetration studies in rats. These in vivo data confirm that in these optimized pan-Trk ligands, acceptable oral absorption and restriction from the CNS can be combined. These properties that are demonstrated in rats are desirable in pan-Trk inhibitors intended for use as oral medicines for chronic pain and can be reasonably expected to translate to human.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Compounds <b>10b</b>, <b>13b</b>, and <b>19</b>: Pharmacokinetic Properties in Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">i.v. administration</th><th class="rowsep1 colsep0" colspan="3" align="center">p.o. administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (hr)</th><th class="colsep0 rowsep0" align="center" char=".">plasma CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (hr)</th><th class="colsep0 rowsep0" align="center" char=".">oral F (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">18.5</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Compounds were administered via intravenous (i.v.) and oral (p.o.) routes to separate groups of two male rats. <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> was determined separately following i.v. infusion in four male rats. Further details of PK and CNS penetration experiments are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Predicted Human Clearance of Pan-Trk Ligands <b>10b</b>, <b>13b</b>, and <b>19</b></h3><div class="NLM_p last">Metabolic pathways of <b>10b</b>, <b>13b</b>, and <b>19</b> were examined in HLM and in hHep in vitro (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>). In HLM, metabolism of all three analogues was identified as occurring through pathways consistent with CYP-mediated oxidation. In separate incubations of compounds in human liver cytosol fraction, disappearance of compounds over time was undetectable. Thus, the pattern of metabolite formation and absence of detectable turnover in human liver cytosol suggested that AO was not involved in metabolism of these compounds. In hHep, the benzamides <b>10b</b> and <b>13b</b> were found to form some of the oxidized metabolites detected in HLM without evidence of phase 2 conjugation pathways. The aminopyridine <b>19</b> also formed oxidized metabolites in hHep but also formed small amounts of glucuronidated products, consistent with conjugation at the aminopyridine moiety. In the absence of metabolism by AO, prediction of systemic CL in human by scaling in vitro metabolic turnover data can be performed with higher confidence than previously possible for the development candidate pan-Trk inhibitor PF-06273340. Turnover of analogues <b>10b</b>, <b>13b</b>, and <b>19</b> in HLM was too low to be quantified (<8 μL/min/mg), whereas in hHep, CL<sub>int</sub> was measurable using the “relay” assay technique designed for compounds exhibiting high metabolic stability.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> CL<sub>int</sub> values were 7.8, 2.0, and 1.4 μL/min/10<sup>6</sup> cells, for <b>10b</b>, <b>13b</b>, and <b>19</b>, respectively, which scaled to systemic plasma CL values in human of 1.5, 0.3, and 0.6 mL/min/kg, respectively, consistent with minimal hepatic extraction.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Solubility of Pan-Trk Ligands <b>10b</b>, <b>13b</b>, and <b>19</b></h3><div class="NLM_p last">Solubility is a drug property that plays a key role in the development potential and PK profile of clinical candidates.<a onclick="showRef(event, 'ref34 ref42'); return false;" href="javascript:void(0);" class="ref ref34 ref42">(34,42)</a> The solubility of our previous development candidate PF-06273340 was low for the crystalline form at approximately 2 μg/mL in a pH 6.5 aqueous phosphate buffer. In comparison, the solubility of <b>10b</b>, <b>13b</b>, and <b>19</b> was significantly higher at 15, 76, and 55 μg/mL, respectively. This improvement in solubility can be attributed to, in part, the higher fraction of sp3 hybridized carbons of <b>10b</b>, <b>13b</b>, and <b>19</b> when compared with PF-06273340, and fewer HBDs in <b>10b</b>, <b>13b</b>, and <b>19</b> when compared with PF-06273340 that can result in high lattice energies.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> Ligands <b>10b</b> and <b>19</b> gave highest measured p<i>K</i><sub>a</sub> values (between 4.2 and 4.7). The improved solubility of <b>10b</b>, <b>13b</b>, and <b>19</b> gave further confidence in the clinical development potential of these analogues.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vivo Efficacy in UV Burn Hyperalgesia Models</h3><div class="NLM_p">Compounds <b>10b</b>, <b>13b</b>, and <b>19</b> were assessed in the UV irradiation-induced thermal hyperalgesia (UVIH) model of inflammatory pain in rats whereby their effects on thermal hyperalgesia resulting from UV irradiation were determined by measuring paw withdrawal latency (PWL) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Single oral doses of <b>10b</b> (0.03, 0.32, and 3 mg/kg), <b>13b</b> (0.15, 1.5, and 15 mg/kg), and <b>19</b> (0.03, 0.32, and 3 mg/kg) were administered 48 h after UV treatment and PWL measured at 1, 3, and 6 h post dose. The doses of compounds were chosen to achieve multiples of TrkA cell IC<sub>50</sub> of 0.1×, 1.0×, and 10× at some time between 1 and 6 h. The effect on hyperalgesia of all three compounds at the highest dose studied is shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, and their effects at all doses administered are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. All three compounds significantly reversed hyperalgesia at the highest two doses employed at each of the time-points studied (<i>p</i> < 0.05, 2-way ANOVA vs vehicle). The positive control ibuprofen (100 mg/kg, p.o.) also reversed thermal hyperalgesia at the 1 and 3 h time-points (individual compound dose response data compared with vehicle and positive control ibuprofen for <b>10b</b>, <b>13b</b>, and <b>19</b> is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>). While no effect on PWL was observed at any dose of <b>10b</b> or <b>19</b> for the contralateral hindpaw, the highest dose of <b>13b</b> displayed a significant effect on contralateral PWL (<i>P</i> < 0.05, data not shown). Unbound plasma concentrations of compounds were determined in animals at 6 h post dose. This demonstrated that statistically significant efficacy was observed at unbound plasma concentrations equivalent to the following multiples of TrkA cell IC<sub>50</sub>: <b>10b</b>: 0.5× (0.03 mg/kg), 4× (3 mg/kg); <b>13b</b>: 0.8× (0.15 mg/kg), 13× (15 mg/kg); <b>19</b>: 0.15× (0.3 mg/kg), 2× (3 mg/kg). Overall, it is possible to say that in these experiments, efficacy was achieved at doses of compounds that corresponded with unbound exposure at multiples of TrkA cell IC<sub>50</sub> of 2×–13×.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effects of <b>10b</b>, <b>13b</b>, and <b>19</b> on UV Irradiation-Induced Hyperalgesia in Rats<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">significance of difference from vehicle</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">1 h</th><th class="colsep0 rowsep0" align="center">3 h</th><th class="colsep0 rowsep0" align="center">6 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">N.S.</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.05</td><td class="colsep0 rowsep0" align="left">N.S.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">N.S.</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.05</td><td class="colsep0 rowsep0" align="left">N.S.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">N.S.</td><td class="colsep0 rowsep0" align="left">N.S.</td><td class="colsep0 rowsep0" align="left">N.S.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.05</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td><td class="colsep0 rowsep0" align="left"><i>p</i> < 0.001</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">The statistical significance of effects on PWL (ipsilateral paw, <i>n</i> = 8) were determined according to two-way ANOVA vs vehicle data (N.S. = not significant (<i>p</i> > 0.05)). Dose response data compared with vehicle and positive control ibuprofen for <b>10b</b>, <b>13b</b>, and <b>19</b> are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></div></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0011.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of compounds <b>10b</b>, <b>13b</b>, and <b>19</b> in the UVIH model in rats at the highest dose studied. Ipsilateral paw data are shown, <i>n</i> = 8 rats per dose group. Statistical significance according to two-way ANOVA vs vehicle data is given in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Dose response data compared with vehicle and positive control ibuprofen for <b>10b</b>, <b>13b</b>, and <b>19</b> is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ligands <b>10b</b>, <b>13b</b>, and <b>19</b> were progressed to either two-week (ligands <b>10b</b> and <b>19</b>) or four-week (<b>13b</b>) exploratory toxicity studies in rats. No adverse effects (including behavioral) were observed at free average concentrations (<i>C</i><sub>avg</sub>) of 725×, 882×, and 133× TrkA cell IC<sub>50</sub> for <b>10b</b>, <b>19</b>, and <b>13b</b>, respectively. Moreover <b>10b</b>, <b>19</b>, and <b>13b</b> exhibited a favorable genotoxicity profile suitable for advancement.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Free-Energy-Based Computational Methods</h3><div class="NLM_p last">The availability of computational methods that can reliably, rapidly, and accurately predict the binding affinities of ligands to a target protein of interest would greatly facilitate SBDD. To this end, we have recently described a collaborative study that compares TrkA binding affinity predictions using two free-energy-based methods, Enhanced Sampling of Molecular dynamics with Approximation of Continuum Solvent (ESMACS) and Thermodynamic Integration with Enhanced Sampling (TIES), to experimentally derived TrkA binding affinities for a set of Pfizer pan-Trk compounds.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Individual binding affinities were calculated in a few hours, exhibiting good correlations with the experimental data of 0.79 and 0.88 from the ESMACS and TIES approaches, respectively. We are now in the process of expanding the pan-Trk data set used to include the compounds in this manuscript and further explore these methods. Moreover, recent developments in conformational sampling of a binding site such as REST (Replica Exchange with Solute Tempering) and/or REST2 will be combined with ESMACS and TIES to provide further enhancement in potency prediction accuracy.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> The results of these ongoing studies will be reported in due course.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p">A typical synthetic route toward the pyrazole compounds <b>1</b> and <b>2</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Phenol <b>21</b> was alkylated by displacement of mesylate <b>22</b> with cesium carbonate in DMF to afford <b>23</b>. A Suzuki reaction with <i>N</i>-methyl pyrazole boronate ester <b>24</b> followed by hydrolysis of the nitrile with potassium hydroxide produced benzamide <b>26</b>. The Boc group was deprotected with HCl, leading to piperidine <b>27</b>. Urea compound <b>1</b> was then formed by reacting <b>27</b> with isocyanate <b>28</b> using pyridine as the base. Amide <b>2</b> was formed via reaction of <b>27</b> with phenyl acetic acid <b>29</b> using HATU and DIPEA.</div><figure id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Hit Molecule <b>2</b> and Lead Molecule <b>3</b> via Mesylate Displacement and Suzuki Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 65%; (ii) <b>24</b>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3,</sub> >99%; (iii) KOH, <i>t</i>BuOH, 96%; (iv) HCl, >99%; (v) <b>28</b>, pyridine, 73%; (vi) <b>29</b>, HATU, DIPEA, DMF, 40%.</p></p></figure><div class="NLM_p">The synthesis of phenyl acetic acid derivatives from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> are described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Aryl bromide <b>30</b> was converted to the boronate ester <b>31</b> through palladium mediated coupling with B<sub>2</sub>Pin<sub>2</sub>. Subsequent Suzuki–Miyaura coupling was performed with the bromoimidazole <b>32</b> to give <b>33</b>. Piperidine <b>35</b> was synthesized via mesylate displacement and deprotection and then coupled with a range of substituted phenyl acetic acids under HATU or EDC conditions to give the desired compounds <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, and <b>7</b>.</div><figure id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenyl Acetic Acid Derivatives via Suzuki Coupling, Mesylate Displacement, and Amide Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) B<sub>2</sub>Pin<sub>2</sub>, PdCl<sub>2</sub>(dppf)·DCM, KOAc, dioxane 100 °C, 16 h, 44%; (ii) <b>32</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>t</i>-Bu)<sub>3</sub>PHBF<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 100 °C, 16 h, 68%; (iii) <b>22</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, (49%); (iv) HCl/dioxane, >99%; (v) HATU or EDC coupling.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> illustrates the preparation of a range of piperidines to give compounds <b>8</b>, <b>9a</b>, <b>9b</b>, <b>10a</b>, and <b>10b</b>. In this sequence, the substituted piperidines (shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) were installed early in the synthesis followed by subsequent Suzuki–Miyaura reaction using iodoimidazole <b>42</b>. S<sub>N</sub>Ar reaction of commercial Boc protected fluoropiperidinol <b>36</b>,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> with 2-chloropyridine <b>37</b> occurred in high yield using potassium <i>t</i>-butoxide as base in DMSO at room temperature to give <b>38</b>. Removal of the Boc group was followed by HATU coupling with phenyl acetic acid to give bromopyridine <b>40</b>. <b>40</b> was converted to the boronate ester and Suzuki coupled with <b>42</b> to give the desired compounds in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Fluoropiperidine Derivatives in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>37</b>, KO<i>t</i>Bu, DMSO, room temperature, 16 h, 72%; (ii) HCl/dioxane, >99%; (iii) <b>29</b>, HATU, TEA, DMF, 93%; (iv) B<sub>2</sub>Pin<sub>2</sub>, PdCl<sub>2</sub>(dppf)·DCM, KOAc, dioxane, 100 °C, 16 h, 61%; (v) <b>42</b>, PdCl<sub>2</sub>(dppf), K<sub>2</sub>CO<sub>3</sub>, DMF-water, 100 °C, 16 h, 24%.</p></p></figure><div class="NLM_p">Compound <b>45</b> was prepared using SnAr conditions at an elevated temperature of 100 °C with gem-difluoro piperidinol <b>43</b> and fluoro aryl <b>44</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Conversion to the boronate ester <b>46</b> and Suzuki–Miyaura coupling with bromoimidazole <b>32</b> led to product <b>47</b>. Boc-deprotection and coupling with acid <b>29</b> using COMU gave 81% yield of compound <b>11</b>.</div><figure id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Difluoropiperidine Derivative <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 24 h, 90%; (ii) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), dioxane, 100 °C 16 h, >99%; (iii) <b>32</b>, Pd<sub>2</sub>dba<sub>3</sub>, <i>t</i>Bu<sub>3</sub>PH·BF<sub>4</sub> Na<sub>2</sub>CO<sub>3</sub> (aq) dioxane, 100 °C 18 h, 25%; (iv) HCl/dioxane, >99%; (v) <b>29</b>, COMU, DIEA, DMF, room temperature, 14 h, 81%.</p></p></figure><div class="NLM_p">The standard preparation toward tertiary alcohols, shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, is described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> producing the four compounds <b>12a</b>, <b>12b</b>, <b>13a</b>, and <b>13b</b>. A variety of fluoro substituted piperidines were used in the S<sub>N</sub>Ar reaction with aryl fluoride <b>49</b> using cesium carbonate as base and DMF as solvent at 100 °C to give ether <b>51</b> (as an example toward <b>13b</b>). Hydrolysis of the nitrile using basic conditions afforded benzamide <b>52</b>, which was then deprotected to give piperidine <b>53</b>. Phenyl acetic acid <b>29</b> was coupled using EDC conditions to give amide <b>54</b>. Hydrogenation of the benzyl ether revealed phenol <b>55</b> which was treated with isobutylene oxide under thermal conditions to give the desired tertiary alcohols shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>.</div><figure id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Tertiary Alcohol Derivatives in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 90%; (ii) KOH, <i>t</i>BuOH, 80 °C, 16 h, 51%; (iii) HCl/dioxane, >99%; (iv) <b>29</b>, EDC, HOBt, DIPEA, 16 h, 82%; (v) H<sub>2</sub> (balloon), Pd/C, EtOH, 2 h, room temperature, 93%; (vi) isobutylene oxide, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 26%.</p></p></figure><div class="NLM_p">To prepare primary alcohol <b>14</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), phenol <b>56</b> was treated with 2-bromo-2-methyl propionic acid to give gem-dimethyl ether <b>57</b>. Saponification to the acid <b>58</b>, followed by in situ generation of a mixed anhydride and reduction with NaBH<sub>4</sub> afforded the corresponding alcohol <b>14</b>.</div><figure id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0017.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Primary Alcohol <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2-bromo-2-methyl proprionic acid, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 98%; (ii) LiOH, THF, H<sub>2</sub>O, room temperature, 4 h, 82%; (iii) isobutyl chloroformate, then NaBH<sub>4</sub>, 51%.</p></p></figure><div class="NLM_p">A typical synthetic route to compounds <b>15</b>, <b>16a</b>, and <b>16b</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) is described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Heteroaryl bromide <b>59</b> was subjected to Suzuki–Miyaura coupling conditions with the <i>N</i>-methyl-pyrazole boronate ester to give excellent yields of the pyrazole product <b>60</b>.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Deprotection with sodium hydroxide and methanol revealed the 2-amino-3-hydroxy pyridine <b>61</b>, which was then treated with (<i>S</i>)-pyrrolidine mesylate to give ether <b>62</b>. Similar Boc deprotection and coupling conditions (vide supra) allowed the generation of compounds <b>15</b>, <b>16a</b>, and <b>16b</b>.</div><figure id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0018.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Route to Compounds <b>15</b>, <b>16a</b>, and <b>16b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>24</b>, PdCl<sub>2</sub>(dppf), Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 90 °C, 90%; (ii) NaOH, MeOH, H<sub>2</sub>O, reflux, 72%; (iii) (<i>S</i>)-<i>tert</i>-butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 85 °C, 52%; (iv) HCl/dioxane, >99%; (v) <b>29</b>, coupling with HATU or T3P, 21–73%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a> details the synthesis of compounds <b>17a</b> and <b>17b</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), which were prepared as a racemic mixture, then separated by chiral chromatography. Epoxide opening of <b>64</b> with HF at 115 °C gave the racemic trans alcohol <b>(±)65</b>. Mitsunobu reaction with nitrobenzoic acid gave ester <b>(±)66</b> which was hydrolyzed to afford cis alcohol <b>(±)67</b>. This was converted to triflate <b>(±)68</b>, which was used for an ether formation with 2-amino-3-hydoxy <b>71</b> (prepared in two steps using a Suzuki reaction coupling first with iodoimidazole <b>42</b> followed by hydrogenolysis of the benzyl group).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> After deprotection of <b>(±)72</b> and coupling with phenyl acetic acid, the racemic material was purified by chiral chromatography to give the two enantiomers <b>17a</b> and <b>17b</b>.</div><figure id="sch8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0019.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthetic Route to Compounds <b>17a</b> and <b>17b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HF·TEA, 115 °C, 81%; (ii) <i>p</i>-nitrobenzoic acid, DIAD, PPh<sub>3</sub>, THF; (iii) 1N NaOH, THF, 57% (over 2 steps); (iv) Tf<sub>2</sub>O, pyridine, DCM, 91%; (v) <b>42</b>, Pd(dppf)Cl<sub>2</sub>·DCM, K<sub>2</sub>CO<sub>3</sub>, DMF, 69%,; (vi) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, EtOH, 88%; (vii) <b>±68</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF room temperature, 63%; (viii) 33% HBr/AcOH, DCM, >99%; (ix) <b>29</b>, HATU, DIEA, then chiral SFC separation, 44%.</p></p></figure><div class="NLM_p">Compounds <b>18a</b> and <b>18b</b> were also prepared in a racemic synthesis (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). 3-Fluoro pyridine <b>75</b> underwent S<sub>N</sub>Ar reaction with racemic gem-difluoro pyrrolidine <b>74</b> using cesium carbonate in THF to afford excellent yields of ether <b>76</b>. Reduction of the nitropyridine via hydrogenation over palladium on carbon gave amine <b>77</b>. Subsequent bromination with NBS gave bromopyridine <b>78</b> and the imidazole was installed via a Stille reaction with imidazole stannane <b>79</b>. Following deprotection, coupling, and separation of enantiomers, the single enantiomers <b>18a</b> and <b>18b</b> were generated.</div><figure id="sch9" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0020.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthetic Route to Compounds <b>18a</b> and <b>18b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, 91%; (ii) H<sub>2</sub>, Pd/C, MeOH, >99%; (iii) NBS, DMF, 82%; (iv) <b>79</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, DMF, 120 °C, 90%; (v) TFA; (vi) <b>29</b>, HATU, TEA, DMF, then chiral SFC separation (35% each enantiomer over 2 steps).</p></p></figure><div class="NLM_p">Using intermediate <b>78</b> from <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>, a palladium-catalyzed carbonylation under pressure in the presence of methanol afforded ester <b>81</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). Amide <b>82</b> was prepared using standard deprotection and coupling conditions. Methyl and ethyl amides <b>19</b> and <b>20</b> were then synthesized by saponification of the alkyl ester to acid <b>83</b> followed by coupling of the primary methyl and ethyl amines. Chiral separation gave the separate enantiomers.</div><figure id="sch10" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0021.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthetic Route to Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) CO (5.2 bar), Pd(OAc)<sub>2</sub>, DPPF, Et<sub>3</sub>N, MeOH, DMF, 80 °C, 65%; (ii) TFA (iii) <b>29</b>, HATU, TEA, DMF, 95% (over 2 steps), (iv) NaOH, MeOH, >99%; (v) MeNH<sub>2</sub>·HCl or EtNH<sub>2</sub>·HCl, HATU, TEA, then chiral SFC separation.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Based on the clinical efficacy of NGF neutralizing antibodies in inflammatory pain, there is substantial interest in the advancement of small molecule inhibitors of TrkA for the treatment of pain. Our current pan-Trk (TrkA, TrkB, and TrkC) inhibitor development candidate PF-06273340 was found to be metabolized via AO-catalyzed reactions, leading to a potential clearance prediction liability, and contingency pan-Trk candidates were sought, whereby AO-mediated metabolism was avoided to mitigate human pharmacokinetic risk. Thus, three candidate quality pan-Trk compounds that have high confidence in human PK prediction were designed: <b>10b</b>, <b>13b</b>, and <b>19</b>. Ligand <b>10b</b> was delivered by optimizing hit molecule <b>1</b>, which was discovered by analysis of the in-house kinase selectivity data set. Candidate molecule <b>13b</b> was designed as a hybrid between development candidate PF-06273340 and <b>10b</b>, wherein the solvent exposed groups were interchanged. Hinge binder and linker modification then led to candidate molecule <b>19</b>. All three compounds were predicted to possess low metabolic clearance in humans that does not proceed via AO-catalyzed reactions, thus addressing the potential clearance prediction liability associated with PF-06273340. Moreover, the high potency, off-target selectivity, in vivo toxicity profile, along with absorption, peripheral restriction, and human CL predictions made all three pan-Trk inhibitors exciting and promising structurally differentiated assets suitable for advancement into a variety of clinical pain studies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General</h3><div class="NLM_p"><sup>1</sup>H nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million (ppm) (δ relative to residual solvent peak) using conventional abbreviations for designation of major peaks: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. The mass spectra (<i>m</i>/<i>z</i>) were recorded electrospray ionization. The following abbreviations were used for common solvents: CDCl<sub>3</sub>, deuterochloroform; DMSO-<i>d</i><sub>6</sub>, deuterodimethyl sulfoxide; CD<sub>3</sub>OD, deuteromethanol. All solvents were reagent grade and, when necessary, were purified and dried by standard methods. Concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at a reduced pressure of ca. 20 Torr. Anhydrous solvents were obtained from commercial sources and used as-is. The chemical yields reported below are unoptimized. Purity criteria: Final compounds isolated as singletons >95% based on LCMS and/or HPLC. The experimental procedures for all of the steps in the synthesis of all target compounds can be found in Pfizer patent applications WO2015092610, WO2016009296, and WO2016020784.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(2-Carbamoyl-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)phenoxy)-<i>N</i>-(4-(trifluoromethoxy)phenyl)piperidine-1-carboxamide (<b>1</b>)</h4><div class="NLM_p last">5-Bromo-2-hydroxybenzonitrile <b>21</b> (20 g, 101.10 mmol) and <i>tert</i>-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate <b>22</b> (33.8 g, 121.21 mmol) were combined in dry DME (400 mL, 0.25 M). Cs<sub>2</sub>CO<sub>3</sub> (40g, 121.21 mmol) was added, and the reaction mixture was heated to 100 °C for 24 h. The reaction mixture was cooled to room temperature; water was added, and the reaction extracted with EtOAc. The organics were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by SiO<sub>2</sub> column chromatography to afford <b>23</b> (25 g, 65%). LCMS [M + 1 – <i>t</i>Bu] 325.0; <sup>1</sup>HNMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.00 (s, 1H), 7.82 (m, 1H), 7.33 (d, <i>J</i> = 9.12 Hz, 1H), 4.82 (m, 1H), 3.55 (m, 2H), 3.29 (m, 2H), 1.90 (m, 2H), 1.63 (m, 2H), 1.45 (s, 9H). Compound <b>23</b> (24 g, 62.9 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole <b>24</b> (15.72 g, 75.7 mmol) were added to DMF (314 mL, 0.2M). Cs<sub>2</sub>CO<sub>3</sub> (61.5 g, 188.9 mmol) in water (88.4 mL) was added to the reaction mixture, and the mixture was purged with N<sub>2</sub> for 1 h. Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (2.5 g 3.14 mmol) was then added, and the reaction mixture was heated to 80 °C for 16 h. The reaction mixture was concentrated to remove most of the solvent, and then water and DCM were added. The reaction mixture was extracted with DCM, and the organic layer washed with water, brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic layer was filtered, concentrated, and purified by SiO<sub>2</sub> column chromatography with EtOAc/Hexanes to obtain <b>25</b> (24 g, >99%). LCMS [M + 1] 383.2; <sup>1</sup>HNMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.15 (s, 1H), 7.94 (d, <i>J</i> = 1.72 Hz, 1H), 7.89 (s, 1H), 7.81 (m, 1H), 7.33 (d, <i>J</i> = 8.88, 1H), 4.79 (m, 1H), 3.85 (s, 3H), 3.57 (m, 2H), 3.30 (m, 2H), 1.90 (m, 2H), 1.62 (m, 2H), 1.41, (s, 9H). General hydrolysis procedure A: To compound <b>25</b> (2.5 g, 6.54 mmol) in <i>t</i>BuOH (25 mL, 0.26 M) was added KOH (732 mg, 13.08 mmol). The reaction mixture was heated to 80 °C for 16 h. The reaction mixture was cooled to room temperature, and EtOAc and water were added. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>26</b> (2.5 g, 96%) and used directly in the next step. LCMS [M + 1] 401.2; <sup>1</sup>HNMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.10 (s, 1H), 7.87 (d, <i>J</i> = 1.8 Hz, 1H), 7.79 (s, 1H), 7.61 (m, 1H), 7.54 (bs, 2H), 7.19 (d, <i>J</i> = 8.64 Hz, 1H), 3.84 (s, 3H), 3.62 (m, 2H), 3.23 (m, 2H), 1.90 (m, 2H), 1.63 (m, 2H), 1.41 (s, 9H). General HCl deprotection procedure B: To compound <b>26</b> (2.5 g, 6.25 mmol) in dioxane (10 mL, 0.63 M) was added 4 M HCl/dioxane (25 mL). The reaction mixture was stirred for 2 h at room temperature and then concentrated in vacuo. Ether was added and stirred for 10 min. The solid was filtered and washed with ether to give <b>27</b> (HCl salt, 2.3 g, >99%). LCMS [M + 1] 301.4; <sup>1</sup>HNMR (400 MHz, <i>d</i>-DMSO) δ ppm 9.07 (bs, 1H), 8.89 (bs, 1H), 8.11 (s, 1H), 7.81 (s, 1H), 7.77 (d, <i>J</i> = 2.36 Hz, 1H), 7.59 (m, 3H), 7.18 (d, <i>J</i> = 8.76 Hz, 1H), 4. 78 (m, 1H), 3.85 (s, 3H), 3.20 (m, 2H), 3.08 (m, 2H), 2.11 (m, 2H), 1.93 (m, 2H). A mixture of <b>27</b> (80 mg, 0.20 mmol) and 1-isocyanato-4-(trifluoromethoxy)benzene <b>28</b> (62.2 mg, 0.306 mmol) in 2 mL of pyridine was stirred at room temperature for 4 h. To the reaction was added an additional 1.5 equiv of 1-isocyanato-4-(trifluoromethoxy)benzene <b>28</b> (62.2 mg, 0.306 mmol), and the mixture stirred at room temperature overnight. The reaction mixture was evaporated with toluene and the residue was purified by ISCO (40 g, MeOH/DCM = 0 to 10%) to give <b>1</b> (75 mg, 73%) as a white solid. LCMS ES+ AP+ 504 [M + H], ES- AP+ 502 [M – H]; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.75 (s, 1H), 8.10 (s, 1H), 7.89 (d, <i>J</i> = 2.3 Hz, 1H), 7.80 (s, 1H), 7.61 (dd, <i>J</i> = 2.5, 8.6 Hz, 1H), 7.59–7.53 (m, 4H), 7.23 (d, <i>J</i> = 8.8 Hz, 3H), 4.82–4.74 (m, 1H), 3.85 (s, 3H), 3.82–3.72 (m, 2H), 3.40–3.32 (m, 2H), 2.05–1.93 (m, 2H), 1.80–1.64 (m, 2H); HRMS for C<sub>24</sub>H<sub>25</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd: 504.1853, Found 504.1853.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)benzamide (<b>2</b>)</h4><div class="NLM_p last">See procedures for compound <b>1</b> steps 1–4 and then the following HATU coupling procedures. General HATU coupling procedure C: DIPEA (0.793 mL, 4.45 mmol) was added to compound <b>27</b> (300 mg, 0.891 mmol) in DMF (5 mL, 0.18 M) and stirred for 10 min. To this reaction mixture was added 2-(4-(trifluoromethoxy)phenyl)acetic acid <b>29</b> (196 mg, 0.89 mmol) and HATU (508 mg, 1.33 mmol) and the mixture stirred at room temperature for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by SiO<sub>2</sub> column chromatography to afford <b>2</b> (180 mg, 40%). LCMS [M + 1] 503.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.10 (s, 1H), 7.86 (d, <i>J</i> = 2.32, 1H), 7.79 (s, 1H), 7.60 (dd, <i>J</i> = 8.52, 2.34 Hz, 1H), 7.54 (m, 2H), 7.35 (d, <i>J</i> = 8.68 Hz, 2H), 7.30 (d, 8.24 Hz, 2H), 7.20 (d, <i>J</i> = 8.72 Hz, 1H), 4.77 (m, 1H), 3.85 (s, 3H), 3.79 (s, 2H), 3.75 (m, 2H), 3.43 (m, 2H), 1.90 (m, 2H), 1.63 (m, 2H); HRMS for C<sub>25</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M] Calcd: 502.1828, Found 502.1832.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-(1-Methyl-1<i>H</i>-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)benzamide (<b>3</b>)</h4><div class="NLM_p last">General B<sub>2</sub>Pin<sub>2</sub> procedure D: A solution of 5-bromo-2-hydroxybenzamide <b>30</b> (25 g, 115.72 mmol), B<sub>2</sub>Pin<sub>2</sub> (44g, 173.58 mmol) and freshly dried KOAc (34 g, 347.17 mmol) in dioxane (500 mL) was degassed with argon for about 20 min. Pd(dppf)Cl<sub>2</sub>-DCM (2.83 g, 3.47 mmol) was added and the resulting reaction mixture was heated at 100 °C for 16 h. The reaction mixture was cooled to room temperature, filtered through Celite, and washed with EtOAc (1 L). Organics were neutralized with 2 N HCl and washed with water (200 mL) and brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude compound was purified by triturating with ether, hexane, and <i>n</i>-heptane to afford <b>31</b> as light brown solid (12 g, 40%). LCMS [M + 1] 264.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 13.45 (s, 1H), 8.55 (bs, 1H), 8.17 (s, 1H), 7.69 (bs, 1H), 7.67 (d, <i>J</i> = 8.24 Hz, 1H), 6.87 (d, <i>J</i> = 8.24 Hz, 1H), 1.29 (s, 12H). General Suzuki procedure E: A stirred solution of <b>31</b> (12.0 g, 45.63 mmol), <b>32</b> (7.35 g, 45.63 mmol) and Na<sub>2</sub>CO<sub>3</sub> (12.1 g, 114.07 mmol) in dioxane-H<sub>2</sub>O (4:1, 200 mL) was degassed with argon for about 20 min. Pd<sub>2</sub>(dba)<sub>3</sub> (2.09 g, 2.28 mmol) and <i>t</i>Bu<sub>3</sub>PHBF<sub>4</sub> (265 mg, 0.913 mmol) were added, and the resulting reaction mixture was heated at 100 °C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The concentrated residue was acidified to pH 5–6 by 6 N HCl, filtered through Celite, and washed with 5% MeOH-DCM (1 L), then with 10% MeOH-DCM + 2% NH<sub>4</sub>OH (1 L), and the filtrate was concentrated to afford <b>33</b> as a brown solid (6.6 g, 67%). LCMS [M + 1] 218.4; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 12.89 (s, 1H), 8.46 (bs, 1H), 8.19 (d, <i>J</i> = 1.8 Hz, 1H), 7.87 (bs, 1H), 7.77 (dd, <i>J</i> = 8.56, 1.74 Hz, 1H), 7.63 (s, 1H), 7.44 (s, 1H), 6.86 (d, <i>J</i> = 8.48, 1H), 3.68 (s, 3H). To a solution of <b>33</b> (120 mg, 0.55 mmol) and <b>22</b> (185 mg, 0.66 mmol) in DMF (3 mL, 0.18 M) was added Cs<sub>2</sub>CO<sub>3</sub> (216 mg, 0.66 mmol), and the mixture was stirred at 90 °C for 4 h. The reaction mixture was cooled to room temperature and diluted with water. The mixture was extracted with EtOAc, and the combined organics were washed with water (4 × 50 mL), brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified by SiO<sub>2</sub> column chromatography (3–4% MeOH/DCM) to afford <b>34</b> as a solid (110 mg, 50%). LCMS [M + 1] 401.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.11 (d, <i>J</i> = 2.28 Hz, 1H), 7.77 (dd, <i>J</i> = 8.52, 2.28 Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.51 (m, 2H), 7.18 (d, <i>J</i> = 8.72 Hz, 1H), 4.70 (m, 1H), 3.67 (s, 3H), 3.62 (m, 2H), 3.22 (m, 2H), 1.99 (m, 2H), 1.64 (m, 2H), 1.41 (s, 9H). Compound <b>35</b> was prepared using general HCl deprotection procedures <b>B</b> with <b>34</b> (100 mg, 0.25 mmol) to afford an off-white solid of <b>35</b> (HCl salt, 90 mg, >99%). LCMS [M + 1] 301.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 9.15 (s, 1H), 9.07 (bs, 1H), 8.83 (bs, 1H), 8.16 (s, 1H), 8.06 (d, <i>J</i> = 2.04 Hz, 1H), 7.90 (dd, <i>J</i> = 8.64, 1.92 Hz, 1H), 7.70 (bs, 1H), 7.61 (bs, 1H), 7.38 (d, <i>J</i> = 8.8 Hz, 1H), 4.88 (m, 1H), 3.88 (s, 3H), 3.22 (m, 2H), 3.11 (m, 2H), 2.14 (m, 2H), 1.95 (m, 2H). General EDC coupling procedure F: TEA (11.29 mL, 80.43 mmol) was added to a suspension of <b>35</b> (6 g, 16.09 mmol) in DCM (140 mL) and stirred for 10 min. To this EDCI (4.63 g, 24.13 mmol), HOBT (3.26 g, 24.13 mmol) and <b>29</b> (3.54 g, 16.09 mmol) were added, and the resulting mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with NaHCO<sub>3</sub> (sat aq), water, and brine. The organics were then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford crude material that was purified by column chromatography (100–200 SiO<sub>2</sub>, 3–4% MeOH/DCM) to afford solid compound <b>3</b> as an off-white solid (4.5 g, 56%). LCMS [M + 1] 503.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.10 (d, <i>J</i> = 2.4 Hz, 1H), 7.77 (dd, <i>J</i> = 2.4, 8.8 Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.52 (br. s., 2H), 7.36 (d, <i>J</i> = 8.8 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 7.19 (d, <i>J</i> = 8.8 Hz, 1H), 4.83–4.71 (m, 1H), 3.86–3.81 (m, <i>J</i> = 5.9 Hz, 1H), 3.79 (s, 2H), 3.77–3.71 (m, 1H), 3.67 (s, 3H), 3.49–3.37 (m, 1H), 3.37–3.34 (m, 1H), 1.98–1.85 (m, 2H), 1.74–1.55 (m, 2H); HRMS for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 503.1901, found 503.1908.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-5-(1-Methyl-1<i>H</i>-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)phenyl)propanoyl)piperidin-4-yl)oxy)benzamide (<b>4</b>)</h4><div class="NLM_p last">See procedures for compound <b>3</b>, then using general EDC coupling procedures <b>F</b> and appropriate carboxylic acid, then chiral separation of enantiomers: LCMS [M + 1] 517.6; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.07 (dd, <i>J</i> = 2.2, 11.0 Hz, 1H), 7.74 (d, <i>J</i> = 8.3 Hz, 1H), 7.59 (s, 1H), 7.53 (s, 2H), 7.46–7.36 (m, 3H), 7.34–7.30 (m, 2H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 4.68 (br. s., 1H), 4.31–4.18 (m, 1H), 3.94–3.67 (m, 2H), 3.66 (s, 3H), 3.47–3.35 (m, 1H), 3.29–3.18 (m, 1H), 2.00–1.76 (m, 2H), 1.71–1.57 (m, 1H), 1.56–1.46 (m, 1H), 1.30 (d, <i>J</i> = 6.4 Hz, 3H); HRMS for C<sub>26</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 517.2057, found 517.2065.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-5-(1-Methyl-1<i>H</i>-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)phenyl)propanoyl)piperidin-4-yl)oxy)benzamide (<b>5</b>)</h4><div class="NLM_p last">See procedures for compound <b>3</b>, then using general EDC coupling procedures <b>F</b> and appropriate carboxylic acid, then chiral separation of enantiomers: LCMS [M + 1] 517.2; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.06 (dd, <i>J</i> = 11.08, 2.04 Hz, 1H), 7.73 (d, <i>J</i> = 8.64 Hz, 1H), 7.59 (s, 1H), 7.53 (bs, 2H), 7.42 (m, 3H), 7.32 (d, <i>J</i> = 8.32 Hz, 2H), 7.14 (d, 8.64 Hz, 1H), 4.68 (m, 1H), 4.25 (m, 1H), 3.82 (m, 2H), 3.66 (s, 3H), 3.45 (m, 1H), 3.24 (m, 1H), 1.88 (m, 2H), 1.63 (m, 1H), 1.53 (m, 1H), 1.30 (d, <i>J</i> = 6.76 Hz, 3H); HRMS for C<sub>26</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 517.2057, found 517.2067.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-((1-(2-(3-Fluoro-4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)benzamide (<b>6</b>)</h4><div class="NLM_p last">See procedures for compound <b>3</b>, then using general HATU coupling procedures <b>C</b> and appropriate carboxylic acid: LCMS [M + 1] 521.4; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.11 (d, <i>J</i> = 2.3 Hz, 1H), 7.77 (dd, <i>J</i> = 2.3, 8.6 Hz, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.54 (br. s., 2H), 7.49 (t, <i>J</i> = 8.4 Hz, 1H), 7.37 (dd, <i>J</i> = 1.7, 11.6 Hz, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.18 (d, <i>J</i> = 8.3 Hz, 1H), 4.85–4.71 (m, 1H), 3.88–3.73 (m, 4H), 3.69 (s, 3H), 3.50–3.40 (m, 1H), 3.39–3.35 (m, 1H), 2.01–1.86 (m, 2H), 1.78–1.54 (m, 2H); HRMS for C<sub>25</sub>H<sub>25</sub>F<sub>4</sub>N<sub>4</sub>O<sub>4</sub><i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 521.1806, found 521.1813.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-((1-(2-(4-Cyclopropoxy-3-fluorophenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)benzamide (<b>7</b>)</h4><div class="NLM_p last">See procedures for compound <b>3</b>, then using general HATU coupling procedures <b>C</b> and appropriate carboxylic acid: LCMS [M + 1] 475.0; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.09 (d, <i>J</i> = 2.3 Hz, 1H), 7.76 (dd, <i>J</i> = 2.4, 8.6 Hz, 1H), 7.60 (s, 1H), 7.54 (d, <i>J</i> = 1.1 Hz, 1H), 7.51 (s, 2H), 7.20–7.11 (m, 3H), 7.01–6.94 (m, 2H), 4.79–4.66 (m, 1H), 3.85–3.74 (m, 5H), 3.67 (s, 3H), 3.47–3.34 (m, 2H), 1.99–1.79 (m, 2H), 1.71–1.48 (m, 2H), 0.79–0.71 (m, 2H), 0.66–0.58 (m, 2H; HRMS for C<sub>27</sub>H<sub>31</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 475.234, found 475.2346.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 5-(1-Methyl-1<i>H</i>-imidazol-4-yl)-2-((1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)nicotinamide (<b>8</b>)</h4><div class="NLM_p last">See procedures for <b>9b</b> using appropriate piperidine and <b>32</b>. LCMS [M + 1] 504.6; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.61 (d, <i>J</i> = 2.4 Hz, 1H), 8.45 (d, <i>J</i> = 2.36 Hz, 1H), 7.73 (bs, 1H), 7.66 (s, 2H), 7.57 (bs, 1H), 7.36 (d, <i>J</i> = 8.6 Hz, 2H), 7.30 (d, 8.32 Hz, 2H), 5.41–5.38 (m, 1H), 3.87–3.76 (m, 4H), 3.68 (s, 3H), 3.49–3.40 (m, 2H), 2.0–1.97 (m, 2H), 1.72–1.68 (m, 2H); HRMS ESI [M + 1] calc for C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> 504.1853; found 504.1859.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(((3<i>R</i>,4<i>R</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)nicotinamide (<b>9a</b>)</h4><div class="NLM_p last">See procedures for <b>9b</b> using appropriate piperidine. LCMS [M + 1] 521.8; <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ ppm 8.64 (br. s., 1H), 8.52 (br. s., 1H), 7.68 (s, 1H), 7.52 (s, 1H), 7.37 (d, <i>J</i> = 7.8 Hz, 2H), 7.24 (d, <i>J</i> = 7.8 Hz, 2H), 5.67–5.51 (m, 1H), 4.80–4.73 (m, 2H), 4.16–3.82 (m, 4H), 3.78 (s, 3H), 3.65–3.60 (m, 1H), 2.23–2.19 (m, 1H), 1.96–1.70 (m, 1H) ; HRMS for C<sub>24</sub>H<sub>24</sub>F<sub>4</sub>N<sub>5</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 522.1759; found 522.1761.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(((3<i>S</i>,4<i>S</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)nicotinamide (<b>9b</b>)</h4><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl (3<i>S</i>,4<i>S</i>)-3-fluoro-4-hydroxypiperidine-1-carboxylate <b>36</b> (512 mg, 2.34 mmol) in DMSO (10 mL) was added <i>t</i>-BuOK (393 mg, 3.50 mmol) at 15 °C. The resulting mixture was stirred at 15 °C for 30 min, then 5-bromo-2-chloronicotinamide <b>37</b> (550 mg, 2.34 mmol) was added at 15 °C. The resulting mixture was stirred at 15 °C for 12 h. To the mixture was added water (15 mL) and EtOAc (25 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (10 mL × 2). The organic layers were combined, washed with water (10 mL × 3) and brine (8 mL × 2), dried over Na<sub>2</sub>SO<sub>4,</sub> filtered, and concentrated in vacuo to give the crude product which was purified by Biotage (SiO<sub>2</sub>, <i>R</i><sub>f</sub> = 0.5 Petroleum ether/EtOAc  = 1:1) to obtain <b>38</b> (700 mg, 72%) as a yellow oil. LCMS [M – Boc + 1] 319; <sup>1</sup>H NMR (400 MHz, CDCl3) δ ppm 8.61 (d,  <i>J</i> = 2.5 Hz, 1H), 8.29 (d, <i>J</i> = 2.5 Hz, 1H), 7.56–7.40 (m, 1H),  6.09–5.88 (m, 1H),  5.51–5.37 (m, 1H), 4.80–4.55 (m, 1H), 4.36–4.15 (m, 1H),  3.93–3.83 (m, 1H), 3.18 (br s, 2H),  2.47–2.35 (m, 1H), 1.67 (br d,  <i>J</i> = 10.3 Hz, 1H), 1.48 (s, 9H). Using general HCl deprotection procedures <b>B</b>, compound <b>38</b> (700 mg, 1.67 mmol) deprotected to give <b>39</b> (550 mg,  >99%) and used directly in the next step. LCMS [M + 1] 319. Using coupling conditions using general HATU procedure <b>C</b>, Compound <b>39</b> (550 mg, 1.55 mmol) coupled with <b>29</b> to give <b>40</b> (750 mg, 93%) as a yellow oil and used directly in the next step. LCMS [M + 1] 521.Using general B<sub>2</sub>Pin<sub>2</sub> procedures <b>D</b>, Compound <b>40</b> (750 mg, 1.44 mmol) afforded <b>41</b> (500 mg, 61%) as a brown oil and used directly in the next step. LCMS [M – pinacol + 1] 486. To a mixture of <b>41</b> (500 mg, 0.88 mmol), <b>42</b> (367 mg, 1.76 mmol), K<sub>2</sub>CO<sub>3</sub> (487 mg, 3.53 mmol) in DMF (15 mL), and water (3 mL) was added Pd(dppf)Cl<sub>2</sub> (64.5 mg, 0.088 mmol) at 20 °C under N<sub>2</sub> atmosphere. The resulting mixture was purged with N<sub>2</sub>  3 times and heated at 100 °C for 12 h. To the mixture was added EtOAc (25 mL) and water (10 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (25 mL × 3). The combined organic layers were washed with water (15 mL × 3) and brine (15 mL × 2), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the crude product, which was purified by prep. TLC (<i>R</i><sub>f</sub>   = 0.4 in DCM/MeOH  = 10:1) to obtain the desired product <b>9b</b> (110 mg, 24%) as an off-white solid. LCMS [M + 1] 521.9; HRMS for C<sub>24</sub>H<sub>23</sub>F<sub>4</sub>N<sub>5</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M] Calcd 521.1686; found 521.1694; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.63 (d, <i>J</i> = 2.4 Hz, 1H), 8.46 (t, <i>J</i> = 2.8 Hz, 1H), 7.74 (d, <i>J</i> = 8.9 Hz, 1H), 7.69 (br. s, 1H), 7.67 (s, 1H), 7.60 (br. s., 1H), 7.36 (d,  <i>J</i> = 10.4 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 5.58–5.43 (m, 1H),  5.06–4.74 (m, 1H),  4.12–3.93 (m, 1H),  3.91–3.71 (m, 3H),  3.68–3.59 (m, 1H),  3.58–3.38 (m, 1H),  2.16–2.01 (m, 1H),  1.89–1.67 (m, 1H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(((3<i>S</i>,4<i>R</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)nicotinamide (<b>10a</b>)</h4><div class="NLM_p last">See procedures for <b>9b</b> using appropriate piperidine. LCMS [M + 1] 522.0; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.64 (d, <i>J</i> = 2.2 Hz, 1H), 8.54 (d, <i>J</i> = 2.2 Hz, 1H), 7.83 (bs, 1H), 7.70 (s, 1H), 7.67 (s, 1H), 7.53 (bs, 1H), 7.36–2.29 (m, 4H), 5.56–5.49 (m, 1H), 5.18–5.03 (m, 1H), 4.63–4.34 (m, 2H), 4.03–3.83 (m, 2H), 3.73–3.63 (m, 4H), 3.25–2.91 (m, 1H), 2.02–1.98 (m, 1H), 1.90–1.76 (m, 1H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-(((3<i>R</i>,4<i>S</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)nicotinamide (<b>10b</b>)</h4><div class="NLM_p last">See procedures for <b>9b</b> using appropriate piperidine. LCMS [M + 1] 522.28; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 8.65 (t, <i>J</i> = 2.5 Hz, 1H), 8.55 (t, <i>J</i> = 2.4 Hz, 1H), 7.83 (br. s., 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.54 (br. s., 1H), 7.41–7.25 (m, 4H), 5.67–5.41 (m, 1H), 5.23–4.95 (m, 0.5H), 4.67–4.34 (m, 1H), 4.33–3.98 (m, 0.5H), 3.92–3.73 (m, 2H), 3.70 (s, 3H), 3.68–3.52 (m, 1H), 3.29–2.90 (m, 1H), 2.09–1.99 (m, 1H), 1.92–1.72 (m, 1H); <sup>19</sup>F NMR (376 MHz, d6-DMSO): δ −57; HRMS for C<sub>24</sub>H<sub>24</sub>F<sub>4</sub>N<sub>5</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 522.1759; found 522.1767.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-((3,3-Difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-5-(1-methyl-1<i>H</i>-imidazol-4-yl)benzamide (<b>11</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 3,3-difluoro-4-hydroxypiperidine-1-carboxylate <b>43</b> (155 mg, 0.66 mmol), 5-bromo-2-fluorobenzamide <b>44</b> (140 mg, 0.64 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (314 mg, 0.96 mmol) were suspended in DMF (3.2 mL) in a 25 mL round-bottom flask and heated at 105 °C for 25 h. The reaction mixture was reduced to near dryness under vacuum and the residue was dissolved in water (30 mL) and EtOAc (20 mL). The EtOAc layer was extracted, and the aqueous was back-extracted with EtOAc (2 × 10 mL). The organics were combined with the crude material from a previous experiment run in a similar manner (0.1 mmol scale in 5-bromo-2-fluorobenzamide), washed with 20% brine solution (2 × 5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the filtrate was concentrated to dryness under vacuum. The residue was purified by SiO<sub>2</sub> chromatography, eluting with an EtOAc/heptane gradient, to obtain <b>45</b> (0.294 g, 90%) as an off-white solid. LCMS [M – Boc+1] 335.2; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 8.29 (br. s., 1H), 7.56 (d, <i>J</i> = 8.8 Hz, 1H), 7.34 (br. s., 1H), 6.89 (d, <i>J</i> = 8.8 Hz, 1H), 5.83 (br. s., 1H), 4.53–4.70 (m, 1H), 4.11 (br. s., 1H), 3.83 (br. s., 1H), 3.49–3.62 (m, 1 H), 3.32 (t, <i>J</i> = 10.9 Hz, 1H), 2.16 (br. s., 1H), 2.03 (br. s., 1H), 1.49 (s, 9H). Using similar conditions as general B<sub>2</sub>Pin<sub>2</sub> procedures <b>D</b> to obtain <b>46</b> and used directly in the next step. Using similar conditions as general Suzuki procedures <b>E</b> to obtain <b>47</b> (74 mg, 25%) as a tan foam. LCMS [M + 1] 437.4; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 8.38 (s, 1H), 8.04 (d, <i>J</i> = 8.8 Hz, 1H), 7.43–7.51 (m, 2H), 7.25 (s, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 5.78 (br. s., 1H), 4.61–4.75 (m, 1H), 4.11 (br. s., 1H), 3.82 (br. s, 1H), 3.73 (s, 3H), 3.53–3.66 (m, 1H), 3.35 (t, <i>J</i> = 10.3 Hz, 1H), 2.18 (br. s., 1H), 2.05 (br. s, 1H), 1.49 (s, 9H). Using similar conditions as general HCl deprotection procedures <b>B</b> to obtain <b>48</b> and used crude directly in the next step. Compound <b>48</b> (67.5 mg, 0.165 mmol) and <b>29</b> (60 mg, 0.27 mmol) were suspended in DMF (1.25 mL) and to the brown mixture was added DIEA (0.16 mL, 0.92 mmol) leading to a dark brown solution. COMU (107 mg, 0.24 mmol) was added as a solid in one portion, and the reaction mixture was stirred at room temperature for 14 h. The reaction mixture was reduced to near dryness under vacuum, and the dark residue was diluted with saturated sodium bicarbonate (20 mL) and EtOAc (20 mL). The organic layer was extracted and the aqueous was back-extracted with EtOAc (10 mL). The organics were combined, washed with saturated brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the filtrate was concentrated under vacuum. The isolate was purified by SiO<sub>2</sub> chromatography, eluting with 0–8% MeOH/DCM to obtain compound <b>11</b> (72 mg, 81% yield) as a light brown solid. LCMS [M + 1] 539.4; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.06 (s, 1H), 7.79 (d, <i>J</i> = 8.8 Hz, 1H), 7.63 (s, 1H), 7.59 (s, 2H), 7.48 (br. s., 1H), 7.33–7.39 (m, 2H), 7.29–7.33 (m, 2H), 7.27 (d, <i>J</i> = 8.80 Hz, 1H), 5.14–5.05 (m, 1H), 4.15–4.32 (m, 1H), 3.71–3.99 (m, 4H), 3.68 (s, 3H), 3.36–3.59 (m, 1H), 2.10–2.02 (m, 1H), 1.72–1.90 (m, 1H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-(((3<i>R</i>,4<i>R</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide (<b>12a</b>)</h4><div class="NLM_p last">See procedures for <b>13b</b> with the appropriate piperidine (30 mg, 52%): LCMS [M + 1] 529.2; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.77 (d, <i>J</i> = 8.3 Hz, 1H), 7.44–7.25 (m, 5H), 6.78 (s, 1H), 6.65 (d, <i>J</i> = 8.8 Hz, 1H), 5.00–4.70 (m, 2H), 4.65 (s, 1H), 4.28–4.06 (m, 1H), 3.98–3.71 (m, 4H), 3.62–3.36 (m, 2H), 3.27–3.18 (m, 1H), 2.13–1.98 (m, 1H), 1.82–1.57 (m, 1H), 1.20 (s, 6H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(((3<i>S</i>,4<i>S</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide (<b>12b</b>)</h4><div class="NLM_p last">See procedures for <b>13b</b> with the appropriate piperidine (30 mg, 26%): LCMS [M + 1] 529.2; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.47–7.24 (m, 5H), 6.78 (d, <i>J</i> = 2.0 Hz, 1H), 6.65 (dd, <i>J</i> = 2.0, 8.8 Hz, 1H), 4.99–4.70 (m, 2H), 4.65 (s, 1H), 4.25–4.04 (m, 1H), 3.94–3.72 (m, 4H), 3.62–3.38 (m, 2H), 3.28–3.17 (m, 1H), 2.12–1.98 (m, 1H), 1.78–1.58 (m, 1H), 1.22 (s, 6H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(((3<i>S</i>,4<i>R</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide (<b>13a</b>)</h4><div class="NLM_p last">See procedures for <b>13b</b> with the appropriate piperidine (35 mg, 38%): LCMS [M + 1] 529.2; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.88 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (d, <i>J</i> = 15.7 Hz, 2H), 7.37–7.23 (m, 4H), 6.81 (br. s., 1H), 6.68 (d, <i>J</i> = 8.8 Hz, 1H), 5.17–4.95 (m, 2H), 4.65 (s, 1H), 4.42–4.28 (m, 1H), 4.01 (d, <i>J</i> = 12.7 Hz, 1H), 3.90–3.65 (m, 4H), 3.58–3.40 (m, 1H), 3.14–2.83 (m, 1H), 2.01–1.88 (m, 1H), 1.79–1.61 (m, 1H), 1.21 (s, 6H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-(((3<i>R</i>,4<i>S</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-4-(2-hydroxy-2-methylpropoxy)benzamide (<b>13b</b>)</h4><div class="NLM_p last">A solution of 4-(benzyloxy)-2-fluorobenzonitrile <b>49</b> (1.0 g, 4.401 mmol), <i>tert</i>-butyl (3<i>R</i>,4<i>S</i>)-3-fluoro-4-hydroxypiperidine-1-carboxylate <b>50</b> (1.065 g, 4.841 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (2.86 g, 8.802 mmol) in DMF (20 mL) was heated at 100 °C for 16 h in a sealed tube. The reaction mixture was diluted with EtOAc and washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The crude was purified by column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexane) to afford <b>51</b> (1.7 g, 90.4%) as a yellow gum. LCMS [M + 1] 427.1; <sup>1</sup>H NMR (400 MHz, <i>d</i>-DMSO) δ ppm 7.66 (d, <i>J</i> = 8.64 Hz, 1H), 7.47–7.35 (m, 5H), 6.99 (s, 1H), 6.78 (dd <i>J</i> = 8.56 Hz, 1H), 5.20 (s, 2H), 4.98–4.86 (m, 3H),4.05–4.03 (m, 2H), 3.84–3.80 (m, 1H), 1.82–1.80 (m, 2H), 1.40 (s, 9H). Using similar conditions as general hydrolysis procedures <b>A</b> to obtain <b>52</b> (900 mg, 51%). LCMS [M + 1] 445.3. Using similar conditions as general HCl deprotection procedures <b>B</b> to obtain <b>53</b> (695 mg, >99%) and used directly in the next step. LCMS [M + 1] 345.2. Using similar conditions as general EDCI coupling procedures <b>F</b> to obtain <b>54</b> (900 mg, 82%). LCMS [M + 1] 547.1. A solution of compound <b>54</b> (900 mg, 1.648 mmol) in EtOH (25 mL) was degassed with argon for about 10 min followed by the addition of Pd/C (400 mg). The resultant mixture was then stirred under H<sub>2</sub> atmosphere (balloon pressure) for 2 h at ambient temperature. The reaction mixture was then filtered through a pad of Celite which was further washed with MeOH. The filtrate was evaporated to dryness in vacuo to afford <b>55</b> (700 mg, 93%) of as a white solid. LCMS [M + 1] 456.9. To a solution of compound <b>55</b> (500 mg, 1.096 mmol) in DMF (8 mL) in a sealed tube were added K<sub>2</sub>CO<sub>3</sub> (302 mg, 2.193 mmol) and isobutylene oxide (0.489 mL, 5.482 mmol). The cap was tightened and the reaction mixture was heated at 100 °C for 16 h. The reaction mixture was brought to room temperature and was diluted with EtOAc. The organic layer was washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude was purified by Combiflash column (5–7% MeOH in DCM) to give <b>13b</b> (150 mg, 26%). LCMS [M + 1] 529.3; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.89 (dd, <i>J</i> = 1.5, 8.8 Hz, 1H), 7.46 (br. s., 1H), 7.41 (br. s., 1H), 7.38–7.34 (m, 2H), 7.33–7.26 (m, 2H), 6.83–6.77 (m, 1H), 6.68 (d, <i>J</i> = 8.8 Hz, 1H), 5.18–5.04 (m, 1H), 5.03–4.95 (m, 1H), 4.73–4.62 (m, 1H), 4.45–4.28 (m, 1H), 4.08–3.88 (m, 1H), 3.85 (s, 1H), 3.79 (s, 2H), 3.74–3.40 (m, 1H), 3.32–3.21 (m, 1H), 3.17–2.80 (m, 1H), 2.05–1.89 (m, 1H), 1.81–1.60 (m, 1H), 1.22 (s, 6H); HRMS for C<sub>25</sub>H<sub>28</sub>F<sub>4</sub>N<sub>2</sub>O<sub>6</sub> MS <i>m</i>/<i>z</i> [M] Calcd 528.1883; found 528.1892.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-(((3<i>S</i>,4<i>R</i>)-3-Fluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)piperidin-4-yl)oxy)-4-((1-hydroxy-2-methylpropan-2-yl)oxy)benzamide (<b>14</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>56</b> (see procedures <b>13b</b> using the appropriate piperidine, 100 mg, 0.219 mmol) in DMF (5 mL) was added 2-bromo-2-methyl propionic acid methyl ester (0.043 mL, 0.329 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (142.5 mg, 0.439 mmol) at room temperature. The reaction mixture was heated to 100–110 °C for 16 h in a sealed tube. The reaction mixture was diluted with EtOAc, and the organic layer was washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solution was then evaporated to obtain the crude compound which was purified through a column using 100–200 SiO<sub>2</sub> with 2% MeOH/DCM to afford <b>57</b> (120 mg, 98%) as an off-white colored sticky compound and used directly in the next step. To a stirred solution of compound <b>57</b> (50 mg, 0.09 mmol) in THF–water (5 mL:1 mL), LiOH (15.1 mg, 0.36 mmol) was added, and the mixture stirred for 4 h at room temperature. The reaction mass was acidified by 1 N HCl (pH 3–4) and extracted with EtOAc. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to obtain compound <b>58</b> (40 mg, 82%) as a light green solid. The next step was performed with this material without any purification. LCMS [M + 1] 543.6. To a solution of compound <b>58</b> (40 mg, 0.074 mmol) in THF (5.0 mL) at 0 °C, TEA (0.021 mL, 0.148 mmol) and isobutyl chloroformate (0.015 mL, 0.111 mmol) were added at 0 °C under N<sub>2</sub>. The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was then filtered through Celite under N<sub>2</sub>. NaBH<sub>4</sub> solution (5.6 mg dissolved in 2 mL water) was then added, and the reaction mixture stirred for another 1 h and then diluted with EtOAc. The organic layer was washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to obtain the crude material, which was purified by preparative TLC using 3% MeOH/DCM to afford <b>14</b> (20 mg, 51%) as an off-white colored solid. LCMS [M + 1] 529.4; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.82 (<i>J</i> = 8.6 Hz, 1H), 7.50 (bs, 1H), 7.43 (bs, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H), 7.29 (d, <i>J</i> = 8.04 Hz, 2H), 6.85 (s, 1H), 6.76 (d, <i>J</i> = 8.64 Hz, 1H), 5.2–4.95 (m, 3H), 4.75–1.33 (m, 1H), 4.10–3.83 (m, 2H), 3.71–3.30 (m, 1H), 3.42 (d, <i>J</i> = 5.72 Hz, 2H), 3.25–2.90 (m, 1H), 1.95–1.93 (m, 1H), 1.85–1.75 (m, 1H), 1.27 (s, 6H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(4-((2-Amino-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl)oxy)piperidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>15</b>)</h4><div class="NLM_p last">See procedures step 1–4 for compound <b>16b</b>, but different coupling using T3P. To a solution of <b>63</b> (50 mg, 0.183 mmol), compound <b>29</b> (40 mg, 0.183 mmol) TEA (0.080 mL, 0.40 mmol) in THF (15 mL) was added T3P (0.27 mL, 0.457 mmol). The reaction mixture was stirred at room temperature for 16 h and then concentrated and diluted with water and DCM. The DCM layer was washed with NaHCO<sub>3</sub> (sat aq) and concentrated. The crude material was purified by prep HPLC to obtain <b>15</b> (18 mg, 21%). LCMS [M + 1] 476.2; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.96 (s, 1H), 7.73 (s, 2H), 7.35 (d, <i>J</i> = 8.68 Hz, 2H), 7.29–7.26 (m, 3H), 4.68–4.65 (m, 1H), 3.81 (s, 3H), 3.77 (s, 2H), 3.66–3.60 (m, 2H), 3.44–3.42 (m, 2H), 1.85–1.82 (m, 2H), 1.60–1.57 (m, 2H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>S</i>)-1-(3-((2-Amino-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl)oxy)pyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>16a</b>)</h4><div class="NLM_p last">See procedures for <b>16b</b> to obtain <b>16a</b> (21 mg, 30%). LCMS [M + 1] 462.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.00 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 1.3 Hz, 1H), 7.76 (s, 1H), 7.39–7.21 (m, 5H), 5.64 (d, <i>J</i> = 8.9 Hz, 2H), 5.20–5.03 (m, 1H), 3.83 (d, <i>J</i> = 2.1 Hz, 3H), 3.79–3.65 (m, 4H), 3.61–3.47 (m, 2H), 2.25–2.17 (m, <i>J</i> = 4.0 Hz, 1H), 2.15–2.05 (m, <i>J</i> = 2.0 Hz, 1H); HRMS for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd: 462.1748; found 462.1752.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>R</i>)-1-(3-((2-Amino-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl)oxy)pyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>16b</b>)</h4><div class="NLM_p last">To a degassed mixture of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (27.5 g, 132 mmol), 6-bromooxazolo[4,5-<i>b</i>]pyridin-2(3H)-one <b>59</b><a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> (23.65 g, 110 mmol), Na<sub>2</sub>CO<sub>3</sub> (37.7 g, 356 mmol), water (117 mL) and 1,4-dioxane (186 mL), was added PdCl<sub>2</sub>(dppf) (6.46 g, 8.83 mmol) and the mixture heated at 90 °C under argon for 18 h. The reaction mixture was cooled to ambient temperature and concentrated under reduced pressure. The residue was suspended in HCl solution (2 L, 1N aqueous) and stirred at ambient temperature for 1 h, and the solids collected by vacuum filtration to afford <b>60</b><a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> as a purple/beige solid (21.4 g, 90%). UPLC [M + 1] 217.08; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.28 (s, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.85 (s, 1H), 3.83 (s, 3H). To a suspension of <b>60</b> (21.4 g, 99.1 mmol) in MeOH (215 mL) was added a solution of NaOH (25.7 g, 643 mmol) in water (215 mL), and the mixture heated at reflux for 18 h. The reaction mixture was cooled to ambient temperature and concentrated under reduced pressure to remove the MeOH. The remaining aqueous phase was adjusted to pH 12 with NaOH, diluted with MeOH (215 mL), and heated at reflux for a further 18 h. The reaction mixture was cooled to ambient temperature, adjusted to pH 6 with HCl (6N aqueous), and concentrated under reduced pressure. The residue was triturated in 9:1 DCM:MeOH (2 × 70 mL) and filtered under vacuum, and the filtrate was concentrated under reduced pressure. The crude material was purified by SiO<sub>2</sub> column chromatography, eluting with MeOH:DCM first, then NH<sub>3</sub>/MeOH (18% ammonia basis) to afford <b>61</b> as a dark green/brown foam (13.5 g, 72%). UPLC [M + 1] 190.98; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.86 (s, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 6.93 (s, 1H), 5.38 (bs, 2H), 3.80 (s, 3H). To a mixture of <b>61</b> (13.3 g, 69.6 mmol), (<i>S</i>)-<i>tert</i>-butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate (22.5 g, 84.8 mmol) and DMF (150 mL), was added Cs<sub>2</sub>CO<sub>3</sub> (34.3 g, 105 mmol) and the mixture heated at 85 °C for 8 h. The reaction mixture was cooled to ambient temperature, poured onto water (1.5 L), diluted with EtOAc (500 mL), and filtered under vacuum. The filtrate layers were separated, and the aqueous layer was extracted into EtOAc (3 × 500 mL). The combined organic extracts were washed with brine (500 mL), dried over MgSO<sub>4</sub>, and filtered, and the solvent removed under reduced pressure. The crude material was purified by SiO<sub>2</sub> column chromatography, eluting with 10% MeOH/EtOAc to afford <b>62</b> (13.0 g, 52%). UPLC [M + 1] 360.26; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.99 (s, 1H), 7.75 (s, 1H), 7.73 (s, 1H), 7.18 (s, 1H), 5.61 (bs, 2H), 4.98–5.02 (m, 1H), 3.80 (s, 3H), 3.60–3.30 (m, 4H), 2.10–2.00 (m, 2H), 1.37 (s, 9H). See general HCl deprotection procedures <b>B</b> using <b>62</b> (13 g, 36.2 mmol) to afford <b>63</b> as the HCl salt (12.7 g, >99%). LCMS [M + 1] 260.05; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.88 (bs, 1H), 9.52 (bs, 1H), 8.22 (s, 1H), 8.09 (bs, 2H), 7.93 (s, 1H), 7.76 (d, <i>J</i> = 4.59 Hz, 2H), 5.48–5.45 (m, 1H), 3.84 (s, 3H), 3.53–3.25 (m, 4H), 2.21–2.12 (m, 2H). Using general HATU coupling procedures <b>C</b> with <b>63</b> (12.3 g, 41.5 mmol) afforded <b>16b</b> as a brown foam (11.4 g, 73%). LCMS [M + 1] 461.92; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.00 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 1.3 Hz, 1H), 7.76 (s, 1H), 7.40–7.29 (m, 3H), 7.29–7.21 (m, 2H), 5.65 (s, 1H), 5.63 (s, 1H), 5.19–5.04 (m, 1H), 3.90–3.84 (m, 1H), 3.83 (d, <i>J</i> = 2.1 Hz, 3H), 3.78–3.67 (m, 3H), 3.62–3.47 (m, 2H), 2.25–2.18 (m, 1H), 2.14–2.06 (m, 1H) ; <sup>19</sup>F NMR (DMSO-<i>d</i><sub>6</sub>, 283 MHz) δ ppm −56.70; HRMS for C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> MS <i>m</i>/<i>z</i> [M] calcd 461.1675; found 461.1661.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-((3<i>S</i>,4<i>S</i>)-3-((2-Amino-5-(1-methyl-1<i>H</i>-imidazol-4-yl)pyridin-3-yl)oxy)-4-fluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>1</b><b>7</b><b>a</b>) and 1-((3<i>R</i>,4<i>R</i>)-3-((2-Amino-5-(1-methyl-1<i>H</i>-imidazol-4-yl)pyridin-3-yl)oxy)-4-fluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>17b</b>)</h4><div class="NLM_p last">A suspension of 6-oxa-3-aza-bicyclo[3.1.0]hexane-3- carboxylic acid benzyl ester <b>64</b> (1.1 g, 5 mmol) in HF·TEA (0.8 mL) was heated to 115 °C in a microwave reactor for 45 min. The reaction mixture was poured into cold saturated NaHCO<sub>3</sub> and then extracted with EtOAc. The EtOAc layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated to an oil. The crude mixture was purified by SiO<sub>2</sub> chromatography (ISCO-Rf-24g column), eluting with a gradient of 0–100% EtOAc-heptane to afford <b>±</b><b>65</b> (974 mg, 81%) as a colorless oil. LCMS-ESI(+) [M + 1] 240; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.42–7.29 (m, 5H), 5.16 (s, 2H), 5.07–4.83 (m, 1H), 4.42 (d, <i>J</i> = 3.2 Hz, 1H), 3.87–3.50 (m, 4H). To a solution of PPh<sub>3</sub> (1.98 g, 7.56 mmol) in THF (21 mL) was added DIAD (1.5 mL, 7.56 mmol). A white precipitate slowly formed. After 60 min, a solution of <b>±</b><b>65</b> (1.51 g, 6.3 mmol) and <i>p</i>-nitrobenzoic acid (1.05 g, 6.3 mmol) in THF (5 mL) was added. The reaction mixture was stirred at room temperature for 67 h and then quenched with saturated NaHCO<sub>3</sub>. The quenched reaction mixture was stirred for 10 min. The mixture was then diluted with water and EtOAc. The EtOAc layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to an oil. The crude reaction mixture was purified by SiO<sub>2</sub> chromatography (ISCO-Rf-40g column) eluting with 0–50% EtOAc-heptane to obtain <b>±</b><b>66</b>. The material was used directly in the next step. LCMS [M + Na] 411. A mixture of <b>±</b><b>66</b> (2.74g) and 1N NaOH (21 mL) in MeOH (30 mL) was stirred at room temperature for 18 h. The reaction mixture was concentrated to remove MeOH and then partitioned between water and EtOAc. The EtOAc layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to an oil. The crude reaction mixture was purified by SiO<sub>2</sub> chromatography (ISCO-Rf-24g column) eluting with a gradient of 0–50% EtOAc-heptane to obtain ± <b>67</b> (860 mg, 57% over 2 steps) as a colorless oil. LCMS-ESI(+) [M + Na] 262; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.43–7.29 (m, 5H), 5.15 (s, 2H), 5.11–4.92 (m, 1H), 4.40–4.25 (m, 1H), 3.92–3.56 (m, 3H), 3.40–3.21 (m, 1H). To a solution of ± <b>67</b> (860 mg, 1.25 mmol) in DCM (30 mL) cooled in an ice–water bath was added pyridine (1.7 mL) followed by the dropwise addition of triflic anhydride (1.5 mL, 1.3 equiv) and the mixture stirred for 45 min. The reaction mixture was quenched with cold citrate buffer (0.5 M, pH 4.5). The DCM layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated to an oil. The crude mixture was purified by SiO<sub>2</sub> chromatography (ISCO-Rf-40g Interchim column) eluting with a gradient of 0–100% EtOAc-heptane to afford <b>±</b><b>68</b> (1.2 g, 91%) as a colorless oil. LCMS-APCI(+) [M + 1] 372, <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.38 (s, 5H), 5.43–4.83 (m, 4H), 3.98 (dd, <i>J</i> = 6.6, 12.0 Hz, 1H), 3.90–3.66 (m, 3H). A solution of 3-(benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine <b>69</b>,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (50 g, 153 mmol), <b>42</b> (26.6 g, 128 mmol), DIPEA (111 mL, 639 mmol) in Industrial Methylated Spirits (750 mL), and water (30 mL) was degassed by bubbling N<sub>2</sub> for 1 h. Pd(dppf)Cl<sub>2</sub>-DCM (5.22 g, 63.9 mmol) was added at once and N<sub>2</sub> was bubbled through the reaction mixture for 15 min. The reaction mixture was stirred at 80 °C for 24 h. The reaction mixture was cooled down and evaporated. The crude was redissolved in DCM (250 mL) and washed with water (250 mL). The organic layer was separated and the water layer was extracted with DCM (2x 250 mL). The organics were combined and evaporated and purified by SiO<sub>2</sub> chromatography eluting 10–15% MeOH/EtOAc to obtain the compound <b>70</b>,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (24.6 g, 69%) as a black solid. LCMS [M + H] 281.12; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.91 (s, 1H), 7.58 (s, 1H), 7.50–7.52 (m, 2H), 7.30–7.42 (m, 5H), 5.68 (bs, 2H), 5.15 (s, 2H), 3.65 (s, 3H). Compound <b>70</b> (68 g, 243 mmol) was dissolved in EtOH (2.5 L). 10% Pd(OH)<sub>2</sub> on carbon (17 g, 12 mmol) was added, and the reaction mixture was hydrogenated at 35 °C, 4 atm of H<sub>2</sub> for 48 h. The reaction slurry was filtered over Celite. Product had low solubility so the Celite pad was thoroughly washed with MeOH:water 1:1 (∼6 L) until washings were colorless. Organics were evaporated to dryness to afford <b>71</b> (40.45 g, 88%) as black solid. LCMS [M + 1] 191; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.44 (bs, 1H), 7.80 (s, 1H), 7.53 (s, 1H), 7.31 (s, 1H), 7.20 (s, 1H), 5.38 (bs, 2H), 3.63 (s, 3H). A mixture of <b>71</b> (256 mg, 1.35 mmol), <b>±</b><b>68</b> (500 mg, 1.35 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (570 mg, 1.75 mmol) in DMF (4.49 mL) was stirred at room temperature for 18 h. The reaction mixture was diluted with water and EtOAc and the EtOAc layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered then concentrated and purified using SiO<sub>2</sub> chromatography (ISCO-Rf-12g column) eluting with a gradient of 0–50% MeOH-EtOAc to obtain <b>±</b><b>72</b> (348 mg, 63%) as a dark brown oil. LCMS-ESI(+) [M + 1] 412; <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ ppm 7.95 (s, 1H), 7.62 (s, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.44–7.24 (m, 6H), 5.41–5.22 (m, 1H, CHF), 5.19–5.08 (m, 3H), 4.01–3.76 (m, 4H), 3.75 (s, 3H). To a solution of <b>±</b><b>72</b> (348 mg, 0. 841 mmol) in DCM (2.8 mL) was added 33% HBr in AcOH (738 uL). The reaction mixture was stirred at room temperature for 26 h and then concentrated to a tan solid. The solid was suspended in MTBE, sonicated and filtered to obtain <b>±</b><b>73</b> (399 mg, >99%). LCMS-ESI(+) [M + 1] 278; <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ ppm 8.98 (s, 1H), 8.07 (s, 1H), 7.97 (d, <i>J</i> = 1.5 Hz, 1H), 7.94 (s, 1H), 5.73–5.51 (m, 2H), 4.10–4.02 (m, 1H), 4.00 (s, 3H), 3.97–3.74 (m, 4H). Using general HATU procedures <b>C</b> with <b>±</b><b>73</b> (65.9 mg, 0.15 mmol) and <b>29</b> (33 mg, 0.15 mmol) to afford <b>±</b><b>17</b> (50 mg, 70%) as a glass. The enantiomers were separated by chiral SFC to give <b>17a</b> as a white solid (16.25 mg, 22%) ∼99% ee (−); LCMS-ESI(+) [M + H] 480; HRMS [M] calc for C<sub>22</sub>H<sub>22</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub> 479.1581; 479.1586; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.01 (d, <i>J</i> = 1.5 Hz, 1H), 7.58 (s, 1H), 7.46 (s, 2H), 7.42–7.23 (m, 4H), 5.74 (d, <i>J</i> = 8.8 Hz, 2H), 5.51–5.25 (m, 1H), 5.24–5.08 (m, 1H), 4.23–3.69 (m, 6H), 3.67 (d, <i>J</i> = 1.5 Hz, 3H) and <b>17b</b> as a white solid (16 mg, 22%) >99% ee (+); LCMS-ESI(+) [M + 1] 480; HRMS for C<sub>22</sub>H<sub>22</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd 480.1653; 480.1655; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.00 (d, <i>J</i> = 1.5 Hz, 1H), 7.56 (s, 1H), 7.45 (s, 2H), 7.40–7.18 (m, 4H), 5.73 (d, <i>J</i> = 8.8 Hz, 2H), 5.54–5.01 (m, 2H), 4.22–3.68 (m, 6H), 3.66 (d, <i>J</i> = 1.2 Hz, 3H).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>R</i>)-1-(4-((2-Amino-5-(1-methyl-1<i>H</i>-imidazol-4-yl)pyridin-3-yl)oxy)-3,3-difluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>1</b><b>8</b><b>a</b>) and (<i>S</i>)-1-(4-((2-Amino-5-(1-methyl-1<i>H</i>-imidazol-4-yl)pyridin-3-yl)oxy)-3,3-difluoropyrrolidin-1-yl)-2-(4-(trifluoromethoxy)phenyl)ethan-1-one (<b>18b</b>)</h4><div class="NLM_p">Compound <b>74</b> (540 mg, 2.42 mmol), 3-fluoro-2-nitropyridine <b>75</b> (361 mg, 2.54 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (1.58 g, 4.84 mmol) in THF (12.1 mL, 0.2 M) was heated to reflux overnight. The solvent was evaporated, water added, and the mixture extracted with EtOAc. The solvent was removed and the residue was purified by column chromatography with 35% EtOAc/heptane to give <b>76</b> (760 mg, 91% yield) as a light yellow oil. LCMS [M+H<sub>2</sub>O] 363.10; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.23 (d, <i>J</i> = 3.91 Hz, 1H), 7.55–7.69 (m, 2H), 4.85 (br. s., 1H), 3.70–3.99 (m, 4H), 1.50 (s, 9H). A mixture of compound <b>76</b> (760 mg, 2.20 mmol) and Pd/C (5% wet, 234 mg, 2.20 mmol) in MeOH (22.0 mL, 0.1 M) was degassed and purged with H<sub>2</sub>, and stirred at room temperature under a H<sub>2</sub> balloon for 4 h. The Pd/C was filtered, and the solvent was removed to give <b>77</b> (700 mg, >99%) as a light yellow oil which was used without further purification. LCMS [M + 1] 316.10. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.78 (d, <i>J</i> = 5.50 Hz, 1H), 7.00 (d, <i>J</i> = 6.97 Hz, 1H), 6.63 (dd, <i>J</i> = 7.89, 5.07 Hz, 1H), 4.67 (br. s., 3H), 3.62–3.94 (m., 4H) 1.49 (s, 9H). To a mixture of compound <b>77</b> (1.29 g, 4.08 mmol) in DMF (81.6 mL, 0.05 M) was added NBS (918 mg, 4.90 mmol) portion-wise, and the whole mixture was stirred at room temperature for 5 min, after which water and EtOAc were added. The layers were separated, and the organic layer was washed with water 3 times followed by brine, concentrated, and purified by column chromatography with 40% EtOAc/heptane to give <b>78</b> (1.32 g, 82%) as a red solid. LCMS [M + 1] 394.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.83 (s, 1H), 7.10 (s, 1H), 4.75 (br. s., 2H), 4.69 (br. s., 1H), 3.87 (br. s., 2H), 3.75 (br. s., 1H), 3.66 (br. s., 1H), 1.46–1.51 (m, 9H). A mixture of <b>78</b> (760 mg, 1.93 mmol), 1-methyl-4-(tributylstannyl)-1<i>H</i>-imidazole <b>79</b> (1.43 g, 3.86 mmol) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (136 mg, 0.193 mmol) in DMF (20 mL, 0.1 M) was microwaved at 120 °C for 30 min. The reaction mixture was then diluted with water and EtOAc. The Pd was filtered, and the aqueous was extracted with EtOAc 3 times. The organic layers were combined, concentrated and purified by column chromatography with 10% MeOH/EtOAc to afford <b>80</b> (690 mg, 90%) as brown oil which solidified upon vacuum. LCMS [M + 1] 396.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.08 (br. s., 1H), 7.50 (br. s., 1H), 7.43 (br. s., 1H), 7.10 (br. s., 1H), 4.83 (br. s., 1H), 4.69 (br. s., 2H), 3.84 (br. s., 3H), 3.62–3.81 (m, 4H), 1.46 (s, 9H). General TFA deprotection procedures G: Compound <b>80</b> (700 mg, 1.77 mmol) was dissolved in 5 mL TFA, and stirred at room temperature for 1 h. The solvent was evaporated, and the residue was dried over vacuum to give 2.46 g of brown oil, which was used directly in the next coupling step. General HATU procedure <b>C</b> was used with <b>29</b>. The crude material was purified by chiral SFC to afford <b>18a</b> (317 mg, 35%) and <b>18b</b> (309 mg, 35%).</div><div id="sec4_1_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Compound <b>18a</b></h5><div class="NLM_p last">LCMS [M + 1] 498.20; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.03 (s, 1H), 7.58 (s, 1H), 7.54 (br. s., 1H), 7.44 (s, 1H), 7.24–7.41 (m, 4H), 5.77 (d, <i>J</i> = 10.88 Hz, 2H), 5.21–5.40 (m, 1H), 4.18–4.46 (m, 1H), 3.99–4.18 (m, 1H), 3.87–3.99 (m, 1H), 3.73–3.86 (m, 3H), 3.60–3.69 (m, 3H); HRMS for C<sub>22</sub>H<sub>21</sub>F<sub>5</sub>N<sub>5</sub>O<sub>3</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd: 498.1559; found 498.1561.</div></div><div id="sec4_1_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Compound <b>18b</b></h5><div class="NLM_p last">LCMS [M + 1] 498.20; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.03 (s, 1H) 7.58 (s, 1H) 7.54 (br. s., 1H) 7.44 (s, 1H) 7.24–7.41 (m, 4H) 5.77 (d, <i>J</i> = 10.76 Hz, 2H) 5.21–5.38 (m, 1H) 4.17–4.46 (m, 1H) 3.98–4.17 (m, 1H) 3.87–3.98 (m, 1H) 3.69–3.86 (m, 3H) 3.67 (d, <i>J</i> = 1.71 Hz, 3H); HRMS for C<sub>22</sub>H<sub>21</sub>F<sub>5</sub>N<sub>5</sub>O<sub>3</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd: 498.1559; found 498.1562.</div></div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>S</i>)-6-Amino-5-((4,4-difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yl)oxy)-<i>N</i>-methylnicotinamide (<b>19</b>)</h4><div class="NLM_p last">Compound <b>78</b> (500 mg, 1.27 mmol) was dissolved in MeOH (35 mL, 0.036 M), Pd(OAc)<sub>2</sub> (23 mg, 0.10 mmol), Et<sub>3</sub>N (575 mg, 5.68 mmol), DPPF (47 mg, 0.085 mmol) and DMF (575 mg, 7.8 mmol) were added. The reaction mixture was heated at 80 °C overnight under 5.2 bar CO, and then cooled to room temperature, filtered, and concentrated. The product was purified by column chromatography with 50% EtOAc/heptane to afford <b>81</b> (307 mg, 65% yield) an off-white solid. LCMS [M + 1] 374.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.44 (s, 1H), 7.55 (s, 1H), 5.38 (br. s., 2H), 4.82 (br. s., 1H), 3.82–3.97 (m, 6H), 3.78 (br. s., 1H), 1.49 (s, 9H). General TFA procedures <b>G</b> and HATU coupling procedures <b>C</b> were used to afford <b>82</b> (370 mg, 95%). LCMS [M + 1] 475.90; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.23–8.29 (m, 1H) 7.57 (dd, <i>J</i> = 10.51, 1.47 Hz, 1H) 7.25–7.40 (m, 4H) 6.86 (br. s., 2H) 5.32–5.48 (m, 1H) 4.17–4.46 (m, 1H) 3.99–4.17 (m, 2H) 3.88–3.99 (m, 1H) 3.79 (d, <i>J</i> = 1.47 Hz, 3H) 3.64–3.77 (m, 2H) 3.18 (d, <i>J</i> = 5.26 Hz, 2H). Compound <b>82</b> (370 mg, 0.778 mmol) was dissolved in MeOH (5 mL, 0.2 M), and NaOH (2.0 N, 156 mg, 1.94 mL, 3.89 mmol) was added. The reaction mixture was heated at 60 °C for 1 h. MeOH was evaporated, and the mixture was acidified by conc. HCl. The material was lyophilized to afford (614 mg, >100% yield) as a white solid which was used without further purification. LCMS [M + 1] 461.85. General HATU coupling procedure <b>C</b> was used with methyl amine followed by standard chiral separation to obtain <b>19</b> (76 mg, 41%); LCMS [M + 1] 475.20; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.16 (s, 1H) 8.05–8.14 (m, 1H) 7.58 (br. s., 1H) 7.24–7.43 (m, 4H) 6.43 (br. s., 1H) 6.40 (br. s., 1H) 5.18–5.35 (m, 1H) 4.17–4.46 (m, 1H) 4.08–4.17 (m, 1H) 3.85–3.99 (m, 1H) 3.63–3.85 (m, 3H) 2.69–2.83 (m, 3H);. HRMS for C<sub>20</sub>H<sub>20</sub>F<sub>5</sub>N<sub>4</sub>O<sub>4</sub> MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> Calcd: 475.1399, Found: 475.1404.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>S</i>)-6-Amino-5-((4,4-difluoro-1-(2-(4-(trifluoromethoxy)phenyl)acetyl)pyrrolidin-3-yl)oxy)-<i>N</i>-ethylnicotinamide (<b>20</b>)</h4><div class="NLM_p last">See procedures for <b>19</b> and general HATU coupling procedure <b>C</b> with ethyl amine, followed by standard chiral separation (20 mg, 25%); LCMS [M + 1] 489.00; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.11–8.21 (m, 2H), 7.59 (d, <i>J</i> = 2.08 Hz, 1H), 7.25–7.41 (m, 4H), 6.41 (s, 1H), 6.44 (s, 1H), 5.19–5.37 (m, 1H), 4.17–4.47 (m, 1H), 4.00–4.17 (m, 1H), 3.87–4.00 (m, 1H), 3.65–3.84 (m, 3H), 3.22–3.29 (m, 2H), 1.12 (td, <i>J</i> = 7.21, 1.47 Hz, 3H).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Computational Modeling Methods</h3><div class="NLM_p last">All molecules were prepared for docking simulation using LigPrep 2.5 (Schrödinger) to consider proper protonation states and tautomers. The docking simulation was performed with Glide 5.8 (Schrödinger) using protein models based on in-house X-ray structures. Docking poses were minimized using the OPLS2005 force field.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Metabolism of Compounds in Human Liver Microsomes (HLM) in Vitro</h3><div class="NLM_p last">Stability of compounds in HLM in vitro was determined at a compound concentration of 1 μM. Incubations (32.5 μL) contained HLM (Pfizer Global supply) at a protein concentration of 0.71 mg/mL and were supplemented with a reducing equivalent regenerating system (isocitrate/isocitrate dehydrogenase). The assay cocktail was incubated at 37 °C for up to 60 min in the presence and absence of NADP<sup>+</sup> (2 mM); samples withdrawn at time intervals, and reactions were terminated by addition to 75 μL of acetonitrile and 65 μL of water. Samples were centrifuged to remove precipitated protein, and the supernatants were dried under a stream of nitrogen. Dried extracts were reconstituted in 100 μL of 50/50 acetonitrile/water +0.1% formic acid and further diluted with 100 μL of 5/95 acetonitrile/water containing 0.1% formic acid. Following further centrifugation, samples (5 μL) were analyzed by LC-MS/MS using a QTOF Premier (s/n: HAA053) mass spectrometer (Waters) operated in positive ion mode, and data were acquired in the multiple reaction monitoring (MRM) mode using argon as the collision gas. The natural log of ratios of peak areas of test compound to a reference internal standard were plotted against incubation time, and apparent intrinsic clearance (CL<sub>int</sub>) was calculated from the slope of the line.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Metabolism of Compounds in Human Hepatocytes (hHep) in Vitro</h3><div class="NLM_p last">Stability of compounds in human hepatocytes (hHEP) (Bioreclamation Inc., NY, United States) in vitro was determined at a compound concentration of 1 μM. Incubations (22.5 μL) in Williams E medium containing 0.75 × 10<sup>6</sup> cells/mL were carried out at 37 °C in an atmosphere of 95/5 air:CO<sub>2</sub> at 95% humidity for up to 240 min. Incubations were terminated with 50 μL of cold acetonitrile, and samples were centrifuged to remove precipitated protein. Samples of 35 μL of supernatant were diluted with 120 μL of water prior to analysis of compound by LC-MS/MS according to the method described for microsomal incubations. CL<sub>int</sub> was calculated as described for HLM above.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Determination of Permeability in RRCK Cell Monolayers</h3><div class="NLM_p last">Apparent permeability (<i>P</i><sub>app</sub>) was determined in the apical to basolateral (A/B) direction in monolayers of low transporter expressing MDCK cells (RRCK) according to published methods.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Determination of Efflux by P-gp and BCRP</h3><div class="NLM_p last">Apparent permeability (<i>P</i><sub>app</sub>) was determined in apical to basolateral (A/B) and basolateral to apical (B/A) directions in monolayers of MDCK cells transfected with either human MDR1 or human BCRP according to published methods.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Efflux ratio (ER) was used as an index of efflux, whereby ER = <i>P</i><sub>app</sub> B/A/<i>P</i><sub>app</sub> A/B.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00633" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00633" class="ext-link">10.1021/acs.jmedchem.8b00633</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings are provided along with surface plasmon resonance data for ligands <b>10b</b>, <b>13b</b>, and <b>19</b>; Trk cell-based assay protocols; metabolite identification data for compounds <b>10b</b>, <b>13b</b>, and <b>19</b>; kinase selectivity data for compounds <b>10b, 13b</b>, and <b>19</b>; ultraviolet irradiation-induced thermal hyperalgesia data in rats for <b>10b</b>, <b>13b</b>, and <b>19</b>; measurement of CNS penetration in rats; solubility determination method; chemical abbreviations; general experimental conditions; commercial starting materials; NMR and LCMS spectra of <b>10b</b>, <b>13b</b>, and <b>19</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Excel spreadsheet of compound names and abbreviations (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf">jm8b00633_si_001.pdf (1.32 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_002.csv">jm8b00633_si_002.csv (5.47 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are 6DKW for compound <b>3</b>, 6DKB for compound <b>10b</b>, 6DKG for compound <b>13b</b>, and 6DKI for compound <b>19</b>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00633" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharan K. Bagal</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D
U.K., The Portway Building,
Granta Park, Cambridge CB21 6GS, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0955-271X" title="Orcid link">http://orcid.org/0000-0003-0955-271X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#becdd6dfccdfd090dcdfd9dfd2fed1cbcad2d1d1d590ddd1d3"><span class="__cf_email__" data-cfemail="14677c7566757a3a7675737578547b6160787b7b7f3a777b79">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Andrews</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., Sandwich, Kent CT13 9NJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce M. Bechle</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianwei Bian</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Bilsland</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Blakemore</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D
U.K., The Portway Building,
Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John F. Braganza</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Bungay</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics & Metabolism, Pfizer Worldwide
R&D U.K., The Portway
Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew S. Corbett</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ciaran N. Cronin</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingrong Jean Cui</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca Dias</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil J. Flanagan</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha E. Greasley</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Grimley</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim James</span> - <span class="hlFld-Affiliation affiliation">Peakdale
Molecular, Discovery
Park House, Ramsgate Road, Sandwich CT13 9ND, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Johnson</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Kitching</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle L. Kraus</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Indrawan McAlpine</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asako Nagata</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sacha Ninkovic</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kiyoyuki Omoto</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D
U.K., The Portway Building,
Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephanie Scales</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah E. Skerratt</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Worldwide R&D
U.K., The Portway Building,
Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianmin Sun</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Tran-Dubé</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gareth J. Waldron</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fen Wang</span> - <span class="hlFld-Affiliation affiliation">Pfizer Worldwide
R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph S. Warmus</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6450-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Dr. Katrina Gore for statistical analysis of UVIH data; Dr. Beth Lunney, Dr. Alan Brown, Dr. Martin Wythes, Dr. Nigel Swain, and Dr. Martin Edwards for useful discussions; Neal Sach for synthesis; and TCG Lifesciences for synthesis and screening.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AB</td><td class="NLM_def"><p class="first last">apical to basolateral</p></td></tr><tr><td class="NLM_term">AO</td><td class="NLM_def"><p class="first last">aldehyde oxidase</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">basolateral to apical</p></td></tr><tr><td class="NLM_term">B<sub>2</sub>Pin<sub>2</sub></td><td class="NLM_def"><p class="first last">bis(pinacolato)diboron</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BDNF</td><td class="NLM_def"><p class="first last">brain derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub></td><td class="NLM_def"><p class="first last">unbound brain/plasma concentration ratio</p></td></tr><tr><td class="NLM_term">ID</td><td class="NLM_def"><p class="first last">compound identification number</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>avg</sub></td><td class="NLM_def"><p class="first last">average plasma concentration</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go related gene</p></td></tr><tr><td class="NLM_term">hHep</td><td class="NLM_def"><p class="first last">human hepatocytes</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">association rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>d</sub></td><td class="NLM_def"><p class="first last">dissociation rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">dissociation constant</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">log <i>d</i></td><td class="NLM_def"><p class="first last">distribution coefficient at pH 7.4</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madine Darby canine kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein (<i>p-</i>glycoprotein)</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NT3</td><td class="NLM_def"><p class="first last">neurotrophin 3</p></td></tr><tr><td class="NLM_term">NT4</td><td class="NLM_def"><p class="first last">neurotrophin 4</p></td></tr><tr><td class="NLM_term">NGF</td><td class="NLM_def"><p class="first last">nerve growth factor</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last"><i>p</i>-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney cell line, permeability measured with low-efflux MDCK cell line</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomyosin related kinase</p></td></tr><tr><td class="NLM_term">UVIH</td><td class="NLM_def"><p class="first last">ultraviolet burn induced hyperalgesia</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaper, S. D.</span></span> <span> </span><span class="NLM_article-title">The Neurotrophin Family of Neurotrophic Factors: An Overview</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>846</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-536-7_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2F978-1-61779-536-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=846&publication_year=2012&pages=1-12&author=S.+D.+Skaper&title=The+Neurotrophin+Family+of+Neurotrophic+Factors%3A+An+Overview&doi=10.1007%2F978-1-61779-536-7_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin family of neurotrophic factors: an overview</span></div><div class="casAuthors">Skaper, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">846</span>
        (<span class="NLM_cas:issue">Neurotrophic Factors</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of closely related proteins that were first identified as survival factors for sympathetic and sensory neurons and have since been shown to control a no. of aspects of survival, development, and function of neurons in both the central and peripheral nervous systems.  Limiting quantities of neurotrophins during development control the nos. of surviving neurons to ensure a match between neurons and the requirement for a suitable d. of target innervation.  Biol. effects of each of the four mammalian neurotrophins are mediated through activation of one or more of the three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC).  In addn., all neurotrophins activate the p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily.  Neurotrophin engagement of Trk receptors leads to activation of Ras, phosphatidylinositol 3-kinase, phospholipase C-γl, and signaling pathways controlled through these proteins, including the mitogen-activated protein kinases.  Neurotrophin availability is required into adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival, morphol., and differentiation.  This chapter will provide an overview of neurotrophin biol., their receptors, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx93j5UxkhubVg90H21EOLACvtfcHk0liHnqwwHCN0Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ&md5=5f575aa213b4e790fc7d1d3b44ead678</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-536-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-536-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DSkaper%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Neurotrophin%2520Family%2520of%2520Neurotrophic%2520Factors%253A%2520An%2520Overview%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D846%26spage%3D1%26epage%3D12%26doi%3D10.1007%2F978-1-61779-536-7_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walicke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span> <span> </span><span class="NLM_article-title">Novel Class of Pain Drugs Based on Antagonism of NGF</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.tips.2005.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=85-91&issue=2&author=F.+F.+Heftiauthor=A.+Rosenthalauthor=P.+A.+Walickeauthor=S.+Wyattauthor=G.+Vergaraauthor=D.+L.+Sheltonauthor=A.+M.+Davies&title=Novel+Class+of+Pain+Drugs+Based+on+Antagonism+of+NGF&doi=10.1016%2Fj.tips.2005.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHefti%26aufirst%3DF.%2BF.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26aulast%3DWyatt%26aufirst%3DS.%26aulast%3DVergara%26aufirst%3DG.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26atitle%3DNovel%2520Class%2520of%2520Pain%2520Drugs%2520Based%2520on%2520Antagonism%2520of%2520NGF%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.1016%2Fj.tips.2005.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1521</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0901510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1056%2FNEJMoa0901510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=20942668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1521&issue=16&author=N.+E.+Laneauthor=T.+J.+Schnitzerauthor=C.+A.+Birbaraauthor=M.+Mokhtaraniauthor=D.+L.+Sheltonauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Tanezumab+for+the+Treatment+of+Pain+from+Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMoa0901510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tanezumab for the treatment of pain from osteoarthritis of the knee</span></div><div class="casAuthors">Lane, Nancy E.; Schnitzer, Thomas J.; Birbara, Charles A.; Mokhtarani, Masoud; Shelton, David L.; Smith, Mike D.; Brown, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1521</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Increased expression of nerve growth factor in injured or inflamed tissue is assocd. with increased pain.  This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor.  Methods: We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 Ag per kg of body wt.) or placebo on days 1 and 56.  The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy.  We also assessed pain, stiffness, and phys. function using the Western Ontario and Mc-Master Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatol.  Committee and Osteoarthritis Research Society International Standing Committee for Clin. Trials Response Criteria Initiative (OMERACT-OARSI); and safety.  Results: When averaged over weeks 1 through 16, the mean redns. from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P < 0.001).  Tanezumab, as compared with placebo, was also assocd. with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P ≤ 0.001).  The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P < 0.001).  The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, resp.  The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%).  Conclusions: In this proof-of-concept study, treatment with tanezumab was assocd. with a redn. in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmt4PNNZ44LVg90H21EOLACvtfcHk0liHnqwwHCN0Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI&md5=fe69490dfa3d47fe8a0c286d6b020d57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0901510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0901510%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DBirbara%26aufirst%3DC.%2BA.%26aulast%3DMokhtarani%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DTanezumab%2520for%2520the%2520Treatment%2520of%2520Pain%2520from%2520Osteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D16%26spage%3D1521%26doi%3D10.1056%2FNEJMoa0901510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Long-Term Open-Label Study of Tanezumab for Moderate to Severe Osteoarthritic Knee Pain</span>. <i>Osteoarthritis Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.joca.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=21251985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=639-646&issue=6&author=T.+J.+Schnitzerauthor=N.+E.+Laneauthor=C.+Birbaraauthor=M.+D.+Smithauthor=S.+L.+Simpsonauthor=M.+T.+Brown&title=Long-Term+Open-Label+Study+of+Tanezumab+for+Moderate+to+Severe+Osteoarthritic+Knee+Pain&doi=10.1016%2Fj.joca.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain</span></div><div class="casAuthors">Schnitzer T J; Lane N E; Birbara C; Smith M D; Simpson S L; Brown M T</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain.  DESIGN:  The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial.  All patients (N=281) received infusions of tanezumab 50μg/kg on Days 1 and 56 with subsequent doses administered at 8-week intervals (up to a total of eight infusions).  The primary endpoint of this study was safety.  Effectiveness evaluations included overall knee pain, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0-100 point visual analog scales.  RESULTS:  Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse events (AEs; 7.5%).  The rate of serious AEs was also low (2.8%) with none considered treatment-related.  Few AEs of abnormal peripheral sensation were reported; hypoesthesia was reported by nine patients (3.2%), paresthesia by seven patients (2.5%), and hyperesthesia, peripheral neuropathy, and sensory disturbance were each reported by one patient (0.4% for each).  Most AEs of abnormal peripheral sensation were rated as mild (95%) and the majority (65%) resolved before study completion.  At Week 8, overall knee pain and SGA improved from baseline by a mean (± standard error) of -12.8 (±1.78) and 8.0 (±1.66), respectively.  Similar improvements occurred for WOMAC subscales.  CONCLUSIONS:  Repeated injections of tanezumab in patients with moderate to severe knee OA provide continued pain relief and improved function with a low incidence of side effects.  Additional studies to define the efficacy and duration of pain reduction and to provide a more complete assessment of long-term safety are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP3rNjPk9h4A20zIbnCCI3fW6udTcc2eYDr7l60i8En7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D&md5=e489a54f543455004fe879ce02744c64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DSimpson%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DLong-Term%2520Open-Label%2520Study%2520of%2520Tanezumab%2520for%2520Moderate%2520to%2520Severe%2520Osteoarthritic%2520Knee%2520Pain%26jtitle%3DOsteoarthritis%2520Cartilage%26date%3D2011%26volume%3D19%26issue%3D6%26spage%3D639%26epage%3D646%26doi%3D10.1016%2Fj.joca.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldwin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossons, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholfield, D.</span></span> <span> </span><span class="NLM_article-title">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated with Interstitial Cystitis</span>. <i>J. Urol. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2010.12.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.juro.2010.12.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=1716-1721&issue=5&author=R.+J.+Evansauthor=R.+M.+Moldwinauthor=N.+Cossonsauthor=A.+Darekarauthor=I.+W.+Millsauthor=D.+Scholfield&title=Proof+of+Concept+Trial+of+Tanezumab+for+the+Treatment+of+Symptoms+Associated+with+Interstitial+Cystitis&doi=10.1016%2Fj.juro.2010.12.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis</span></div><div class="casAuthors">Evans, R. J.; Moldwin, R. M.; Cossons, N.; Darekar, A.; Mills, I. W.; Scholfield, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1716-1721</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.  Materials and Methods: Patients with interstitial cystitis received a single i.v. dose of 200 μg/kg tanezumab or placebo.  Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days.  Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment.  The primary end point was change in av. daily numerical rating scale pain score from baseline to week 6.  Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 h, and mean voided vol. per micturition.  The incidence of adverse events was also assessed.  Results: A total of 34 patients received tanezumab and 30 received placebo.  At week 6 tanezumab produced a significant redn. from baseline in av. daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]).  A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo.  Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided vol. per micturition.  The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%).  Conclusions: Tanezumab has shown preliminary efficacy in the treatment of pain assocd. with interstitial cystitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8VBnrLDcAbVg90H21EOLACvtfcHk0lhqdHHuRM5ldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D&md5=5ac5f081d2cc6eb9b8190148923bcd4f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2010.12.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2010.12.088%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DMoldwin%26aufirst%3DR.%2BM.%26aulast%3DCossons%26aufirst%3DN.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DI.%2BW.%26aulast%3DScholfield%26aufirst%3DD.%26atitle%3DProof%2520of%2520Concept%2520Trial%2520of%2520Tanezumab%2520for%2520the%2520Treatment%2520of%2520Symptoms%2520Associated%2520with%2520Interstitial%2520Cystitis%26jtitle%3DJ.%2520Urol.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2011%26volume%3D185%26issue%3D5%26spage%3D1716%26epage%3D1721%26doi%3D10.1016%2Fj.juro.2010.12.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borenstein, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2248</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.pain.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=2248-2258&issue=10&author=N.+Katzauthor=D.+G.+Borensteinauthor=C.+Birbaraauthor=C.+Bramsonauthor=M.+A.+Nemethauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Efficacy+and+Safety+of+Tanezumab+in+the+Treatment+of+Chronic+Low+Back+Pain&doi=10.1016%2Fj.pain.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DBorenstein%26aufirst%3DD.%2BG.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DBramson%26aufirst%3DC.%26aulast%3DNemeth%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tanezumab%2520in%2520the%2520Treatment%2520of%2520Chronic%2520Low%2520Back%2520Pain%26jtitle%3DPain%26date%3D2011%26volume%3D152%26issue%3D10%26spage%3D2248%26epage%3D2258%26doi%3D10.1016%2Fj.pain.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Discover Non-ATP Site Kinase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1039/C2MD20180A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1039%2FC2MD20180A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=41-51&issue=1&author=L.+K.+Gavrinauthor=E.+Saiah&title=Approaches+to+Discover+Non-ATP+Site+Kinase+Inhibitors&doi=10.1039%2FC2MD20180A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to discover non-ATP site kinase inhibitors</span></div><div class="casAuthors">Gavrin, Lori Krim; Saiah, Eddine</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The catalytic domain of kinases shows a high degree of sequence homol., esp. for kinases that belong to the same family.  They share a common ATP binding site with a conserved activation loop and similar three-dimensional structure.  Consequently, a major challenge in kinase research exists in achieving selectivity among the >500 family members, since they all process the same substrate.  In addn. to requiring selectivity against other kinases, ATP site inhibitors must also bind tightly to overcome the high physiol. concn. of ATP in the cell.  Furthermore, the development of novel ATP site inhibitors is becoming increasingly challenging, as many ATP competitive scaffolds have previously been disclosed.  In order to develop compds. with better selectivity among kinases, inhibitors that bind outside the ATP site show great promise and are currently being explored by many groups.  This review will highlight the most commonly used methods to discover small mol. Type III and IV kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xJcf4-RJ9rVg90H21EOLACvtfcHk0lhqdHHuRM5ldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N&md5=97acf2247e5516c1649c1d964c867656</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2FC2MD20180A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20180A%26sid%3Dliteratum%253Aachs%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DSaiah%26aufirst%3DE.%26atitle%3DApproaches%2520to%2520Discover%2520Non-ATP%2520Site%2520Kinase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D41%26epage%3D51%26doi%3D10.1039%2FC2MD20180A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lh2FjdmxfqCqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&issue=22&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+Discovery+of+a+Potent%2C+Selective%2C+and+Peripherally+Restricted+Pan-Trk+Inhibitor+%28PF-06273340%29+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lh2FjdmxfqCqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520Discovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Peripherally%2520Restricted%2520Pan-Trk%2520Inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Function of NGF/TrkA Signaling in the Cholinergic Neurons of the Murine Basal Forebrain</span>. Ph.D Dissertation, <span class="NLM_publisher-name">Ludwig-Maximilians-University</span>, <span class="NLM_publisher-loc">Munich</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mueller&title=In+Vivo+Function+of+NGF%2FTrkA+Signaling+in+the+Cholinergic+Neurons+of+the+Murine+Basal+Forebrain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DM.%26atitle%3DIn%2520Vivo%2520Function%2520of%2520NGF%252FTrkA%2520Signaling%2520in%2520the%2520Cholinergic%2520Neurons%2520of%2520the%2520Murine%2520Basal%2520Forebrain%26pub%3DLudwig-Maximilians-University%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span>; <span class="NLM_string-name">Kordower, J. H.</span></span> In  <i>Nerve Growth Factor Systems in Alzheimer’s Disease</i>; <span class="NLM_publisher-name">Kluwer Academic/Plenum Publishers</span>: <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">731</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=681-731&author=E.+J.+Mufson&author=J.+H.+Kordower&title=Nerve+Growth+Factor+Systems+in+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26btitle%3DNerve%2520Growth%2520Factor%2520Systems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26pub%3DKluwer%2520Academic%252FPlenum%2520Publishers%26date%3D1999%26spage%3D681%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ortiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4065</span>– <span class="NLM_lpage">4079</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6314-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1523%2FJNEUROSCI.6314-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22442072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=4065-4079&issue=12&author=E.+Sanchez-Ortizauthor=D.+Yuiauthor=D.+Songauthor=Y.+Liauthor=J.+L.+Rubensteinauthor=L.+F.+Reichardtauthor=L.+F.+Parada&title=TrkA+Gene+Ablation+in+Basal+Forebrain+Results+in+Dysfunction+of+the+Cholinergic+Circuitry&doi=10.1523%2FJNEUROSCI.6314-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry</span></div><div class="casAuthors">Sanchez-Ortiz, Efrain; Yui, Daishi; Song, Dongli; Li, Yun; Rubenstein, John L.; Reichardt, Louis F.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4065-4079</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Dysfunction of basal forebrain cholinergic neurons (BFCNs) is an early pathol. hallmark of Alzheimer's disease (AD).  Numerous studies have indicated that nerve growth factor (NGF) supports survival and phenotypic differentiation of BFCNs.  Consistent with a potential link to AD pathogenesis, TrkA, a NGF receptor, is expressed in cholinergic forebrain neuronal populations including those in BF and striatum, and is markedly reduced in individuals with mild cognitive impairment (MCI) without dementia and early-stage AD.  To investigate the role of TrkA in the development, connectivity, and function of the BF cholinergic system and its contribution to AD pathol., we have generated a forebrain-specific conditional TrkA knock-out mouse line.  Our findings show a key role for TrkA signaling in establishing the BF cholinergic circuitry through the ERK pathway, and demonstrate that the normal developmental increase of choline acetyltransferase expression becomes critically dependent on TrkA signaling before neuronal connections are established.  Moreover, the anatomical and physiol. deficits caused by lack of TrkA signaling in BFCNs have selective impact on cognitive activity.  These data demonstrate that TrkA loss results in cholinergic BF dysfunction and cognitive decline that is reminiscent of MCI and early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qproimMfdrVg90H21EOLACvtfcHk0lh18hEo_iJ53Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D&md5=fac45c446552ea69e72cdd15200d54c2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6314-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6314-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Ortiz%26aufirst%3DE.%26aulast%3DYui%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRubenstein%26aufirst%3DJ.%2BL.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DTrkA%2520Gene%2520Ablation%2520in%2520Basal%2520Forebrain%2520Results%2520in%2520Dysfunction%2520of%2520the%2520Cholinergic%2520Circuitry%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26issue%3D12%26spage%3D4065%26epage%3D4079%26doi%3D10.1523%2FJNEUROSCI.6314-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span> <span> </span><span class="NLM_article-title">Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1144</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1196/annals.1418.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1196%2Fannals.1418.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1144&publication_year=2008&pages=97-112&author=M.+P.+Mattson&title=Glutamate+and+Neurotrophic+Factors+in+Neuronal+Plasticity+and+Disease&doi=10.1196%2Fannals.1418.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1196%2Fannals.1418.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1418.005%26sid%3Dliteratum%253Aachs%26aulast%3DMattson%26aufirst%3DM.%2BP.%26atitle%3DGlutamate%2520and%2520Neurotrophic%2520Factors%2520in%2520Neuronal%2520Plasticity%2520and%2520Disease%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2008%26volume%3D1144%26spage%3D97%26epage%3D112%26doi%3D10.1196%2Fannals.1418.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span> <span> </span><span class="NLM_article-title">TrkB Signalling Pathways in LTP and Learning</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nrn2738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrn2738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19927149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=850-860&issue=12&author=L.+Minichiello&title=TrkB+Signalling+Pathways+in+LTP+and+Learning&doi=10.1038%2Fnrn2738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB signaling pathways in LTP and learning</span></div><div class="casAuthors">Minichiello, Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mechanisms that underlie learning is one of the most fascinating and central aims of neurobiol. research.  Hippocampal long-term potentiation (LTP) is widely regarded as a prime candidate for the cellular mechanism of learning.  Receptor tyrosine kinase TrkB (also known as NTRK2), known primarily for its function during PNS and CNS development, has emerged in recent years as a potent regulator of hippocampal LTP.  Here, the author describes efforts to understand the signaling pathways and mol. mechanisms that underlie the involvement of TrkB in LTP and learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0ZpLjq1-0LVg90H21EOLACvtfcHk0lh18hEo_iJ53Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF&md5=61bde8b20f142253bcf101c3d418edba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrn2738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2738%26sid%3Dliteratum%253Aachs%26aulast%3DMinichiello%26aufirst%3DL.%26atitle%3DTrkB%2520Signalling%2520Pathways%2520in%2520LTP%2520and%2520Learning%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D850%26epage%3D860%26doi%3D10.1038%2Fnrn2738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, M.</span></span> <span> </span><span class="NLM_article-title">Trk B Signaling in Dopamine 1 Receptor Neurons Regulates Food Intake and Body Weight</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1002/oby.20382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Foby.20382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=23512795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2372-2376&issue=11&author=B.+L.+Masonauthor=M.+K.+Loboauthor=L.+F.+Paradaauthor=M.+Lutter&title=Trk+B+Signaling+in+Dopamine+1+Receptor+Neurons+Regulates+Food+Intake+and+Body+Weight&doi=10.1002%2Foby.20382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight</span></div><div class="casAuthors">Mason, Brittany L.; Lobo, Mary Kay; Parada, Luis F.; Lutter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2372-2376</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Loss of BDNF-TrkB signaling results in obesity in both humans and mice; however, the neural circuit that mediates this effect is unknown.  The role of TrkB signaling in dopamine-1 receptor expressing neurons in body wt. regulation was tested.  Methods : Mice with a floxed allele of the TrkB gene were paired with mice expressing Cre-recombinase under control of the D1 promoter to conditionally knock out expression of TrkB receptors from D1-neurons.  Results : Deletion of TrkB receptors from D1 neurons results in obesity in chow fed mice due to increased feed efficiency.  In contrast, loss of Trk B signaling in D1 neurons induced hyperphagia and hyperglycemia in mice maintained on high fat diet.  Conclusions : These findings indicate TrkB signaling in D1 neurons regulates body wt. by distinct mechanisms for chow and high fat diet and may be important for defending the body against the development of obesity and obesity-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV2qD8g4-gkLVg90H21EOLACvtfcHk0lh7hq7D-iStIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM&md5=6876ea2b71a0f18c54c3d66638306471</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Foby.20382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20382%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DB.%2BL.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLutter%26aufirst%3DM.%26atitle%3DTrk%2520B%2520Signaling%2520in%2520Dopamine%25201%2520Receptor%2520Neurons%2520Regulates%2520Food%2520Intake%2520and%2520Body%2520Weight%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2372%26epage%3D2376%26doi%3D10.1002%2Foby.20382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">The Lighter Side of BDNF</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R1053</span>– <span class="NLM_lpage">R1069</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00776.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1152%2Fajpregu.00776.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=R1053-R1069&issue=5&author=E.+E.+Nobleauthor=C.+J.+Billingtonauthor=C.+M.+Kotzauthor=C.+Wang&title=The+Lighter+Side+of+BDNF&doi=10.1152%2Fajpregu.00776.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00776.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00776.2010%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BE.%26aulast%3DBillington%26aufirst%3DC.%2BJ.%26aulast%3DKotz%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DThe%2520Lighter%2520Side%2520of%2520BDNF%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2011%26volume%3D300%26issue%3D5%26spage%3DR1053%26epage%3DR1069%26doi%3D10.1152%2Fajpregu.00776.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, G. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connie Hung, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rahilly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, I. S.</span></span> <span> </span><span class="NLM_article-title">A De Novo Mutation Affecting Human TrkB Associated with Severe Obesity and Developmental Delay</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1038/nn1336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnn1336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=15494731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1187-1189&issue=11&author=G.+S.+H.+Yeoauthor=C.-C.+Connie+Hungauthor=J.+Rochfordauthor=J.+Keoghauthor=J.+Grayauthor=S.+Sivaramakrishnanauthor=S.+O%E2%80%99Rahillyauthor=I.+S.+Farooqi&title=A+De+Novo+Mutation+Affecting+Human+TrkB+Associated+with+Severe+Obesity+and+Developmental+Delay&doi=10.1038%2Fnn1336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo mutation affecting human TrkB associated with severe obesity and developmental delay</span></div><div class="casAuthors">Yeo, Giles S. H.; Connie Hung, Chiao-Chien; Rochford, Justin; Keogh, Julia; Gray, Juliette; Sivaramakrishnan, Shoba; O'Rahilly, Stephen; Farooqi, I. Sadaf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187-1189</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An 8-yr-old male with a complex developmental syndrome and severe obesity was heterozygous for a de novo missense mutation resulting in a Y722C substitution in the neurotrophin receptor TrkB.  This mutation markedly impaired receptor autophosphorylation and signaling to MAP kinase.  Mutation of NTRK2, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic obesity.  The assocd. impairment in memory, learning and nociception seen in the proband reflects the crucial role of TrkB in the human nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOFn7CEYjaXLVg90H21EOLACvtfcHk0ljV4bUXLhkT-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D&md5=1df8713e7b0f3b437cb552a81c2ca628</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnn1336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1336%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DG.%2BS.%2BH.%26aulast%3DConnie%2BHung%26aufirst%3DC.-C.%26aulast%3DRochford%26aufirst%3DJ.%26aulast%3DKeogh%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DSivaramakrishnan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Rahilly%26aufirst%3DS.%26aulast%3DFarooqi%26aufirst%3DI.%2BS.%26atitle%3DA%2520De%2520Novo%2520Mutation%2520Affecting%2520Human%2520TrkB%2520Associated%2520with%2520Severe%2520Obesity%2520and%2520Developmental%2520Delay%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26issue%3D11%26spage%3D1187%26epage%3D1189%26doi%3D10.1038%2Fnn1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrén, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoulfas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzaghi, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leingärtner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesarollo, L.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin-3 Induced by Tri-Iodothyronine in Cerebellar Granule Cells Promotes Purkinje Cell Differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1083/jcb.122.2.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1083%2Fjcb.122.2.443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1993&pages=443-450&issue=2&author=D.+Lindholmauthor=E.+Castr%C3%A9nauthor=P.+Tsoulfasauthor=R.+Kolbeckauthor=M.+d.+P.+Berzaghiauthor=A.+Leing%C3%A4rtnerauthor=C.+Heisenbergauthor=L.+Tessarolloauthor=L.+Paradaauthor=H.+Thoenenauthor=L.+Tesarollo&title=Neurotrophin-3+Induced+by+Tri-Iodothyronine+in+Cerebellar+Granule+Cells+Promotes+Purkinje+Cell+Differentiation&doi=10.1083%2Fjcb.122.2.443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1083%2Fjcb.122.2.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.122.2.443%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DCastr%25C3%25A9n%26aufirst%3DE.%26aulast%3DTsoulfas%26aufirst%3DP.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DBerzaghi%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DLeing%25C3%25A4rtner%26aufirst%3DA.%26aulast%3DHeisenberg%26aufirst%3DC.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DParada%26aufirst%3DL.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DTesarollo%26aufirst%3DL.%26atitle%3DNeurotrophin-3%2520Induced%2520by%2520Tri-Iodothyronine%2520in%2520Cerebellar%2520Granule%2520Cells%2520Promotes%2520Purkinje%2520Cell%2520Differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1993%26volume%3D122%26issue%3D2%26spage%3D443%26epage%3D450%26doi%3D10.1083%2Fjcb.122.2.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, R. A.</span></span> <span> </span><span class="NLM_article-title">Functional Roles of Neurotrophin 3 in the Developing and Mature Sympathetic Nervous System</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1007/BF02740622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2FBF02740622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=8989769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=185-197&issue=3&author=X.-F.+Zhouauthor=R.+A.+Rush&title=Functional+Roles+of+Neurotrophin+3+in+the+Developing+and+Mature+Sympathetic+Nervous+System&doi=10.1007%2FBF02740622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system</span></div><div class="casAuthors">Zhou, Xin-Fu; Rush, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana</span>)
        </div><div class="casAbstract">A review, with ∼75 refs., on the evidence published in recent years indicating that another member of the NGF family, neurotrophin 3 (NT3), plays both a complementary and overlapping role in the development and maturation of sympathetic neurons.  In migratory neural crest cells, expression of the high-affinity receptor, trkC, and promotion of mitosis by NT3 suggest an involvement in gangliogenesis, since sympathetic neuroblasts express both NT3 and trkC and require NT3 for their proliferation, differentiation, and survival, it has been proposed that the factor acts at this developmental stage as an autocrine or paracrine factor.  However, NT3 also acts in parallel with NGF to promote the survival of postmitotic neurons during late development.  Both trkC and trkA are expressed in sympathetic neurons and function as high-affinity receptors for NT3.  NT3 is synthesized in sympathetic effector tissues and the endogenous factor is retrogradely transported to accumulate within the cell soma.  Thus, in addn. to its role in the differentiation of sympathetic neurons, NT3, like NGF, is also an effector tissue-derived neurotrophic factor for these neurons in maturity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr975ZuRFusjrVg90H21EOLACvtfcHk0lidgAwujHxWEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D&md5=871d2498b71e56ae44f375bd21a3df2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2FBF02740622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02740622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.-F.%26aulast%3DRush%26aufirst%3DR.%2BA.%26atitle%3DFunctional%2520Roles%2520of%2520Neurotrophin%25203%2520in%2520the%2520Developing%2520and%2520Mature%2520Sympathetic%2520Nervous%2520System%26jtitle%3DMol.%2520Neurobiol.%26date%3D1996%26volume%3D13%26issue%3D3%26spage%3D185%26epage%3D197%26doi%3D10.1007%2FBF02740622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk Kinase Inhibitors as New Treatments for Cancer and Pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&issue=3&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+Kinase+Inhibitors+as+New+Treatments+for+Cancer+and+Pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0liUjNsqUDM8SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520Kinase%2520Inhibitors%2520as%2520New%2520Treatments%2520for%2520Cancer%2520and%2520Pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span> <span> </span><span class="NLM_article-title">Restricting Cns Penetration of Drugs to Minimise Adverse Events: Role of Drug Transporters</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.ddtec.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=25027378" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=e79-85&author=S.+Bagalauthor=P.+Bungay&title=Restricting+Cns+Penetration+of+Drugs+to+Minimise+Adverse+Events%3A+Role+of+Drug+Transporters&doi=10.1016%2Fj.ddtec.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DBungay%26aufirst%3DP.%26atitle%3DRestricting%2520Cns%2520Penetration%2520of%2520Drugs%2520to%2520Minimise%2520Adverse%2520Events%253A%2520Role%2520of%2520Drug%2520Transporters%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2014%26volume%3D12%26spage%3De79%26epage%3D85%26doi%3D10.1016%2Fj.ddtec.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speed, W.</span></span> <span> </span><span class="NLM_article-title">Full Efficacy with No CNS Side-Effects: Unachievable Panacea or Reality?? DMPK Considerations in Design of Drugs with Limited Brain Penetration</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.617847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.3109%2F00498254.2011.617847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=11-27&issue=1&author=S.+Coleauthor=S.+Bagalauthor=A.+El-Kattanauthor=K.+Fennerauthor=T.+Hayauthor=S.+Kempshallauthor=G.+Lunnauthor=M.+Varmaauthor=P.+Stuppleauthor=W.+Speed&title=Full+Efficacy+with+No+CNS+Side-Effects%3A+Unachievable+Panacea+or+Reality%3F%3F+DMPK+Considerations+in+Design+of+Drugs+with+Limited+Brain+Penetration&doi=10.3109%2F00498254.2011.617847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.617847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.617847%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DHay%26aufirst%3DT.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DVarma%26aufirst%3DM.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DSpeed%26aufirst%3DW.%26atitle%3DFull%2520Efficacy%2520with%2520No%2520CNS%2520Side-Effects%253A%2520Unachievable%2520Panacea%2520or%2520Reality%253F%253F%2520DMPK%2520Considerations%2520in%2520Design%2520of%2520Drugs%2520with%2520Limited%2520Brain%2520Penetration%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D1%26spage%3D11%26epage%3D27%26doi%3D10.3109%2F00498254.2011.617847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span> <span> </span><span class="NLM_article-title">Strategies to Minimize Cns Toxicity: In Vitro High-Throughput Assays and Computational Modeling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.677028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1517%2F17425255.2012.677028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=531-542&issue=5&author=T.+T.+Wagerauthor=J.+L.+Lirasauthor=S.+Menteauthor=P.+Trapa&title=Strategies+to+Minimize+Cns+Toxicity%3A+In+Vitro+High-Throughput+Assays+and+Computational+Modeling&doi=10.1517%2F17425255.2012.677028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling</span></div><div class="casAuthors">Wager, Travis T.; Liras, Jennifer L.; Mente, Scot; Trapa, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Healthy functioning of the brain is dependent on the ability of the blood-brain barrier (BBB) and other central nervous system (CNS) barriers to protect the neurocompartments from potential disruptive and damaging xenobiotic agents.  In vitro high-throughput (HT) screens and computational models that assess a compd.'s ability to pass through or disrupt the BBB have become important tools in the identification of new well-tolerated peripheral drugs and safer chem. products such as pesticides.  Leveraging these HT in vitro assays and computational BBB tools together with the current understanding of brain penetration may enable the drug discovery community to minimize access of drug candidates into the CNS compartment.  Areas covered: This article reviews aspects of the most recent in vitro and computational approaches designed to provide an early assessment of a compd.'s ability to access the neurocompartment.  This article also provides insight into using these tools to identify compds. that have restricted access to the neurocompartment.  Expert opinion: The development of safer peripheral-acting medicines and chem. products can be achieved through prospective design and early assessment with HT assays of the BBB in conjunction with computational models.  Exclusion or significantly reduced access of a compd. to the neurocompartment will increase the odds of identifying a compd. with reduced CNS-related adverse drug reactions.  A holistic approach to compd. design and evaluation that incorporates prospective design principles (e.g., optimization of physicochem. properties), leverages HT in vitro assays and integrates the use of BBB computational models may yield the best-in-class' peripherally acting product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOhde-T8d1UrVg90H21EOLACvtfcHk0lgHhvTRhLSfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D&md5=d4bb73a8839594465407435be2019601</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.677028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.677028%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DTrapa%26aufirst%3DP.%26atitle%3DStrategies%2520to%2520Minimize%2520Cns%2520Toxicity%253A%2520In%2520Vitro%2520High-Throughput%2520Assays%2520and%2520Computational%2520Modeling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D531%26epage%3D542%26doi%3D10.1517%2F17425255.2012.677028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span> <span> </span><span class="NLM_article-title">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fclpt.2013.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=23588303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=80-94&issue=1&author=J.+C.+Kalvassauthor=J.+W.+Polliauthor=D.+L.+Bourdetauthor=B.+Fengauthor=S.+M.+Huangauthor=X.+Liuauthor=Q.+R.+Smithauthor=L.+K.+Zhangauthor=M.%0AJ.+Zamek-Gliszczynski&title=Why+Clinical+Modulation+of+Efflux+Transport+at+the+Human+Blood-Brain+Barrier+Is+Unlikely%3A+The+ITC+Evidence-Based+Position&doi=10.1038%2Fclpt.2013.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span></div><div class="casAuthors">Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S.-M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theor. possibility of adverse central nervous system (CNS) effects identified in preclin. studies.  In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 80-94. doi:10.1038/clpt.2013.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfxdzZMTG6_7Vg90H21EOLACvtfcHk0lgHhvTRhLSfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D&md5=c106f689e1c83f58eb6d0dbc527cf0fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.34%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DWhy%2520Clinical%2520Modulation%2520of%2520Efflux%2520Transport%2520at%2520the%2520Human%2520Blood-Brain%2520Barrier%2520Is%2520Unlikely%253A%2520The%2520ITC%2520Evidence-Based%2520Position%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D80%26epage%3D94%26doi%3D10.1038%2Fclpt.2013.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane Transporters in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=20190787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&issue=3&author=K.+M.+Giacominiauthor=S.-M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+R.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+Wah+Yeeauthor=M.%0AJ.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+Transporters+in+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane transporters in drug development</span></div><div class="casAuthors">Giacomini, Kathleen M.; Huang, Shiew-Mei; Tweedie, Donald J.; Benet, Leslie Z.; Brouwer, Kim L. R.; Chu, Xiaoyan; Dahlin, Amber; Evers, Raymond; Fischer, Volker; Hillgren, Kathleen M.; Hoffmaster, Keith A.; Ishikawa, Toshihisa; Keppler, Dietrich; Kim, Richard B.; Lee, Caroline A.; Niemi, Mikko; Polli, Joseph W.; Sugiyama, Yuicchi; Swaan, Peter W.; Ware, Joseph A.; Wright, Stephen H.; Wah Yee, Sook; Zamek-Gliszczynski, Maciej J.; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-236</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs.  This presents several key questions for drug development, including which transporters are clin. important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters.  In addn., what criteria should trigger follow-up clin. studies, and which clin. studies should be conducted if needed.  In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clin. studies on the currently recognized most important drug transporter interactions.  The recommendations are generally intended to support clin. development and filing of a new drug application.  Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clin. trial enrollment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metab. and excretion properties of the drug mol., and information required for drug labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBIf0gk93W7Vg90H21EOLACvtfcHk0ljBBQK2V8HQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D&md5=89d9ce746284c1814fb01cd9b9a72027</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.-M.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DWah%2BYee%26aufirst%3DS.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520Transporters%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.%0AD.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljBBQK2V8HQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing Drug Exposure in the CNS While Maintaining Good Oral Absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&issue=12&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+Drug+Exposure+in+the+CNS+While+Maintaining+Good+Oral+Absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520Drug%2520Exposure%2520in%2520the%2520CNS%2520While%2520Maintaining%2520Good%2520Oral%2520Absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of Nonlinear Intestinal Absorption of Cyp3a4 and P-Glycoprotein Substrates from Their in Vitro Km Values</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/s11095-011-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2Fs11095-011-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&issue=3&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+Nonlinear+Intestinal+Absorption+of+Cyp3a4+and+P-Glycoprotein+Substrates+from+Their+in+Vitro+Km+Values&doi=10.1007%2Fs11095-011-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520Nonlinear%2520Intestinal%2520Absorption%2520of%2520Cyp3a4%2520and%2520P-Glycoprotein%2520Substrates%2520from%2520Their%2520in%2520Vitro%2520Km%2520Values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26issue%3D3%26spage%3D651%26epage%3D668%26doi%3D10.1007%2Fs11095-011-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. D.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Gibson, K. R.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Ryckmans, T.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Stupple, P. A.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-D]Pyrimidine Derivatives as Inhibitors of Tropomyosin-Related Kinases and Their Preparation and Use in the Treatment of Pain</span>. <span class="NLM_patent">WO2012137089A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+D.+Andrews&author=S.+K.+Bagal&author=K.+R.+Gibson&author=K.+Omoto&author=T.+Ryckmans&author=S.+E.+Skerratt&author=P.+A.+Stupple&title=Pyrrolo%5B2%2C3-D%5DPyrimidine+Derivatives+as+Inhibitors+of+Tropomyosin-Related+Kinases+and+Their+Preparation+and+Use+in+the+Treatment+of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BD.%26atitle%3DPyrrolo%255B2%252C3-D%255DPyrimidine%2520Derivatives%2520as%2520Inhibitors%2520of%2520Tropomyosin-Related%2520Kinases%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Pain%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loudon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Amerongen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeneveld, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, R. P.</span></span> <span> </span><span class="NLM_article-title">Demonstration of an Anti-Hyperalgesic Effect of a Novel Pan-Trk Inhibitor PF-06273340 in a Battery of Human Evoked Pain Models</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1111/bcp.13448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1111%2Fbcp.13448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=29178434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=301-309&issue=2&author=P.+Loudonauthor=P.+Siebengaauthor=D.+Gormanauthor=K.+Goreauthor=P.+Duaauthor=G.+van+Amerongenauthor=J.+L.+Hayauthor=G.+J.+Groeneveldauthor=R.+P.+Butt&title=Demonstration+of+an+Anti-Hyperalgesic+Effect+of+a+Novel+Pan-Trk+Inhibitor+PF-06273340+in+a+Battery+of+Human+Evoked+Pain+Models&doi=10.1111%2Fbcp.13448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models</span></div><div class="casAuthors">Loudon, Peter; Siebenga, Pieter; Gorman, Donal; Gore, Katrina; Dua, Pinky; van Amerongen, Guido; Hay, Justin L.; Groeneveld, Geert Jan; Butt, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications.  NGF signals through tyrosine kinase receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75 receptor.  PF-06273340 is a small mol. inhibitor of Trks A, B and C that reduces pain in nonclin. models, and the present study aimed to investigate the pharmacodynamics of this first-in-class mol. in humans.  A randomized, double-blind, single-dose, placebo- and active-controlled five-period crossover study was conducted in healthy human subjects (NCT02260947).  Subjects received five treatments: PF-06273340 50 mg, PF-06273340 400 mg, pregabalin 300 mg, ibuprofen 600 mg and placebo.  The five primary endpoints were the pain detection threshold for the thermal pain tests and the pain tolerance threshold for the cold pressor, elec. stair and pressure pain tests.  The trial had predefined decision rules based on 95% confidence that the PF-06273340 effect was better than that of placebo.  Twenty subjects entered the study, with 18 completing all five periods.  The high dose of PF-06273340 met the decision rules on the UV B skin thermal pain endpoint [least squares (LS) mean vs. placebo: 1.13, 95% confidence interval: 0.64-1.61], but not on the other four primary endpoints.  The low dose did not meet the decision criteria for any of the five primary endpoints.  Pregabalin (cold pressor and elec. stair tests) and ibuprofen (UVB thermal pain) showed significant analgesic effects on expected endpoints.  The study demonstrated, for the first time, the translation of nonclin. effects into man in an inflammatory pain analgesic pharmacodynamic endpoint using a pan-Trk inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZcem5M2HecbVg90H21EOLACvtfcHk0lj-4D8zx28DFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7s%253D&md5=9eeed9ba7e290cf9c3537f30ecd2dc03</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13448%26sid%3Dliteratum%253Aachs%26aulast%3DLoudon%26aufirst%3DP.%26aulast%3DSiebenga%26aufirst%3DP.%26aulast%3DGorman%26aufirst%3DD.%26aulast%3DGore%26aufirst%3DK.%26aulast%3DDua%26aufirst%3DP.%26aulast%3Dvan%2BAmerongen%26aufirst%3DG.%26aulast%3DHay%26aufirst%3DJ.%2BL.%26aulast%3DGroeneveld%26aufirst%3DG.%2BJ.%26aulast%3DButt%26aufirst%3DR.%2BP.%26atitle%3DDemonstration%2520of%2520an%2520Anti-Hyperalgesic%2520Effect%2520of%2520a%2520Novel%2520Pan-Trk%2520Inhibitor%2520PF-06273340%2520in%2520a%2520Battery%2520of%2520Human%2520Evoked%2520Pain%2520Models%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26issue%3D2%26spage%3D301%26epage%3D309%26doi%3D10.1111%2Fbcp.13448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Swain, N. A.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Andrews, M. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Acylpiperidine Ethers as Tropomyosin-Related Kinase Inhibitors</span>. <span class="NLM_patent">WO2015092610A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+E.+Skerratt&author=S.+K.+Bagal&author=N.+A.+Swain&author=K.+Omoto&author=M.+D.+Andrews&title=Preparation+of+N-Acylpiperidine+Ethers+as+Tropomyosin-Related+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26atitle%3DPreparation%2520of%2520N-Acylpiperidine%2520Ethers%2520as%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalkai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasieczny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steidl-Nichols, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span> <span> </span><span class="NLM_article-title">Early Evaluation of Compound Qt Prolongation Effects: A Predictive 384-Well Fluorescence Polarization Binding Assay for Measuring Herg Blockade</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2006.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.vascn.2006.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=255-264&issue=3&author=M.+Deaconauthor=D.+Singletonauthor=N.+Szalkaiauthor=R.+Pasiecznyauthor=C.+Peacockauthor=D.+Priceauthor=J.+Boydauthor=H.+Boydauthor=J.+V.+Steidl-Nicholsauthor=C.+Williams&title=Early+Evaluation+of+Compound+Qt+Prolongation+Effects%3A+A+Predictive+384-Well+Fluorescence+Polarization+Binding+Assay+for+Measuring+Herg+Blockade&doi=10.1016%2Fj.vascn.2006.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2006.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2006.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DM.%26aulast%3DSingleton%26aufirst%3DD.%26aulast%3DSzalkai%26aufirst%3DN.%26aulast%3DPasieczny%26aufirst%3DR.%26aulast%3DPeacock%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DBoyd%26aufirst%3DJ.%26aulast%3DBoyd%26aufirst%3DH.%26aulast%3DSteidl-Nichols%26aufirst%3DJ.%2BV.%26aulast%3DWilliams%26aufirst%3DC.%26atitle%3DEarly%2520Evaluation%2520of%2520Compound%2520Qt%2520Prolongation%2520Effects%253A%2520A%2520Predictive%2520384-Well%2520Fluorescence%2520Polarization%2520Binding%2520Assay%2520for%2520Measuring%2520Herg%2520Blockade%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2007%26volume%3D55%26issue%3D3%26spage%3D255%26epage%3D264%26doi%3D10.1016%2Fj.vascn.2006.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Herg Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&issue=17&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+Herg+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgwZi2MSnvyeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Herg%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D17%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lhQhXMkDlhszQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a New Permeability Assay Using Low-Efflux MDCKII Cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+New+Permeability+Assay+Using+Low-Efflux+MDCKII+Cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lhQhXMkDlhszQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Permeability%2520Assay%2520Using%2520Low-Efflux%2520MDCKII%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Swain, N. A.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">McAlpine, I. J.</span></span> <span> </span><span class="NLM_article-title">N-Acylpiperidine Ether Tropomyosin-Related Kinase Inhibitors</span>. <span class="NLM_patent">WO2016009296A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+K.+Bagal&author=K.+Omoto&author=S.+E.+Skerratt&author=N.+A.+Swain&author=J.+J.+Cui&author=I.+J.+McAlpine&title=N-Acylpiperidine+Ether+Tropomyosin-Related+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DN-Acylpiperidine%2520Ether%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span>; <span class="NLM_string-name">Scott Obach, R.</span></span> <span> </span><span class="NLM_article-title">Chapter 10: Alcohols and Phenols: Absorption, Distribution, Metabolism and Excretion</span>. In  <i>Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>, Ed.; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge UK</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">485</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1039%2F9781849731102-00460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=460-485&author=Z.+Miao&author=R.+Scott+Obachauthor=D.+A.+Smith&title=Metabolism%2C+Pharmacokinetics+and+Toxicity+of+Functional+Groups%3A+Impact+of+Chemical+Building+Blocks+on+ADMET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2F9781849731102-00460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849731102-00460%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DChapter%252010%253A%2520Alcohols%2520and%2520Phenols%253A%2520Absorption%252C%2520Distribution%252C%2520Metabolism%2520and%2520Excretion%26btitle%3DMetabolism%252C%2520Pharmacokinetics%2520and%2520Toxicity%2520of%2520Functional%2520Groups%253A%2520Impact%2520of%2520Chemical%2520Building%2520Blocks%2520on%2520ADMET%26aulast%3DSmith%26aufirst%3DD.%2BA.%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2010%26spage%3D460%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Scaffold Mining of Kinase Hinge Binders in Crystal Structure Database</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9700-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2Fs10822-013-9700-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=13-23&issue=1&author=L.+Xingauthor=B.+Raiauthor=E.+A.+Lunney&title=Scaffold+Mining+of+Kinase+Hinge+Binders+in+Crystal+Structure+Database&doi=10.1007%2Fs10822-013-9700-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9700-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9700-4%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DScaffold%2520Mining%2520of%2520Kinase%2520Hinge%2520Binders%2520in%2520Crystal%2520Structure%2520Database%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2014%26volume%3D28%26issue%3D1%26spage%3D13%26epage%3D23%26doi%3D10.1007%2Fs10822-013-9700-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Tran-Dube, M. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Acylpyrrolidine Ether Derivatives as TrkA Antagonists</span>. <span class="NLM_patent">WO2016020784</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+K.+Bagal&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+J.+Cui&author=S.+E.+Greasley&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=M.+B.+Tran-Dube&title=Preparation+of+N-Acylpyrrolidine+Ether+Derivatives+as+TrkA+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DPreparation%2520of%2520N-Acylpyrrolidine%2520Ether%2520Derivatives%2520as%2520TrkA%2520Antagonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peet, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span> <span> </span><span class="NLM_article-title">The Kinetics of Binding to P38 Map Kinase by Analogues of BIRB 796</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3101</span>– <span class="NLM_lpage">3104</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00656-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2FS0960-894X%2803%2900656-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3101-3104&issue=18&author=J.+Reganauthor=C.+A.+Pargellisauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=E.+R.+Hickeyauthor=G.+W.+Peetauthor=A.+Protoauthor=A.+Swinamerauthor=N.+Moss&title=The+Kinetics+of+Binding+to+P38+Map+Kinase+by+Analogues+of+BIRB+796&doi=10.1016%2FS0960-894X%2803%2900656-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900656-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900656-5%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DThe%2520Kinetics%2520of%2520Binding%2520to%2520P38%2520Map%2520Kinase%2520by%2520Analogues%2520of%2520BIRB%2520796%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26issue%3D18%26spage%3D3101%26epage%3D3104%26doi%3D10.1016%2FS0960-894X%2803%2900656-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolford, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">A Novel Relay Method for Determining Low-Clearance Values</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1865</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1124%2Fdmd.112.046425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22645091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1860-1865&issue=9&author=L.+Diauthor=P.+Trapaauthor=R.+S.+Obachauthor=K.+Atkinsonauthor=Y.-A.+Biauthor=A.+C.+Wolfordauthor=B.+Tanauthor=T.+S.+McDonaldauthor=Y.+Laiauthor=L.+M.+Tremaine&title=A+Novel+Relay+Method+for+Determining+Low-Clearance+Values&doi=10.1124%2Fdmd.112.046425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A novel relay method for determining low-clearance values</span></div><div class="casAuthors">Di, Li; Trapa, Patrick; Obach, R. Scott; Atkinson, Karen; Bi, Yi-An; Wolford, Angela C.; Tan, Beijing; McDonald, Thomas S.; Lai, Yurong; Tremaine, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1860-1865</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel relay method has been developed using cryopreserved human hepatocytes to measure intrinsic clearance of low-clearance compds.  The relay method involved transferring the supernatant from hepatocyte incubations to freshly thawed hepatocytes at the end of the 4-h incubation to prolong the exposure time to active enzymes in hepatocytes.  An accumulative incubation time of 20 h or longer in hepatocytes can be achieved using the method.  The relay method was validated using seven com. drugs (diazepam, disopyramide, theophylline, timolol, tolbutamide, S-warfarin, and zolmitriptan) that were metabolized by various cytochrome P450s with low human in vivo intrinsic clearance at approx. 2 to 15 mL · min-1 · kg-1.  The results showed that the relay method produced excellent predictions of human in vivo clearance.  The difference between in vitro and in vivo intrinsic clearance was within 2-fold for most compds., which is similar to the std. prediction accuracy for moderate to high clearance compds. using hepatocytes.  The relay method is a straightforward, relatively low cost, and easy-to-use new tool to address the challenges of low clearance in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1LvwK-CqOLVg90H21EOLACvtfcHk0lgv7BZrwRtsCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShur7O&md5=faab456749ff398ad63d11eff6412fbc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046425%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DAtkinson%26aufirst%3DK.%26aulast%3DBi%26aufirst%3DY.-A.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DT.%2BS.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DA%2520Novel%2520Relay%2520Method%2520for%2520Determining%2520Low-Clearance%2520Values%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D9%26spage%3D1860%26epage%3D1865%26doi%3D10.1124%2Fdmd.112.046425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span> <span> </span><span class="NLM_article-title">Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection</span>. In  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+Yazdanian&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYazdanian%26aufirst%3DM.%26atitle%3DOverview%2520of%2520Determination%2520of%2520Biopharmaceutical%2520Properties%2520for%2520Development%2520Candidate%2520Selection%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgv7BZrwRtsCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yalkowsky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valvani, S. C.</span></span> <span> </span><span class="NLM_article-title">Solubility and Partitioning I: Solubility of Nonelectrolytes in Water</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1002/jps.2600690814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Fjps.2600690814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1980&pages=912-922&issue=8&author=S.+H.+Yalkowskyauthor=S.+C.+Valvani&title=Solubility+and+Partitioning+I%3A+Solubility+of+Nonelectrolytes+in+Water&doi=10.1002%2Fjps.2600690814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600690814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600690814%26sid%3Dliteratum%253Aachs%26aulast%3DYalkowsky%26aufirst%3DS.%2BH.%26aulast%3DValvani%26aufirst%3DS.%2BC.%26atitle%3DSolubility%2520and%2520Partitioning%2520I%253A%2520Solubility%2520of%2520Nonelectrolytes%2520in%2520Water%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1980%26volume%3D69%26issue%3D8%26spage%3D912%26epage%3D922%26doi%3D10.1002%2Fjps.2600690814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveney, P. V.</span></span> <span> </span><span class="NLM_article-title">Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00780</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00780" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVyrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=897-909&issue=4&author=S.+Wanauthor=A.+P.+Bhatiauthor=S.+Skerrattauthor=K.+Omotoauthor=V.+Shanmugasundaramauthor=S.+K.+Bagalauthor=P.+V.+Coveney&title=Evaluation+and+Characterization+of+Trk+Kinase+Inhibitors+for+the+Treatment+of+Pain%3A+Reliable+Binding+Affinity+Predictions+from+Theory+and+Computation&doi=10.1021%2Facs.jcim.6b00780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation</span></div><div class="casAuthors">Wan, Shunzhou; Bhati, Agastya P.; Skerratt, Sarah; Omoto, Kiyoyuki; Shanmugasundaram, Veerabahu; Bagal, Sharan K.; Coveney, Peter V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-909</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of ligand binding affinity to the target protein of interest is a primary objective in small-mol. drug discovery.  Until now, the prediction of binding affinities by computational methods has not been widely applied in the drug discovery process, mainly due to its lack of accuracy and reproducibility, as well as the long turnaround times required to obtain results.  Herein, the authors report on a collaborative study that compares tropomyosin receptor kinase A (TrkA) binding affinity predictions using two recently formulated fast computational approaches - namely ESMACS (Enhanced Sampling of Mol. dynamics with Approxn. of Continuum Solvent) and TIES (Thermodn. Integration with Enhanced Sampling) - to exptl. derived TrkA binding affinities for a set of Pfizer pan-Trk compds.  ESMACS gives precise and reproducible results and is applicable to highly diverse sets of compds.  It also provides detailed chem. insight into the nature of ligand-protein binding.  TIES can predict and thus optimize more subtle changes in binding affinities between compds. of similar structure.  Individual binding affinities were calcd. in a few hours, exhibiting good correlations with the exptl. data of 0.79 and 0.88 from ESMACS and TIES approaches resp.  The speed, level of accuracy and precision of the calcns. are such that the affinity predictions can be used to rapidly explain the effects of compd. modifications on TrkA binding affinity.  The methods could therefore be used as tools to guide lead optimization efforts across multiple prospective structurally-enabled programs in the drug discovery setting for a wide range of compds. and targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounHo5S0rFTrVg90H21EOLACvtfcHk0lj28qeQgBXaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVyrurc%253D&md5=2e366f56c1ee8c2f2b2760b9098e2030</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00780%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DS.%26aulast%3DBhati%26aufirst%3DA.%2BP.%26aulast%3DSkerratt%26aufirst%3DS.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DCoveney%26aufirst%3DP.%2BV.%26atitle%3DEvaluation%2520and%2520Characterization%2520of%2520Trk%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Pain%253A%2520Reliable%2520Binding%2520Affinity%2520Predictions%2520from%2520Theory%2520and%2520Computation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D4%26spage%3D897%26epage%3D909%26doi%3D10.1021%2Facs.jcim.6b00780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">On Achieving High Accuracy and Reliability in the Calculation of Relative Protein–Ligand Binding Affinities</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1073/pnas.1114017109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1073%2Fpnas.1114017109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=1937-1942&issue=6&author=L.+Wangauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=On+Achieving+High+Accuracy+and+Reliability+in+the+Calculation+of+Relative+Protein%E2%80%93Ligand+Binding+Affinities&doi=10.1073%2Fpnas.1114017109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1114017109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1114017109%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOn%2520Achieving%2520High%2520Accuracy%2520and%2520Reliability%2520in%2520the%2520Calculation%2520of%2520Relative%2520Protein%25E2%2580%2593Ligand%2520Binding%2520Affinities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D6%26spage%3D1937%26epage%3D1942%26doi%3D10.1073%2Fpnas.1114017109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span> <span> </span><span class="NLM_article-title">Replica Exchange with Solute Scaling: A More Efficient Version of Replica Exchange with Solute Tempering (REST2)</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">9431</span>– <span class="NLM_lpage">9438</span>, <span class="refDoi"> DOI: 10.1021/jp204407d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp204407d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFymurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2011&pages=9431-9438&issue=30&author=L.+Wangauthor=R.+A.+Friesnerauthor=B.+J.+Berne&title=Replica+Exchange+with+Solute+Scaling%3A+A+More+Efficient+Version+of+Replica+Exchange+with+Solute+Tempering+%28REST2%29&doi=10.1021%2Fjp204407d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Replica Exchange with Solute Scaling: A More Efficient Version of Replica Exchange with Solute Tempering (REST2)</span></div><div class="casAuthors">Wang, Lingle; Friesner, Richard A.; Berne, B. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">9431-9438</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small change in the Hamiltonian scaling in Replica Exchange with Solute Tempering (REST) is found to improve its sampling efficiency greatly, esp. for the sampling of aq. protein solns. in which there are large-scale solute conformation changes.  Like the original REST (REST1), the new version (which the authors call REST2) also bypasses the poor scaling with system size of the std. Temp. Replica Exchange Method (TREM), reducing the no. of replicas (parallel processes) from what must be used in TREM.  This redn. is accomplished by deforming the Hamiltonian function for each replica in such a way that the acceptance probability for the exchange of replica configurations does not depend on the no. of explicit water mols. in the system.  For proof of concept, REST2 is compared with TREM and with REST1 for the folding of the trpcage and β-hairpin in water.  The comparisons confirm that REST2 greatly reduces the no. of CPUs required by regular replica exchange and greatly increases the sampling efficiency over REST1.  This method reduces the CPU time required for calcg. thermodn. avs. and for the ab initio folding of proteins in explicit water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYjGgEHE_cMbVg90H21EOLACvtfcHk0lj28qeQgBXaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFymurs%253D&md5=8acb0d670bcb70eacfc30e32d5dfb6dd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjp204407d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp204407d%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26atitle%3DReplica%2520Exchange%2520with%2520Solute%2520Scaling%253A%2520A%2520More%2520Efficient%2520Version%2520of%2520Replica%2520Exchange%2520with%2520Solute%2520Tempering%2520%2528REST2%2529%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2011%26volume%3D115%26issue%3D30%26spage%3D9431%26epage%3D9438%26doi%3D10.1021%2Fjp204407d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darout, E.</span>; <span class="NLM_string-name">Guimaraes, C.</span>; <span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">McClure, K. F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyridinyl Pyrimidinyl Piperidine Compounds as GPR119 Modulators for Therapy</span>. <span class="NLM_patent">WO2013011402A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=E.+Darout&author=C.+Guimaraes&author=V.+Mascitti&author=K.+F.+McClure&title=Preparation+of+Pyridinyl+Pyrimidinyl+Piperidine+Compounds+as+GPR119+Modulators+for+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDarout%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520Pyridinyl%2520Pyrimidinyl%2520Piperidine%2520Compounds%2520as%2520GPR119%2520Modulators%2520for%2520Therapy%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Funk, L. A.</span>; <span class="NLM_string-name">Jia, L.</span>; <span class="NLM_string-name">Kung, P.-P.</span>; <span class="NLM_string-name">Meng, J. J.</span>; <span class="NLM_string-name">Nambu, M. D.</span>; <span class="NLM_string-name">Pairish, M. A.</span>; <span class="NLM_string-name">Shen, H.</span>; <span class="NLM_string-name">Tran-Dube, M. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Aminoheteroaryl Compounds as C-Met Tyrosine Kinase Inhibitors</span>. <span class="NLM_patent">WO2006021886A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+J.+Cui&author=L.+A.+Funk&author=L.+Jia&author=P.-P.+Kung&author=J.+J.+Meng&author=M.+D.+Nambu&author=M.+A.+Pairish&author=H.+Shen&author=M.+B.+Tran-Dube&title=Preparation+of+Aminoheteroaryl+Compounds+as+C-Met+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26atitle%3DPreparation%2520of%2520Aminoheteroaryl%2520Compounds%2520as%2520C-Met%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span>; <span class="NLM_string-name">Richardson, P. F.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Richter, D. T.</span>; <span class="NLM_string-name">Burke, B. J.</span>; <span class="NLM_string-name">Gajiwala, K.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Linton, M. A.</span>; <span class="NLM_string-name">Le, P.
T. Q.</span>; <span class="NLM_string-name">Hoffman, J. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives and Triazoles as Axl Inhibitors</span>. <span class="NLM_patent">WO2016097918</span> <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+W.+Johnson&author=P.+F.+Richardson&author=M.+R.+Collins&author=D.+T.+Richter&author=B.+J.+Burke&author=K.+Gajiwala&author=S.+Ninkovic&author=M.+A.+Linton&author=P.%0AT.+Q.+Le&author=J.+E.+Hoffman&title=Preparation+of+Pyrimidine+Derivatives+and+Triazoles+as+Axl+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520and%2520Triazoles%2520as%2520Axl%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelesky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-Methyl-2-Phenyloxazol-4-Yl)Ethoxy)Phenyl)Propanoic Acid (PF-407288) in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1124%2Fdmd.108.024489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19225039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=946-955&author=L.+Zhouauthor=K.+Schmidtauthor=F.+R.+Nelsonauthor=V.+Zeleskyauthor=M.+D.+Troutmanauthor=B.+Feng&title=The+Effect+of+Breast+Cancer+Resistance+Protein+and+P-Glycoprotein+on+the+Brain+Penetration+of+Flavopiridol%2C+Imatinib+Mesylate+%28Gleevec%29%2C+Prazosin%2C+and+2-Methoxy-3-%284-%282-%285-Methyl-2-Phenyloxazol-4-Yl%29Ethoxy%29Phenyl%29Propanoic+Acid+%28PF-407288%29+in+Mice&doi=10.1124%2Fdmd.108.024489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice</span></div><div class="casAuthors">Zhou, Lin; Schmidt, Kari; Nelson, Frederick R.; Zelesky, Veronica; Troutman, Matthew D.; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">946-955</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of breast cancer resistance protein (Bcrp) and the combined activities of Bcrp and P-glycoprotein (P-gp, Mdr1a/1b) in limiting the brain penetration of drugs at the blood-brain barrier (BBB) were investigated using wild-type FVB, Mdr1a/1b(-/-), (-/-), Bcrp(-/-), and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice.  Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were detd.  Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport assocd. with Bcrp.  The brain/plasma (B/P) ratios at 0.5 and 2 h in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice were 1- to 2-fold for both compds., whereas the ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 5-fold of those obsd. in FVB mice.  For imatinib, a better substrate of P-gp than Bcrp, the B/P ratios in Bcrp(-/-) were comparable to those in FVB mice, whereas the B/P ratios in Mdr1a/1b(-/-), (-/-) and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 4- and 28-fold of those in FVB mice at both time points, resp.  Finally, the Bcrp-specific substrate PF-407288 exhibited comparable B/P ratios in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice and slightly but significantly increased B/P ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in FVB mice.  The B/P ratios of compds. in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in Mdr1a/1b(-/-), (-/-) mice clearly demonstrate that Bcrp impairs the brain penetration of its substrates.  Moreover, P-gp and Bcrp at BBB function synergistically to limit the brain penetration of shared substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvZVpc58zzbVg90H21EOLACvtfcHk0lipAJ9TXbxCjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D&md5=422881b70fa04474e0242a9c3a095093</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024489%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DZelesky%26aufirst%3DV.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DThe%2520Effect%2520of%2520Breast%2520Cancer%2520Resistance%2520Protein%2520and%2520P-Glycoprotein%2520on%2520the%2520Brain%2520Penetration%2520of%2520Flavopiridol%252C%2520Imatinib%2520Mesylate%2520%2528Gleevec%2529%252C%2520Prazosin%252C%2520and%25202-Methoxy-3-%25284-%25282-%25285-Methyl-2-Phenyloxazol-4-Yl%2529Ethoxy%2529Phenyl%2529Propanoic%2520Acid%2520%2528PF-407288%2529%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D946%26epage%3D955%26doi%3D10.1124%2Fdmd.108.024489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jeffrey N. Levy, Juan V. Alegre-Requena, Renrong Liu, Robert S. Paton, <span class="NLM_string-name hlFld-ContribAuthor">Andrew McNally</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Halogenation of Pyridines Using Designed Phosphine Reagents. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (25)
                                     , 11295-11305. <a href="https://doi.org/10.1021/jacs.0c04674" title="DOI URL">https://doi.org/10.1021/jacs.0c04674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c04674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c04674%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSelective%252BHalogenation%252Bof%252BPyridines%252BUsing%252BDesigned%252BPhosphine%252BReagents%26aulast%3DLevy%26aufirst%3DJeffrey%2BN.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D10062020%26date%3D29052020%26volume%3D142%26issue%3D25%26spage%3D11295%26epage%3D11305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shaoyong Lu, Xinheng He, Duan Ni, <span class="NLM_string-name hlFld-ContribAuthor">Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6405-6421. <a href="https://doi.org/10.1021/acs.jmedchem.8b01749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAllosteric%252BModulator%252BDiscovery%25253A%252BFrom%252BSerendipity%252Bto%252BStructure-Based%252BDesign%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D11112018%26date%3D07032019%26date%3D28022019%26volume%3D62%26issue%3D14%26spage%3D6405%26epage%3D6421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francis  Giraud</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Pereira</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>, <span class="hlFld-ContribAuthor ">Pascale  Moreau</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2696. <a href="https://doi.org/10.3390/molecules26092696" title="DOI URL">https://doi.org/10.3390/molecules26092696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092696%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252BPain%252BManagement%25253A%252BRelevant%252BProtein%252BKinases%252Band%252BTheir%252BInhibitors%26aulast%3DGiraud%26aufirst%3DFrancis%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacques  LePaih</span>, <span class="hlFld-ContribAuthor ">Dane A.  Goff</span>, <span class="hlFld-ContribAuthor ">Rajinder  Singh</span>, <span class="hlFld-ContribAuthor ">Simon J.  Shaw</span>. </span><span class="cited-content_cbyCitation_article-title">Efforts towards a Noyori reduction of a 3-fluorpiperidin-4-one with dynamic kinetic resolution. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>66 </em>, 152764. <a href="https://doi.org/10.1016/j.tetlet.2020.152764" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152764</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152764%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DEfforts%252Btowards%252Ba%252BNoyori%252Breduction%252Bof%252Ba%252B3-fluorpiperidin-4-one%252Bwith%252Bdynamic%252Bkinetic%252Bresolution%26aulast%3DLePaih%26aufirst%3DJacques%26date%3D2021%26volume%3D66%26spage%3D152764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenichiro  Takaba</span>. </span><span class="cited-content_cbyCitation_article-title">Application of FMO for Protein–ligand Binding Affinity Prediction. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 281-294. <a href="https://doi.org/10.1007/978-981-15-9235-5_13" title="DOI URL">https://doi.org/10.1007/978-981-15-9235-5_13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-9235-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-9235-5_13%26sid%3Dliteratum%253Aachs%26atitle%3DApplication%252Bof%252BFMO%252Bfor%252BProtein%2525E2%252580%252593ligand%252BBinding%252BAffinity%252BPrediction%26aulast%3DTakaba%26aufirst%3DKenichiro%26date%3D2021%26date%3D2021%26spage%3D281%26epage%3D294%26pub%3DSpringer%2520Singapore%26atitle%3DRecent%252BAdvances%252Bof%252Bthe%252BFragment%252BMolecular%252BOrbital%252BMethod%26aulast%3DMochizuki%26aufirst%3DYuji%26date%3D2021%26volume%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emiliano  Cocco</span>, <span class="hlFld-ContribAuthor ">Ji Eun  Lee</span>, <span class="hlFld-ContribAuthor ">Srinivasaraghavan  Kannan</span>, <span class="hlFld-ContribAuthor ">Alison M.  Schram</span>, <span class="hlFld-ContribAuthor ">Helen H.  Won</span>, <span class="hlFld-ContribAuthor ">Sophie  Shifman</span>, <span class="hlFld-ContribAuthor ">Amanda  Kulick</span>, <span class="hlFld-ContribAuthor ">Laura  Baldino</span>, <span class="hlFld-ContribAuthor ">Eneda  Toska</span>, <span class="hlFld-ContribAuthor ">Amaia  Arruabarrena-Aristorena</span>, <span class="hlFld-ContribAuthor ">Srushti  Kittane</span>, <span class="hlFld-ContribAuthor ">Fan  Wu</span>, <span class="hlFld-ContribAuthor ">Yanyan  Cai</span>, <span class="hlFld-ContribAuthor ">Sabrina  Arena</span>, <span class="hlFld-ContribAuthor ">Benedetta  Mussolin</span>, <span class="hlFld-ContribAuthor ">Ram  Kannan</span>, <span class="hlFld-ContribAuthor ">Neil  Vasan</span>, <span class="hlFld-ContribAuthor ">Alexander N.  Gorelick</span>, <span class="hlFld-ContribAuthor ">Michael F.  Berger</span>, <span class="hlFld-ContribAuthor ">Ofra  Novoplansky</span>, <span class="hlFld-ContribAuthor ">Sankar  Jagadeeshan</span>, <span class="hlFld-ContribAuthor ">Yi  Liao</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>, <span class="hlFld-ContribAuthor ">Sandra  Misale</span>, <span class="hlFld-ContribAuthor ">Barry S.  Taylor</span>, <span class="hlFld-ContribAuthor ">Alberto  Bardelli</span>, <span class="hlFld-ContribAuthor ">Jaclyn F.  Hechtman</span>, <span class="hlFld-ContribAuthor ">David M.  Hyman</span>, <span class="hlFld-ContribAuthor ">Moshe  Elkabets</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">Chandra S.  Verma</span>, <span class="hlFld-ContribAuthor ">Andrea  Ventura</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>. </span><span class="cited-content_cbyCitation_article-title">TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 126-141. <a href="https://doi.org/10.1158/2159-8290.CD-20-0571" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-20-0571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-20-0571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-20-0571%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DTRK%252BxDFG%252BMutations%252BTrigger%252Ba%252BSensitivity%252BSwitch%252Bfrom%252BType%252BI%252Bto%252BII%252BKinase%252BInhibitors%26aulast%3DCocco%26aufirst%3DEmiliano%26date%3D2021%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D126%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Rajendran  Vairagoundar</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic inhibitor leads of human tropomyosin receptor kinase A (
              h
              TrkA). </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 370-377. <a href="https://doi.org/10.1039/C9MD00554D" title="DOI URL">https://doi.org/10.1039/C9MD00554D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00554D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00554D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252Binhibitor%252Bleads%252Bof%252Bhuman%252Btropomyosin%252Breceptor%252Bkinase%252BA%252B%252528%252Bh%252BTrkA%252529%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D3%26spage%3D370%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Noritaka  Furuya</span>, <span class="hlFld-ContribAuthor ">Takaki  Momose</span>, <span class="hlFld-ContribAuthor ">Kenji  Katsuno</span>, <span class="hlFld-ContribAuthor ">Nobuhiko  Fushimi</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Muranaka</span>, <span class="hlFld-ContribAuthor ">Chiaki  Handa</span>, <span class="hlFld-ContribAuthor ">Masaaki  Sawa</span>, <span class="hlFld-ContribAuthor ">Tomonaga  Ozawa</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Kinoshita</span>. </span><span class="cited-content_cbyCitation_article-title">An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (1)
                                     , 126775. <a href="https://doi.org/10.1016/j.bmcl.2019.126775" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126775%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAn%252Bisoform-selective%252Binhibitor%252Bof%252Btropomyosin%252Breceptor%252Bkinase%252BA%252Bbehaves%252Bas%252Bmolecular%252Bglue%26aulast%3DFuruya%26aufirst%3DNoritaka%26date%3D2020%26volume%3D30%26issue%3D1%26spage%3D126775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Shunjie  Bai</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Chen</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>, <span class="hlFld-ContribAuthor ">Zihong  Liang</span>, <span class="hlFld-ContribAuthor ">Xunzhong  Qi</span>, <span class="hlFld-ContribAuthor ">Hailan  Shen</span>, <span class="hlFld-ContribAuthor ">Peng  Xie</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Diterpene Ginkgolides Exert an Antidepressant Effect Through the NT3-TrkA and Ras-MAPK Pathways</p>. </span><span class="cited-content_cbyCitation_journal-name">Drug Design, Development and Therapy</span><span> <strong>2020,</strong> <em>Volume 14 </em>, 1279-1294. <a href="https://doi.org/10.2147/DDDT.S229145" title="DOI URL">https://doi.org/10.2147/DDDT.S229145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/DDDT.S229145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FDDDT.S229145%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Design%252C%2520Development%2520and%2520Therapy%26atitle%3D%25253Cp%25253EDiterpene%252BGinkgolides%252BExert%252Ban%252BAntidepressant%252BEffect%252BThrough%252Bthe%252BNT3-TrkA%252Band%252BRas-MAPK%252BPathways%25253C%25252Fp%25253E%26aulast%3DWang%26aufirst%3DTing%26date%3D2020%26date%3D2020%26volume%3DVolume%252014%26spage%3D1279%26epage%3D1294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Julie A.  White</span>, <span class="hlFld-ContribAuthor ">Dennis  Huczek</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Lead identification and characterization of hTrkA type 2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (22)
                                     , 126680. <a href="https://doi.org/10.1016/j.bmcl.2019.126680" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126680%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bidentification%252Band%252Bcharacterization%252Bof%252BhTrkA%252Btype%252B2%252Binhibitors%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26volume%3D29%26issue%3D22%26spage%3D126680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (19)
                                     , 126624. <a href="https://doi.org/10.1016/j.bmcl.2019.126624" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126624%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DType%252B2%252Binhibitor%252Bleads%252Bof%252Bhuman%252Btropomyosin%252Breceptor%252Bkinase%252B%252528hTrkA%252529%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26volume%3D29%26issue%3D19%26spage%3D126624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip G.  Conaghan</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Cook</span>, <span class="hlFld-ContribAuthor ">John A.  Hamilton</span>, <span class="hlFld-ContribAuthor ">Paul P.  Tak</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic options for targeting inflammatory osteoarthritis pain. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Rheumatology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (6)
                                     , 355-363. <a href="https://doi.org/10.1038/s41584-019-0221-y" title="DOI URL">https://doi.org/10.1038/s41584-019-0221-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41584-019-0221-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41584-019-0221-y%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Rheumatology%26atitle%3DTherapeutic%252Boptions%252Bfor%252Btargeting%252Binflammatory%252Bosteoarthritis%252Bpain%26aulast%3DConaghan%26aufirst%3DPhilip%2BG.%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D6%26spage%3D355%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emiliano  Cocco</span>, <span class="hlFld-ContribAuthor ">Ji Eun  Lee</span>, <span class="hlFld-ContribAuthor ">Srinivasaraghavan  Kannan</span>, <span class="hlFld-ContribAuthor ">Alison M.  Schram</span>, <span class="hlFld-ContribAuthor ">Helen  Won</span>, <span class="hlFld-ContribAuthor ">Sophie  Shifman</span>, <span class="hlFld-ContribAuthor ">Amanda  Kulick</span>, <span class="hlFld-ContribAuthor ">Laura  Baldino</span>, <span class="hlFld-ContribAuthor ">Eneda  Toska</span>, <span class="hlFld-ContribAuthor ">Sabrina  Arena</span>, <span class="hlFld-ContribAuthor ">Benedetta  Mussolin</span>, <span class="hlFld-ContribAuthor ">Ram  Kannan</span>, <span class="hlFld-ContribAuthor ">Neil  Vasan</span>, <span class="hlFld-ContribAuthor ">Alexander N.  Gorelick</span>, <span class="hlFld-ContribAuthor ">Michael F.  Berger</span>, <span class="hlFld-ContribAuthor ">Yi  Liao</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>, <span class="hlFld-ContribAuthor ">Alberto  Bardelli</span>, <span class="hlFld-ContribAuthor ">Jacklyn  Hechtman</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">David M.  Hyman</span>, <span class="hlFld-ContribAuthor ">Chandra  Verma</span>, <span class="hlFld-ContribAuthor ">Andrea  Ventura</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>. </span><span class="cited-content_cbyCitation_article-title">TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SSRN Electronic Journal</span><span> <strong>2019,</strong> <em>61 </em><a href="https://doi.org/10.2139/ssrn.3501844" title="DOI URL">https://doi.org/10.2139/ssrn.3501844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2139/ssrn.3501844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2139%2Fssrn.3501844%26sid%3Dliteratum%253Aachs%26jtitle%3DSSRN%2520Electronic%2520Journal%26atitle%3DTRK%252BxDFG%252BMutations%252BTrigger%252Ba%252BSensitivity%252BSwitch%252Bfrom%252BType%252BI%252Bto%252BII%252BKinase%252BInhibitors%26aulast%3DCocco%26aufirst%3DEmiliano%26date%3D2019%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0001.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pfizer Pan-Trk development candidate PF-06273340 and hit molecule <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Discovery of benzamide lead molecule <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Co-crystal structure of lead molecule <b>3</b> bound to TrkA protein in a DFG-out conformation highlighting key protein–ligand interactions with black dashed lines. (B) Co-crystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting binding site surface with brown representing hydrophobic regions, green neutral polarity regions, and blue polar regions. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKW">6DKW</a> for compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0004.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structure of ligand <b>10b</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>10b</b> is shown in magenta, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKB">6DKB</a> for compound <b>10b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0005.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of the bound ligand conformation in TrkA protein of DFG-out binders PF-06273340 (gray) and compound <b>10b</b> (magenta).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0006.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Co-crystal structure of ligand <b>13b</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>13b</b> is shown in orange, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKG">6DKG</a> for compound <b>13b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0007.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Generation of aminopyridine pan-Trk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0008.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Overlay of the bound ligand conformation in TrkA protein of lead molecule <b>3</b> (blue, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and aminopyridine <b>15</b> (green) docked into TrkA protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0009.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery of aminopyridine amide <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0010.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Co-crystal structure of aminopyridine <b>19</b> bound to TrkA protein in a DFG-out conformation, highlighting key protein–ligand interactions with black dashed lines. Ligand <b>19</b> is shown in yellow, and TrkA protein is shown in green. Some protein residues were omitted for clarity. PDB code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKI">6DKI</a> for compound <b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0011.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of compounds <b>10b</b>, <b>13b</b>, and <b>19</b> in the UVIH model in rats at the highest dose studied. Ipsilateral paw data are shown, <i>n</i> = 8 rats per dose group. Statistical significance according to two-way ANOVA vs vehicle data is given in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Dose response data compared with vehicle and positive control ibuprofen for <b>10b</b>, <b>13b</b>, and <b>19</b> is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Hit Molecule <b>2</b> and Lead Molecule <b>3</b> via Mesylate Displacement and Suzuki Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 65%; (ii) <b>24</b>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3,</sub> >99%; (iii) KOH, <i>t</i>BuOH, 96%; (iv) HCl, >99%; (v) <b>28</b>, pyridine, 73%; (vi) <b>29</b>, HATU, DIPEA, DMF, 40%.</p></p></figure><figure data-id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenyl Acetic Acid Derivatives via Suzuki Coupling, Mesylate Displacement, and Amide Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) B<sub>2</sub>Pin<sub>2</sub>, PdCl<sub>2</sub>(dppf)·DCM, KOAc, dioxane 100 °C, 16 h, 44%; (ii) <b>32</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>t</i>-Bu)<sub>3</sub>PHBF<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 100 °C, 16 h, 68%; (iii) <b>22</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, (49%); (iv) HCl/dioxane, >99%; (v) HATU or EDC coupling.</p></p></figure><figure data-id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Fluoropiperidine Derivatives in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>37</b>, KO<i>t</i>Bu, DMSO, room temperature, 16 h, 72%; (ii) HCl/dioxane, >99%; (iii) <b>29</b>, HATU, TEA, DMF, 93%; (iv) B<sub>2</sub>Pin<sub>2</sub>, PdCl<sub>2</sub>(dppf)·DCM, KOAc, dioxane, 100 °C, 16 h, 61%; (v) <b>42</b>, PdCl<sub>2</sub>(dppf), K<sub>2</sub>CO<sub>3</sub>, DMF-water, 100 °C, 16 h, 24%.</p></p></figure><figure data-id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Difluoropiperidine Derivative <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 24 h, 90%; (ii) B<sub>2</sub>pin<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), dioxane, 100 °C 16 h, >99%; (iii) <b>32</b>, Pd<sub>2</sub>dba<sub>3</sub>, <i>t</i>Bu<sub>3</sub>PH·BF<sub>4</sub> Na<sub>2</sub>CO<sub>3</sub> (aq) dioxane, 100 °C 18 h, 25%; (iv) HCl/dioxane, >99%; (v) <b>29</b>, COMU, DIEA, DMF, room temperature, 14 h, 81%.</p></p></figure><figure data-id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Tertiary Alcohol Derivatives in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 90%; (ii) KOH, <i>t</i>BuOH, 80 °C, 16 h, 51%; (iii) HCl/dioxane, >99%; (iv) <b>29</b>, EDC, HOBt, DIPEA, 16 h, 82%; (v) H<sub>2</sub> (balloon), Pd/C, EtOH, 2 h, room temperature, 93%; (vi) isobutylene oxide, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 26%.</p></p></figure><figure data-id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0017.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Primary Alcohol <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2-bromo-2-methyl proprionic acid, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h, 98%; (ii) LiOH, THF, H<sub>2</sub>O, room temperature, 4 h, 82%; (iii) isobutyl chloroformate, then NaBH<sub>4</sub>, 51%.</p></p></figure><figure data-id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0018.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Route to Compounds <b>15</b>, <b>16a</b>, and <b>16b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <b>24</b>, PdCl<sub>2</sub>(dppf), Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 90 °C, 90%; (ii) NaOH, MeOH, H<sub>2</sub>O, reflux, 72%; (iii) (<i>S</i>)-<i>tert</i>-butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 85 °C, 52%; (iv) HCl/dioxane, >99%; (v) <b>29</b>, coupling with HATU or T3P, 21–73%.</p></p></figure><figure data-id="sch8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0019.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthetic Route to Compounds <b>17a</b> and <b>17b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HF·TEA, 115 °C, 81%; (ii) <i>p</i>-nitrobenzoic acid, DIAD, PPh<sub>3</sub>, THF; (iii) 1N NaOH, THF, 57% (over 2 steps); (iv) Tf<sub>2</sub>O, pyridine, DCM, 91%; (v) <b>42</b>, Pd(dppf)Cl<sub>2</sub>·DCM, K<sub>2</sub>CO<sub>3</sub>, DMF, 69%,; (vi) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, EtOH, 88%; (vii) <b>±68</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF room temperature, 63%; (viii) 33% HBr/AcOH, DCM, >99%; (ix) <b>29</b>, HATU, DIEA, then chiral SFC separation, 44%.</p></p></figure><figure data-id="sch9" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0020.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthetic Route to Compounds <b>18a</b> and <b>18b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, THF, 91%; (ii) H<sub>2</sub>, Pd/C, MeOH, >99%; (iii) NBS, DMF, 82%; (iv) <b>79</b>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, DMF, 120 °C, 90%; (v) TFA; (vi) <b>29</b>, HATU, TEA, DMF, then chiral SFC separation (35% each enantiomer over 2 steps).</p></p></figure><figure data-id="sch10" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/medium/jm-2018-006336_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0021.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthetic Route to Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-15/acs.jmedchem.8b00633/20180802/images/large/jm-2018-006336_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00633&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) CO (5.2 bar), Pd(OAc)<sub>2</sub>, DPPF, Et<sub>3</sub>N, MeOH, DMF, 80 °C, 65%; (ii) TFA (iii) <b>29</b>, HATU, TEA, DMF, 95% (over 2 steps), (iv) NaOH, MeOH, >99%; (v) MeNH<sub>2</sub>·HCl or EtNH<sub>2</sub>·HCl, HATU, TEA, then chiral SFC separation.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaper, S. D.</span></span> <span> </span><span class="NLM_article-title">The Neurotrophin Family of Neurotrophic Factors: An Overview</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>846</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-536-7_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2F978-1-61779-536-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=846&publication_year=2012&pages=1-12&author=S.+D.+Skaper&title=The+Neurotrophin+Family+of+Neurotrophic+Factors%3A+An+Overview&doi=10.1007%2F978-1-61779-536-7_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin family of neurotrophic factors: an overview</span></div><div class="casAuthors">Skaper, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">846</span>
        (<span class="NLM_cas:issue">Neurotrophic Factors</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of closely related proteins that were first identified as survival factors for sympathetic and sensory neurons and have since been shown to control a no. of aspects of survival, development, and function of neurons in both the central and peripheral nervous systems.  Limiting quantities of neurotrophins during development control the nos. of surviving neurons to ensure a match between neurons and the requirement for a suitable d. of target innervation.  Biol. effects of each of the four mammalian neurotrophins are mediated through activation of one or more of the three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC).  In addn., all neurotrophins activate the p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily.  Neurotrophin engagement of Trk receptors leads to activation of Ras, phosphatidylinositol 3-kinase, phospholipase C-γl, and signaling pathways controlled through these proteins, including the mitogen-activated protein kinases.  Neurotrophin availability is required into adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival, morphol., and differentiation.  This chapter will provide an overview of neurotrophin biol., their receptors, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx93j5UxkhubVg90H21EOLACvtfcHk0liNZmEyPHA87A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ&md5=5f575aa213b4e790fc7d1d3b44ead678</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-536-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-536-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DSkaper%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Neurotrophin%2520Family%2520of%2520Neurotrophic%2520Factors%253A%2520An%2520Overview%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D846%26spage%3D1%26epage%3D12%26doi%3D10.1007%2F978-1-61779-536-7_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walicke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span> <span> </span><span class="NLM_article-title">Novel Class of Pain Drugs Based on Antagonism of NGF</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.tips.2005.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=85-91&issue=2&author=F.+F.+Heftiauthor=A.+Rosenthalauthor=P.+A.+Walickeauthor=S.+Wyattauthor=G.+Vergaraauthor=D.+L.+Sheltonauthor=A.+M.+Davies&title=Novel+Class+of+Pain+Drugs+Based+on+Antagonism+of+NGF&doi=10.1016%2Fj.tips.2005.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHefti%26aufirst%3DF.%2BF.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26aulast%3DWyatt%26aufirst%3DS.%26aulast%3DVergara%26aufirst%3DG.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26atitle%3DNovel%2520Class%2520of%2520Pain%2520Drugs%2520Based%2520on%2520Antagonism%2520of%2520NGF%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.1016%2Fj.tips.2005.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1521</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0901510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1056%2FNEJMoa0901510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=20942668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1521&issue=16&author=N.+E.+Laneauthor=T.+J.+Schnitzerauthor=C.+A.+Birbaraauthor=M.+Mokhtaraniauthor=D.+L.+Sheltonauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Tanezumab+for+the+Treatment+of+Pain+from+Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMoa0901510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tanezumab for the treatment of pain from osteoarthritis of the knee</span></div><div class="casAuthors">Lane, Nancy E.; Schnitzer, Thomas J.; Birbara, Charles A.; Mokhtarani, Masoud; Shelton, David L.; Smith, Mike D.; Brown, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1521</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Increased expression of nerve growth factor in injured or inflamed tissue is assocd. with increased pain.  This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor.  Methods: We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 Ag per kg of body wt.) or placebo on days 1 and 56.  The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy.  We also assessed pain, stiffness, and phys. function using the Western Ontario and Mc-Master Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatol.  Committee and Osteoarthritis Research Society International Standing Committee for Clin. Trials Response Criteria Initiative (OMERACT-OARSI); and safety.  Results: When averaged over weeks 1 through 16, the mean redns. from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P < 0.001).  Tanezumab, as compared with placebo, was also assocd. with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P ≤ 0.001).  The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P < 0.001).  The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, resp.  The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%).  Conclusions: In this proof-of-concept study, treatment with tanezumab was assocd. with a redn. in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmt4PNNZ44LVg90H21EOLACvtfcHk0lirL8fETyV7Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI&md5=fe69490dfa3d47fe8a0c286d6b020d57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0901510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0901510%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DBirbara%26aufirst%3DC.%2BA.%26aulast%3DMokhtarani%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DTanezumab%2520for%2520the%2520Treatment%2520of%2520Pain%2520from%2520Osteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D16%26spage%3D1521%26doi%3D10.1056%2FNEJMoa0901510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Long-Term Open-Label Study of Tanezumab for Moderate to Severe Osteoarthritic Knee Pain</span>. <i>Osteoarthritis Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.joca.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=21251985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=639-646&issue=6&author=T.+J.+Schnitzerauthor=N.+E.+Laneauthor=C.+Birbaraauthor=M.+D.+Smithauthor=S.+L.+Simpsonauthor=M.+T.+Brown&title=Long-Term+Open-Label+Study+of+Tanezumab+for+Moderate+to+Severe+Osteoarthritic+Knee+Pain&doi=10.1016%2Fj.joca.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain</span></div><div class="casAuthors">Schnitzer T J; Lane N E; Birbara C; Smith M D; Simpson S L; Brown M T</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain.  DESIGN:  The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial.  All patients (N=281) received infusions of tanezumab 50μg/kg on Days 1 and 56 with subsequent doses administered at 8-week intervals (up to a total of eight infusions).  The primary endpoint of this study was safety.  Effectiveness evaluations included overall knee pain, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0-100 point visual analog scales.  RESULTS:  Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse events (AEs; 7.5%).  The rate of serious AEs was also low (2.8%) with none considered treatment-related.  Few AEs of abnormal peripheral sensation were reported; hypoesthesia was reported by nine patients (3.2%), paresthesia by seven patients (2.5%), and hyperesthesia, peripheral neuropathy, and sensory disturbance were each reported by one patient (0.4% for each).  Most AEs of abnormal peripheral sensation were rated as mild (95%) and the majority (65%) resolved before study completion.  At Week 8, overall knee pain and SGA improved from baseline by a mean (± standard error) of -12.8 (±1.78) and 8.0 (±1.66), respectively.  Similar improvements occurred for WOMAC subscales.  CONCLUSIONS:  Repeated injections of tanezumab in patients with moderate to severe knee OA provide continued pain relief and improved function with a low incidence of side effects.  Additional studies to define the efficacy and duration of pain reduction and to provide a more complete assessment of long-term safety are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP3rNjPk9h4A20zIbnCCI3fW6udTcc2eaNPxJwMAhzfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D&md5=e489a54f543455004fe879ce02744c64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DSimpson%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DLong-Term%2520Open-Label%2520Study%2520of%2520Tanezumab%2520for%2520Moderate%2520to%2520Severe%2520Osteoarthritic%2520Knee%2520Pain%26jtitle%3DOsteoarthritis%2520Cartilage%26date%3D2011%26volume%3D19%26issue%3D6%26spage%3D639%26epage%3D646%26doi%3D10.1016%2Fj.joca.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldwin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossons, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholfield, D.</span></span> <span> </span><span class="NLM_article-title">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated with Interstitial Cystitis</span>. <i>J. Urol. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2010.12.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.juro.2010.12.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=1716-1721&issue=5&author=R.+J.+Evansauthor=R.+M.+Moldwinauthor=N.+Cossonsauthor=A.+Darekarauthor=I.+W.+Millsauthor=D.+Scholfield&title=Proof+of+Concept+Trial+of+Tanezumab+for+the+Treatment+of+Symptoms+Associated+with+Interstitial+Cystitis&doi=10.1016%2Fj.juro.2010.12.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis</span></div><div class="casAuthors">Evans, R. J.; Moldwin, R. M.; Cossons, N.; Darekar, A.; Mills, I. W.; Scholfield, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1716-1721</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.  Materials and Methods: Patients with interstitial cystitis received a single i.v. dose of 200 μg/kg tanezumab or placebo.  Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days.  Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment.  The primary end point was change in av. daily numerical rating scale pain score from baseline to week 6.  Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 h, and mean voided vol. per micturition.  The incidence of adverse events was also assessed.  Results: A total of 34 patients received tanezumab and 30 received placebo.  At week 6 tanezumab produced a significant redn. from baseline in av. daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]).  A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo.  Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided vol. per micturition.  The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%).  Conclusions: Tanezumab has shown preliminary efficacy in the treatment of pain assocd. with interstitial cystitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8VBnrLDcAbVg90H21EOLACvtfcHk0lhZQjY5MpqP3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D&md5=5ac5f081d2cc6eb9b8190148923bcd4f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2010.12.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2010.12.088%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DMoldwin%26aufirst%3DR.%2BM.%26aulast%3DCossons%26aufirst%3DN.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DI.%2BW.%26aulast%3DScholfield%26aufirst%3DD.%26atitle%3DProof%2520of%2520Concept%2520Trial%2520of%2520Tanezumab%2520for%2520the%2520Treatment%2520of%2520Symptoms%2520Associated%2520with%2520Interstitial%2520Cystitis%26jtitle%3DJ.%2520Urol.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2011%26volume%3D185%26issue%3D5%26spage%3D1716%26epage%3D1721%26doi%3D10.1016%2Fj.juro.2010.12.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borenstein, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2248</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.pain.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=2248-2258&issue=10&author=N.+Katzauthor=D.+G.+Borensteinauthor=C.+Birbaraauthor=C.+Bramsonauthor=M.+A.+Nemethauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Efficacy+and+Safety+of+Tanezumab+in+the+Treatment+of+Chronic+Low+Back+Pain&doi=10.1016%2Fj.pain.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DBorenstein%26aufirst%3DD.%2BG.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DBramson%26aufirst%3DC.%26aulast%3DNemeth%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tanezumab%2520in%2520the%2520Treatment%2520of%2520Chronic%2520Low%2520Back%2520Pain%26jtitle%3DPain%26date%3D2011%26volume%3D152%26issue%3D10%26spage%3D2248%26epage%3D2258%26doi%3D10.1016%2Fj.pain.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Discover Non-ATP Site Kinase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1039/C2MD20180A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1039%2FC2MD20180A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=41-51&issue=1&author=L.+K.+Gavrinauthor=E.+Saiah&title=Approaches+to+Discover+Non-ATP+Site+Kinase+Inhibitors&doi=10.1039%2FC2MD20180A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to discover non-ATP site kinase inhibitors</span></div><div class="casAuthors">Gavrin, Lori Krim; Saiah, Eddine</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The catalytic domain of kinases shows a high degree of sequence homol., esp. for kinases that belong to the same family.  They share a common ATP binding site with a conserved activation loop and similar three-dimensional structure.  Consequently, a major challenge in kinase research exists in achieving selectivity among the >500 family members, since they all process the same substrate.  In addn. to requiring selectivity against other kinases, ATP site inhibitors must also bind tightly to overcome the high physiol. concn. of ATP in the cell.  Furthermore, the development of novel ATP site inhibitors is becoming increasingly challenging, as many ATP competitive scaffolds have previously been disclosed.  In order to develop compds. with better selectivity among kinases, inhibitors that bind outside the ATP site show great promise and are currently being explored by many groups.  This review will highlight the most commonly used methods to discover small mol. Type III and IV kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xJcf4-RJ9rVg90H21EOLACvtfcHk0lhDlUyNjCzOTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N&md5=97acf2247e5516c1649c1d964c867656</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2FC2MD20180A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20180A%26sid%3Dliteratum%253Aachs%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DSaiah%26aufirst%3DE.%26atitle%3DApproaches%2520to%2520Discover%2520Non-ATP%2520Site%2520Kinase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D41%26epage%3D51%26doi%3D10.1039%2FC2MD20180A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lhDlUyNjCzOTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&issue=22&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+Discovery+of+a+Potent%2C+Selective%2C+and+Peripherally+Restricted+Pan-Trk+Inhibitor+%28PF-06273340%29+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lhDlUyNjCzOTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520Discovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Peripherally%2520Restricted%2520Pan-Trk%2520Inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Function of NGF/TrkA Signaling in the Cholinergic Neurons of the Murine Basal Forebrain</span>. Ph.D Dissertation, <span class="NLM_publisher-name">Ludwig-Maximilians-University</span>, <span class="NLM_publisher-loc">Munich</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mueller&title=In+Vivo+Function+of+NGF%2FTrkA+Signaling+in+the+Cholinergic+Neurons+of+the+Murine+Basal+Forebrain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DM.%26atitle%3DIn%2520Vivo%2520Function%2520of%2520NGF%252FTrkA%2520Signaling%2520in%2520the%2520Cholinergic%2520Neurons%2520of%2520the%2520Murine%2520Basal%2520Forebrain%26pub%3DLudwig-Maximilians-University%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span>; <span class="NLM_string-name">Kordower, J. H.</span></span> In  <i>Nerve Growth Factor Systems in Alzheimer’s Disease</i>; <span class="NLM_publisher-name">Kluwer Academic/Plenum Publishers</span>: <span class="NLM_year">1999</span>; pp  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">731</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=681-731&author=E.+J.+Mufson&author=J.+H.+Kordower&title=Nerve+Growth+Factor+Systems+in+Alzheimer%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26btitle%3DNerve%2520Growth%2520Factor%2520Systems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26pub%3DKluwer%2520Academic%252FPlenum%2520Publishers%26date%3D1999%26spage%3D681%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ortiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4065</span>– <span class="NLM_lpage">4079</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6314-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1523%2FJNEUROSCI.6314-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22442072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=4065-4079&issue=12&author=E.+Sanchez-Ortizauthor=D.+Yuiauthor=D.+Songauthor=Y.+Liauthor=J.+L.+Rubensteinauthor=L.+F.+Reichardtauthor=L.+F.+Parada&title=TrkA+Gene+Ablation+in+Basal+Forebrain+Results+in+Dysfunction+of+the+Cholinergic+Circuitry&doi=10.1523%2FJNEUROSCI.6314-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry</span></div><div class="casAuthors">Sanchez-Ortiz, Efrain; Yui, Daishi; Song, Dongli; Li, Yun; Rubenstein, John L.; Reichardt, Louis F.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4065-4079</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Dysfunction of basal forebrain cholinergic neurons (BFCNs) is an early pathol. hallmark of Alzheimer's disease (AD).  Numerous studies have indicated that nerve growth factor (NGF) supports survival and phenotypic differentiation of BFCNs.  Consistent with a potential link to AD pathogenesis, TrkA, a NGF receptor, is expressed in cholinergic forebrain neuronal populations including those in BF and striatum, and is markedly reduced in individuals with mild cognitive impairment (MCI) without dementia and early-stage AD.  To investigate the role of TrkA in the development, connectivity, and function of the BF cholinergic system and its contribution to AD pathol., we have generated a forebrain-specific conditional TrkA knock-out mouse line.  Our findings show a key role for TrkA signaling in establishing the BF cholinergic circuitry through the ERK pathway, and demonstrate that the normal developmental increase of choline acetyltransferase expression becomes critically dependent on TrkA signaling before neuronal connections are established.  Moreover, the anatomical and physiol. deficits caused by lack of TrkA signaling in BFCNs have selective impact on cognitive activity.  These data demonstrate that TrkA loss results in cholinergic BF dysfunction and cognitive decline that is reminiscent of MCI and early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qproimMfdrVg90H21EOLACvtfcHk0lhy3CovzycSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D&md5=fac45c446552ea69e72cdd15200d54c2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6314-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6314-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Ortiz%26aufirst%3DE.%26aulast%3DYui%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRubenstein%26aufirst%3DJ.%2BL.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DTrkA%2520Gene%2520Ablation%2520in%2520Basal%2520Forebrain%2520Results%2520in%2520Dysfunction%2520of%2520the%2520Cholinergic%2520Circuitry%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26issue%3D12%26spage%3D4065%26epage%3D4079%26doi%3D10.1523%2FJNEUROSCI.6314-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span> <span> </span><span class="NLM_article-title">Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1144</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1196/annals.1418.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1196%2Fannals.1418.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1144&publication_year=2008&pages=97-112&author=M.+P.+Mattson&title=Glutamate+and+Neurotrophic+Factors+in+Neuronal+Plasticity+and+Disease&doi=10.1196%2Fannals.1418.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1196%2Fannals.1418.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1418.005%26sid%3Dliteratum%253Aachs%26aulast%3DMattson%26aufirst%3DM.%2BP.%26atitle%3DGlutamate%2520and%2520Neurotrophic%2520Factors%2520in%2520Neuronal%2520Plasticity%2520and%2520Disease%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2008%26volume%3D1144%26spage%3D97%26epage%3D112%26doi%3D10.1196%2Fannals.1418.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span> <span> </span><span class="NLM_article-title">TrkB Signalling Pathways in LTP and Learning</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nrn2738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrn2738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19927149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=850-860&issue=12&author=L.+Minichiello&title=TrkB+Signalling+Pathways+in+LTP+and+Learning&doi=10.1038%2Fnrn2738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB signaling pathways in LTP and learning</span></div><div class="casAuthors">Minichiello, Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mechanisms that underlie learning is one of the most fascinating and central aims of neurobiol. research.  Hippocampal long-term potentiation (LTP) is widely regarded as a prime candidate for the cellular mechanism of learning.  Receptor tyrosine kinase TrkB (also known as NTRK2), known primarily for its function during PNS and CNS development, has emerged in recent years as a potent regulator of hippocampal LTP.  Here, the author describes efforts to understand the signaling pathways and mol. mechanisms that underlie the involvement of TrkB in LTP and learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0ZpLjq1-0LVg90H21EOLACvtfcHk0lhmwK4-isl5NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF&md5=61bde8b20f142253bcf101c3d418edba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrn2738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2738%26sid%3Dliteratum%253Aachs%26aulast%3DMinichiello%26aufirst%3DL.%26atitle%3DTrkB%2520Signalling%2520Pathways%2520in%2520LTP%2520and%2520Learning%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D850%26epage%3D860%26doi%3D10.1038%2Fnrn2738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, M.</span></span> <span> </span><span class="NLM_article-title">Trk B Signaling in Dopamine 1 Receptor Neurons Regulates Food Intake and Body Weight</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1002/oby.20382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Foby.20382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=23512795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2372-2376&issue=11&author=B.+L.+Masonauthor=M.+K.+Loboauthor=L.+F.+Paradaauthor=M.+Lutter&title=Trk+B+Signaling+in+Dopamine+1+Receptor+Neurons+Regulates+Food+Intake+and+Body+Weight&doi=10.1002%2Foby.20382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight</span></div><div class="casAuthors">Mason, Brittany L.; Lobo, Mary Kay; Parada, Luis F.; Lutter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2372-2376</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Loss of BDNF-TrkB signaling results in obesity in both humans and mice; however, the neural circuit that mediates this effect is unknown.  The role of TrkB signaling in dopamine-1 receptor expressing neurons in body wt. regulation was tested.  Methods : Mice with a floxed allele of the TrkB gene were paired with mice expressing Cre-recombinase under control of the D1 promoter to conditionally knock out expression of TrkB receptors from D1-neurons.  Results : Deletion of TrkB receptors from D1 neurons results in obesity in chow fed mice due to increased feed efficiency.  In contrast, loss of Trk B signaling in D1 neurons induced hyperphagia and hyperglycemia in mice maintained on high fat diet.  Conclusions : These findings indicate TrkB signaling in D1 neurons regulates body wt. by distinct mechanisms for chow and high fat diet and may be important for defending the body against the development of obesity and obesity-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV2qD8g4-gkLVg90H21EOLACvtfcHk0liHE2jlp-Jdfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM&md5=6876ea2b71a0f18c54c3d66638306471</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Foby.20382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20382%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DB.%2BL.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLutter%26aufirst%3DM.%26atitle%3DTrk%2520B%2520Signaling%2520in%2520Dopamine%25201%2520Receptor%2520Neurons%2520Regulates%2520Food%2520Intake%2520and%2520Body%2520Weight%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2372%26epage%3D2376%26doi%3D10.1002%2Foby.20382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">The Lighter Side of BDNF</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R1053</span>– <span class="NLM_lpage">R1069</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00776.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1152%2Fajpregu.00776.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=R1053-R1069&issue=5&author=E.+E.+Nobleauthor=C.+J.+Billingtonauthor=C.+M.+Kotzauthor=C.+Wang&title=The+Lighter+Side+of+BDNF&doi=10.1152%2Fajpregu.00776.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00776.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00776.2010%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BE.%26aulast%3DBillington%26aufirst%3DC.%2BJ.%26aulast%3DKotz%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DThe%2520Lighter%2520Side%2520of%2520BDNF%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2011%26volume%3D300%26issue%3D5%26spage%3DR1053%26epage%3DR1069%26doi%3D10.1152%2Fajpregu.00776.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, G. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connie Hung, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rahilly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, I. S.</span></span> <span> </span><span class="NLM_article-title">A De Novo Mutation Affecting Human TrkB Associated with Severe Obesity and Developmental Delay</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1038/nn1336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnn1336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=15494731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1187-1189&issue=11&author=G.+S.+H.+Yeoauthor=C.-C.+Connie+Hungauthor=J.+Rochfordauthor=J.+Keoghauthor=J.+Grayauthor=S.+Sivaramakrishnanauthor=S.+O%E2%80%99Rahillyauthor=I.+S.+Farooqi&title=A+De+Novo+Mutation+Affecting+Human+TrkB+Associated+with+Severe+Obesity+and+Developmental+Delay&doi=10.1038%2Fnn1336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo mutation affecting human TrkB associated with severe obesity and developmental delay</span></div><div class="casAuthors">Yeo, Giles S. H.; Connie Hung, Chiao-Chien; Rochford, Justin; Keogh, Julia; Gray, Juliette; Sivaramakrishnan, Shoba; O'Rahilly, Stephen; Farooqi, I. Sadaf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187-1189</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An 8-yr-old male with a complex developmental syndrome and severe obesity was heterozygous for a de novo missense mutation resulting in a Y722C substitution in the neurotrophin receptor TrkB.  This mutation markedly impaired receptor autophosphorylation and signaling to MAP kinase.  Mutation of NTRK2, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic obesity.  The assocd. impairment in memory, learning and nociception seen in the proband reflects the crucial role of TrkB in the human nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOFn7CEYjaXLVg90H21EOLACvtfcHk0lgT4ZOeflZb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D&md5=1df8713e7b0f3b437cb552a81c2ca628</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnn1336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1336%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DG.%2BS.%2BH.%26aulast%3DConnie%2BHung%26aufirst%3DC.-C.%26aulast%3DRochford%26aufirst%3DJ.%26aulast%3DKeogh%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DSivaramakrishnan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Rahilly%26aufirst%3DS.%26aulast%3DFarooqi%26aufirst%3DI.%2BS.%26atitle%3DA%2520De%2520Novo%2520Mutation%2520Affecting%2520Human%2520TrkB%2520Associated%2520with%2520Severe%2520Obesity%2520and%2520Developmental%2520Delay%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26issue%3D11%26spage%3D1187%26epage%3D1189%26doi%3D10.1038%2Fnn1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrén, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoulfas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzaghi, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leingärtner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesarollo, L.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin-3 Induced by Tri-Iodothyronine in Cerebellar Granule Cells Promotes Purkinje Cell Differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1083/jcb.122.2.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1083%2Fjcb.122.2.443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1993&pages=443-450&issue=2&author=D.+Lindholmauthor=E.+Castr%C3%A9nauthor=P.+Tsoulfasauthor=R.+Kolbeckauthor=M.+d.+P.+Berzaghiauthor=A.+Leing%C3%A4rtnerauthor=C.+Heisenbergauthor=L.+Tessarolloauthor=L.+Paradaauthor=H.+Thoenenauthor=L.+Tesarollo&title=Neurotrophin-3+Induced+by+Tri-Iodothyronine+in+Cerebellar+Granule+Cells+Promotes+Purkinje+Cell+Differentiation&doi=10.1083%2Fjcb.122.2.443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1083%2Fjcb.122.2.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.122.2.443%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DCastr%25C3%25A9n%26aufirst%3DE.%26aulast%3DTsoulfas%26aufirst%3DP.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DBerzaghi%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DLeing%25C3%25A4rtner%26aufirst%3DA.%26aulast%3DHeisenberg%26aufirst%3DC.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DParada%26aufirst%3DL.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DTesarollo%26aufirst%3DL.%26atitle%3DNeurotrophin-3%2520Induced%2520by%2520Tri-Iodothyronine%2520in%2520Cerebellar%2520Granule%2520Cells%2520Promotes%2520Purkinje%2520Cell%2520Differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1993%26volume%3D122%26issue%3D2%26spage%3D443%26epage%3D450%26doi%3D10.1083%2Fjcb.122.2.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, R. A.</span></span> <span> </span><span class="NLM_article-title">Functional Roles of Neurotrophin 3 in the Developing and Mature Sympathetic Nervous System</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1007/BF02740622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2FBF02740622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=8989769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=185-197&issue=3&author=X.-F.+Zhouauthor=R.+A.+Rush&title=Functional+Roles+of+Neurotrophin+3+in+the+Developing+and+Mature+Sympathetic+Nervous+System&doi=10.1007%2FBF02740622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system</span></div><div class="casAuthors">Zhou, Xin-Fu; Rush, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana</span>)
        </div><div class="casAbstract">A review, with ∼75 refs., on the evidence published in recent years indicating that another member of the NGF family, neurotrophin 3 (NT3), plays both a complementary and overlapping role in the development and maturation of sympathetic neurons.  In migratory neural crest cells, expression of the high-affinity receptor, trkC, and promotion of mitosis by NT3 suggest an involvement in gangliogenesis, since sympathetic neuroblasts express both NT3 and trkC and require NT3 for their proliferation, differentiation, and survival, it has been proposed that the factor acts at this developmental stage as an autocrine or paracrine factor.  However, NT3 also acts in parallel with NGF to promote the survival of postmitotic neurons during late development.  Both trkC and trkA are expressed in sympathetic neurons and function as high-affinity receptors for NT3.  NT3 is synthesized in sympathetic effector tissues and the endogenous factor is retrogradely transported to accumulate within the cell soma.  Thus, in addn. to its role in the differentiation of sympathetic neurons, NT3, like NGF, is also an effector tissue-derived neurotrophic factor for these neurons in maturity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr975ZuRFusjrVg90H21EOLACvtfcHk0lgT4ZOeflZb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D&md5=871d2498b71e56ae44f375bd21a3df2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2FBF02740622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02740622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.-F.%26aulast%3DRush%26aufirst%3DR.%2BA.%26atitle%3DFunctional%2520Roles%2520of%2520Neurotrophin%25203%2520in%2520the%2520Developing%2520and%2520Mature%2520Sympathetic%2520Nervous%2520System%26jtitle%3DMol.%2520Neurobiol.%26date%3D1996%26volume%3D13%26issue%3D3%26spage%3D185%26epage%3D197%26doi%3D10.1007%2FBF02740622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk Kinase Inhibitors as New Treatments for Cancer and Pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&issue=3&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+Kinase+Inhibitors+as+New+Treatments+for+Cancer+and+Pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0lgT4ZOeflZb9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520Kinase%2520Inhibitors%2520as%2520New%2520Treatments%2520for%2520Cancer%2520and%2520Pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span> <span> </span><span class="NLM_article-title">Restricting Cns Penetration of Drugs to Minimise Adverse Events: Role of Drug Transporters</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.ddtec.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=25027378" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=e79-85&author=S.+Bagalauthor=P.+Bungay&title=Restricting+Cns+Penetration+of+Drugs+to+Minimise+Adverse+Events%3A+Role+of+Drug+Transporters&doi=10.1016%2Fj.ddtec.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DBungay%26aufirst%3DP.%26atitle%3DRestricting%2520Cns%2520Penetration%2520of%2520Drugs%2520to%2520Minimise%2520Adverse%2520Events%253A%2520Role%2520of%2520Drug%2520Transporters%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2014%26volume%3D12%26spage%3De79%26epage%3D85%26doi%3D10.1016%2Fj.ddtec.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speed, W.</span></span> <span> </span><span class="NLM_article-title">Full Efficacy with No CNS Side-Effects: Unachievable Panacea or Reality?? DMPK Considerations in Design of Drugs with Limited Brain Penetration</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.617847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.3109%2F00498254.2011.617847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=11-27&issue=1&author=S.+Coleauthor=S.+Bagalauthor=A.+El-Kattanauthor=K.+Fennerauthor=T.+Hayauthor=S.+Kempshallauthor=G.+Lunnauthor=M.+Varmaauthor=P.+Stuppleauthor=W.+Speed&title=Full+Efficacy+with+No+CNS+Side-Effects%3A+Unachievable+Panacea+or+Reality%3F%3F+DMPK+Considerations+in+Design+of+Drugs+with+Limited+Brain+Penetration&doi=10.3109%2F00498254.2011.617847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.617847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.617847%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DHay%26aufirst%3DT.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DVarma%26aufirst%3DM.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DSpeed%26aufirst%3DW.%26atitle%3DFull%2520Efficacy%2520with%2520No%2520CNS%2520Side-Effects%253A%2520Unachievable%2520Panacea%2520or%2520Reality%253F%253F%2520DMPK%2520Considerations%2520in%2520Design%2520of%2520Drugs%2520with%2520Limited%2520Brain%2520Penetration%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D1%26spage%3D11%26epage%3D27%26doi%3D10.3109%2F00498254.2011.617847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span> <span> </span><span class="NLM_article-title">Strategies to Minimize Cns Toxicity: In Vitro High-Throughput Assays and Computational Modeling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.677028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1517%2F17425255.2012.677028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=531-542&issue=5&author=T.+T.+Wagerauthor=J.+L.+Lirasauthor=S.+Menteauthor=P.+Trapa&title=Strategies+to+Minimize+Cns+Toxicity%3A+In+Vitro+High-Throughput+Assays+and+Computational+Modeling&doi=10.1517%2F17425255.2012.677028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling</span></div><div class="casAuthors">Wager, Travis T.; Liras, Jennifer L.; Mente, Scot; Trapa, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Healthy functioning of the brain is dependent on the ability of the blood-brain barrier (BBB) and other central nervous system (CNS) barriers to protect the neurocompartments from potential disruptive and damaging xenobiotic agents.  In vitro high-throughput (HT) screens and computational models that assess a compd.'s ability to pass through or disrupt the BBB have become important tools in the identification of new well-tolerated peripheral drugs and safer chem. products such as pesticides.  Leveraging these HT in vitro assays and computational BBB tools together with the current understanding of brain penetration may enable the drug discovery community to minimize access of drug candidates into the CNS compartment.  Areas covered: This article reviews aspects of the most recent in vitro and computational approaches designed to provide an early assessment of a compd.'s ability to access the neurocompartment.  This article also provides insight into using these tools to identify compds. that have restricted access to the neurocompartment.  Expert opinion: The development of safer peripheral-acting medicines and chem. products can be achieved through prospective design and early assessment with HT assays of the BBB in conjunction with computational models.  Exclusion or significantly reduced access of a compd. to the neurocompartment will increase the odds of identifying a compd. with reduced CNS-related adverse drug reactions.  A holistic approach to compd. design and evaluation that incorporates prospective design principles (e.g., optimization of physicochem. properties), leverages HT in vitro assays and integrates the use of BBB computational models may yield the best-in-class' peripherally acting product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOhde-T8d1UrVg90H21EOLACvtfcHk0lgAnFO3IBhrNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D&md5=d4bb73a8839594465407435be2019601</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.677028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.677028%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DTrapa%26aufirst%3DP.%26atitle%3DStrategies%2520to%2520Minimize%2520Cns%2520Toxicity%253A%2520In%2520Vitro%2520High-Throughput%2520Assays%2520and%2520Computational%2520Modeling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D531%26epage%3D542%26doi%3D10.1517%2F17425255.2012.677028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span> <span> </span><span class="NLM_article-title">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fclpt.2013.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=23588303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=80-94&issue=1&author=J.+C.+Kalvassauthor=J.+W.+Polliauthor=D.+L.+Bourdetauthor=B.+Fengauthor=S.+M.+Huangauthor=X.+Liuauthor=Q.+R.+Smithauthor=L.+K.+Zhangauthor=M.%0AJ.+Zamek-Gliszczynski&title=Why+Clinical+Modulation+of+Efflux+Transport+at+the+Human+Blood-Brain+Barrier+Is+Unlikely%3A+The+ITC+Evidence-Based+Position&doi=10.1038%2Fclpt.2013.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span></div><div class="casAuthors">Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S.-M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theor. possibility of adverse central nervous system (CNS) effects identified in preclin. studies.  In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 80-94. doi:10.1038/clpt.2013.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfxdzZMTG6_7Vg90H21EOLACvtfcHk0lgAnFO3IBhrNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D&md5=c106f689e1c83f58eb6d0dbc527cf0fa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.34%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DWhy%2520Clinical%2520Modulation%2520of%2520Efflux%2520Transport%2520at%2520the%2520Human%2520Blood-Brain%2520Barrier%2520Is%2520Unlikely%253A%2520The%2520ITC%2520Evidence-Based%2520Position%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D80%26epage%3D94%26doi%3D10.1038%2Fclpt.2013.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane Transporters in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=20190787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&issue=3&author=K.+M.+Giacominiauthor=S.-M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+R.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+Wah+Yeeauthor=M.%0AJ.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+Transporters+in+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane transporters in drug development</span></div><div class="casAuthors">Giacomini, Kathleen M.; Huang, Shiew-Mei; Tweedie, Donald J.; Benet, Leslie Z.; Brouwer, Kim L. R.; Chu, Xiaoyan; Dahlin, Amber; Evers, Raymond; Fischer, Volker; Hillgren, Kathleen M.; Hoffmaster, Keith A.; Ishikawa, Toshihisa; Keppler, Dietrich; Kim, Richard B.; Lee, Caroline A.; Niemi, Mikko; Polli, Joseph W.; Sugiyama, Yuicchi; Swaan, Peter W.; Ware, Joseph A.; Wright, Stephen H.; Wah Yee, Sook; Zamek-Gliszczynski, Maciej J.; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-236</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs.  This presents several key questions for drug development, including which transporters are clin. important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters.  In addn., what criteria should trigger follow-up clin. studies, and which clin. studies should be conducted if needed.  In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clin. studies on the currently recognized most important drug transporter interactions.  The recommendations are generally intended to support clin. development and filing of a new drug application.  Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clin. trial enrollment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metab. and excretion properties of the drug mol., and information required for drug labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBIf0gk93W7Vg90H21EOLACvtfcHk0ljINC4Cll6shA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D&md5=89d9ce746284c1814fb01cd9b9a72027</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.-M.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DWah%2BYee%26aufirst%3DS.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520Transporters%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.%0AD.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljINC4Cll6shA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing Drug Exposure in the CNS While Maintaining Good Oral Absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&issue=12&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+Drug+Exposure+in+the+CNS+While+Maintaining+Good+Oral+Absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520Drug%2520Exposure%2520in%2520the%2520CNS%2520While%2520Maintaining%2520Good%2520Oral%2520Absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of Nonlinear Intestinal Absorption of Cyp3a4 and P-Glycoprotein Substrates from Their in Vitro Km Values</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/s11095-011-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2Fs11095-011-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&issue=3&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+Nonlinear+Intestinal+Absorption+of+Cyp3a4+and+P-Glycoprotein+Substrates+from+Their+in+Vitro+Km+Values&doi=10.1007%2Fs11095-011-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520Nonlinear%2520Intestinal%2520Absorption%2520of%2520Cyp3a4%2520and%2520P-Glycoprotein%2520Substrates%2520from%2520Their%2520in%2520Vitro%2520Km%2520Values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26issue%3D3%26spage%3D651%26epage%3D668%26doi%3D10.1007%2Fs11095-011-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. D.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Gibson, K. R.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Ryckmans, T.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Stupple, P. A.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-D]Pyrimidine Derivatives as Inhibitors of Tropomyosin-Related Kinases and Their Preparation and Use in the Treatment of Pain</span>. <span class="NLM_patent">WO2012137089A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+D.+Andrews&author=S.+K.+Bagal&author=K.+R.+Gibson&author=K.+Omoto&author=T.+Ryckmans&author=S.+E.+Skerratt&author=P.+A.+Stupple&title=Pyrrolo%5B2%2C3-D%5DPyrimidine+Derivatives+as+Inhibitors+of+Tropomyosin-Related+Kinases+and+Their+Preparation+and+Use+in+the+Treatment+of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BD.%26atitle%3DPyrrolo%255B2%252C3-D%255DPyrimidine%2520Derivatives%2520as%2520Inhibitors%2520of%2520Tropomyosin-Related%2520Kinases%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Pain%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loudon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebenga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Amerongen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeneveld, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, R. P.</span></span> <span> </span><span class="NLM_article-title">Demonstration of an Anti-Hyperalgesic Effect of a Novel Pan-Trk Inhibitor PF-06273340 in a Battery of Human Evoked Pain Models</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1111/bcp.13448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1111%2Fbcp.13448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=29178434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=301-309&issue=2&author=P.+Loudonauthor=P.+Siebengaauthor=D.+Gormanauthor=K.+Goreauthor=P.+Duaauthor=G.+van+Amerongenauthor=J.+L.+Hayauthor=G.+J.+Groeneveldauthor=R.+P.+Butt&title=Demonstration+of+an+Anti-Hyperalgesic+Effect+of+a+Novel+Pan-Trk+Inhibitor+PF-06273340+in+a+Battery+of+Human+Evoked+Pain+Models&doi=10.1111%2Fbcp.13448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models</span></div><div class="casAuthors">Loudon, Peter; Siebenga, Pieter; Gorman, Donal; Gore, Katrina; Dua, Pinky; van Amerongen, Guido; Hay, Justin L.; Groeneveld, Geert Jan; Butt, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-309</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications.  NGF signals through tyrosine kinase receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75 receptor.  PF-06273340 is a small mol. inhibitor of Trks A, B and C that reduces pain in nonclin. models, and the present study aimed to investigate the pharmacodynamics of this first-in-class mol. in humans.  A randomized, double-blind, single-dose, placebo- and active-controlled five-period crossover study was conducted in healthy human subjects (NCT02260947).  Subjects received five treatments: PF-06273340 50 mg, PF-06273340 400 mg, pregabalin 300 mg, ibuprofen 600 mg and placebo.  The five primary endpoints were the pain detection threshold for the thermal pain tests and the pain tolerance threshold for the cold pressor, elec. stair and pressure pain tests.  The trial had predefined decision rules based on 95% confidence that the PF-06273340 effect was better than that of placebo.  Twenty subjects entered the study, with 18 completing all five periods.  The high dose of PF-06273340 met the decision rules on the UV B skin thermal pain endpoint [least squares (LS) mean vs. placebo: 1.13, 95% confidence interval: 0.64-1.61], but not on the other four primary endpoints.  The low dose did not meet the decision criteria for any of the five primary endpoints.  Pregabalin (cold pressor and elec. stair tests) and ibuprofen (UVB thermal pain) showed significant analgesic effects on expected endpoints.  The study demonstrated, for the first time, the translation of nonclin. effects into man in an inflammatory pain analgesic pharmacodynamic endpoint using a pan-Trk inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZcem5M2HecbVg90H21EOLACvtfcHk0lieQNWkvxxarg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ois7s%253D&md5=9eeed9ba7e290cf9c3537f30ecd2dc03</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13448%26sid%3Dliteratum%253Aachs%26aulast%3DLoudon%26aufirst%3DP.%26aulast%3DSiebenga%26aufirst%3DP.%26aulast%3DGorman%26aufirst%3DD.%26aulast%3DGore%26aufirst%3DK.%26aulast%3DDua%26aufirst%3DP.%26aulast%3Dvan%2BAmerongen%26aufirst%3DG.%26aulast%3DHay%26aufirst%3DJ.%2BL.%26aulast%3DGroeneveld%26aufirst%3DG.%2BJ.%26aulast%3DButt%26aufirst%3DR.%2BP.%26atitle%3DDemonstration%2520of%2520an%2520Anti-Hyperalgesic%2520Effect%2520of%2520a%2520Novel%2520Pan-Trk%2520Inhibitor%2520PF-06273340%2520in%2520a%2520Battery%2520of%2520Human%2520Evoked%2520Pain%2520Models%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26issue%3D2%26spage%3D301%26epage%3D309%26doi%3D10.1111%2Fbcp.13448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Swain, N. A.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Andrews, M. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Acylpiperidine Ethers as Tropomyosin-Related Kinase Inhibitors</span>. <span class="NLM_patent">WO2015092610A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+E.+Skerratt&author=S.+K.+Bagal&author=N.+A.+Swain&author=K.+Omoto&author=M.+D.+Andrews&title=Preparation+of+N-Acylpiperidine+Ethers+as+Tropomyosin-Related+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26atitle%3DPreparation%2520of%2520N-Acylpiperidine%2520Ethers%2520as%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalkai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasieczny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steidl-Nichols, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span> <span> </span><span class="NLM_article-title">Early Evaluation of Compound Qt Prolongation Effects: A Predictive 384-Well Fluorescence Polarization Binding Assay for Measuring Herg Blockade</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2006.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2Fj.vascn.2006.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=255-264&issue=3&author=M.+Deaconauthor=D.+Singletonauthor=N.+Szalkaiauthor=R.+Pasiecznyauthor=C.+Peacockauthor=D.+Priceauthor=J.+Boydauthor=H.+Boydauthor=J.+V.+Steidl-Nicholsauthor=C.+Williams&title=Early+Evaluation+of+Compound+Qt+Prolongation+Effects%3A+A+Predictive+384-Well+Fluorescence+Polarization+Binding+Assay+for+Measuring+Herg+Blockade&doi=10.1016%2Fj.vascn.2006.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2006.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2006.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DM.%26aulast%3DSingleton%26aufirst%3DD.%26aulast%3DSzalkai%26aufirst%3DN.%26aulast%3DPasieczny%26aufirst%3DR.%26aulast%3DPeacock%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DBoyd%26aufirst%3DJ.%26aulast%3DBoyd%26aufirst%3DH.%26aulast%3DSteidl-Nichols%26aufirst%3DJ.%2BV.%26aulast%3DWilliams%26aufirst%3DC.%26atitle%3DEarly%2520Evaluation%2520of%2520Compound%2520Qt%2520Prolongation%2520Effects%253A%2520A%2520Predictive%2520384-Well%2520Fluorescence%2520Polarization%2520Binding%2520Assay%2520for%2520Measuring%2520Herg%2520Blockade%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2007%26volume%3D55%26issue%3D3%26spage%3D255%26epage%3D264%26doi%3D10.1016%2Fj.vascn.2006.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Herg Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&issue=17&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+Herg+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lieQNWkvxxarg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Herg%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D17%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lh_8SiX3ZfuhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a New Permeability Assay Using Low-Efflux MDCKII Cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+New+Permeability+Assay+Using+Low-Efflux+MDCKII+Cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lh_8SiX3ZfuhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Permeability%2520Assay%2520Using%2520Low-Efflux%2520MDCKII%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Swain, N. A.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">McAlpine, I. J.</span></span> <span> </span><span class="NLM_article-title">N-Acylpiperidine Ether Tropomyosin-Related Kinase Inhibitors</span>. <span class="NLM_patent">WO2016009296A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+K.+Bagal&author=K.+Omoto&author=S.+E.+Skerratt&author=N.+A.+Swain&author=J.+J.+Cui&author=I.+J.+McAlpine&title=N-Acylpiperidine+Ether+Tropomyosin-Related+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DN-Acylpiperidine%2520Ether%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span>; <span class="NLM_string-name">Scott Obach, R.</span></span> <span> </span><span class="NLM_article-title">Chapter 10: Alcohols and Phenols: Absorption, Distribution, Metabolism and Excretion</span>. In  <i>Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>, Ed.; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge UK</span>, <span class="NLM_year">2010</span>; pp  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">485</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1039%2F9781849731102-00460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=460-485&author=Z.+Miao&author=R.+Scott+Obachauthor=D.+A.+Smith&title=Metabolism%2C+Pharmacokinetics+and+Toxicity+of+Functional+Groups%3A+Impact+of+Chemical+Building+Blocks+on+ADMET"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2F9781849731102-00460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849731102-00460%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26atitle%3DChapter%252010%253A%2520Alcohols%2520and%2520Phenols%253A%2520Absorption%252C%2520Distribution%252C%2520Metabolism%2520and%2520Excretion%26btitle%3DMetabolism%252C%2520Pharmacokinetics%2520and%2520Toxicity%2520of%2520Functional%2520Groups%253A%2520Impact%2520of%2520Chemical%2520Building%2520Blocks%2520on%2520ADMET%26aulast%3DSmith%26aufirst%3DD.%2BA.%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2010%26spage%3D460%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Scaffold Mining of Kinase Hinge Binders in Crystal Structure Database</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9700-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1007%2Fs10822-013-9700-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=13-23&issue=1&author=L.+Xingauthor=B.+Raiauthor=E.+A.+Lunney&title=Scaffold+Mining+of+Kinase+Hinge+Binders+in+Crystal+Structure+Database&doi=10.1007%2Fs10822-013-9700-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9700-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9700-4%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DScaffold%2520Mining%2520of%2520Kinase%2520Hinge%2520Binders%2520in%2520Crystal%2520Structure%2520Database%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2014%26volume%3D28%26issue%3D1%26spage%3D13%26epage%3D23%26doi%3D10.1007%2Fs10822-013-9700-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Tran-Dube, M. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Acylpyrrolidine Ether Derivatives as TrkA Antagonists</span>. <span class="NLM_patent">WO2016020784</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+K.+Bagal&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+J.+Cui&author=S.+E.+Greasley&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=M.+B.+Tran-Dube&title=Preparation+of+N-Acylpyrrolidine+Ether+Derivatives+as+TrkA+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DPreparation%2520of%2520N-Acylpyrrolidine%2520Ether%2520Derivatives%2520as%2520TrkA%2520Antagonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peet, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span> <span> </span><span class="NLM_article-title">The Kinetics of Binding to P38 Map Kinase by Analogues of BIRB 796</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3101</span>– <span class="NLM_lpage">3104</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00656-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1016%2FS0960-894X%2803%2900656-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3101-3104&issue=18&author=J.+Reganauthor=C.+A.+Pargellisauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=E.+R.+Hickeyauthor=G.+W.+Peetauthor=A.+Protoauthor=A.+Swinamerauthor=N.+Moss&title=The+Kinetics+of+Binding+to+P38+Map+Kinase+by+Analogues+of+BIRB+796&doi=10.1016%2FS0960-894X%2803%2900656-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900656-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900656-5%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DThe%2520Kinetics%2520of%2520Binding%2520to%2520P38%2520Map%2520Kinase%2520by%2520Analogues%2520of%2520BIRB%2520796%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26issue%3D18%26spage%3D3101%26epage%3D3104%26doi%3D10.1016%2FS0960-894X%2803%2900656-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolford, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">A Novel Relay Method for Determining Low-Clearance Values</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1865</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.046425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1124%2Fdmd.112.046425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=22645091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1860-1865&issue=9&author=L.+Diauthor=P.+Trapaauthor=R.+S.+Obachauthor=K.+Atkinsonauthor=Y.-A.+Biauthor=A.+C.+Wolfordauthor=B.+Tanauthor=T.+S.+McDonaldauthor=Y.+Laiauthor=L.+M.+Tremaine&title=A+Novel+Relay+Method+for+Determining+Low-Clearance+Values&doi=10.1124%2Fdmd.112.046425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A novel relay method for determining low-clearance values</span></div><div class="casAuthors">Di, Li; Trapa, Patrick; Obach, R. Scott; Atkinson, Karen; Bi, Yi-An; Wolford, Angela C.; Tan, Beijing; McDonald, Thomas S.; Lai, Yurong; Tremaine, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1860-1865</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel relay method has been developed using cryopreserved human hepatocytes to measure intrinsic clearance of low-clearance compds.  The relay method involved transferring the supernatant from hepatocyte incubations to freshly thawed hepatocytes at the end of the 4-h incubation to prolong the exposure time to active enzymes in hepatocytes.  An accumulative incubation time of 20 h or longer in hepatocytes can be achieved using the method.  The relay method was validated using seven com. drugs (diazepam, disopyramide, theophylline, timolol, tolbutamide, S-warfarin, and zolmitriptan) that were metabolized by various cytochrome P450s with low human in vivo intrinsic clearance at approx. 2 to 15 mL · min-1 · kg-1.  The results showed that the relay method produced excellent predictions of human in vivo clearance.  The difference between in vitro and in vivo intrinsic clearance was within 2-fold for most compds., which is similar to the std. prediction accuracy for moderate to high clearance compds. using hepatocytes.  The relay method is a straightforward, relatively low cost, and easy-to-use new tool to address the challenges of low clearance in drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz1LvwK-CqOLVg90H21EOLACvtfcHk0ljkhf0NG0vA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShur7O&md5=faab456749ff398ad63d11eff6412fbc</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.046425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.046425%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DAtkinson%26aufirst%3DK.%26aulast%3DBi%26aufirst%3DY.-A.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DMcDonald%26aufirst%3DT.%2BS.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DA%2520Novel%2520Relay%2520Method%2520for%2520Determining%2520Low-Clearance%2520Values%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D9%26spage%3D1860%26epage%3D1865%26doi%3D10.1124%2Fdmd.112.046425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span> <span> </span><span class="NLM_article-title">Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection</span>. In  <i>Current Protocols in Pharmacology</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+Yazdanian&title=Current+Protocols+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYazdanian%26aufirst%3DM.%26atitle%3DOverview%2520of%2520Determination%2520of%2520Biopharmaceutical%2520Properties%2520for%2520Development%2520Candidate%2520Selection%26btitle%3DCurrent%2520Protocols%2520in%2520Pharmacology%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&issue=21&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljkhf0NG0vA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D21%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yalkowsky, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valvani, S. C.</span></span> <span> </span><span class="NLM_article-title">Solubility and Partitioning I: Solubility of Nonelectrolytes in Water</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1002/jps.2600690814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1002%2Fjps.2600690814" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1980&pages=912-922&issue=8&author=S.+H.+Yalkowskyauthor=S.+C.+Valvani&title=Solubility+and+Partitioning+I%3A+Solubility+of+Nonelectrolytes+in+Water&doi=10.1002%2Fjps.2600690814"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600690814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600690814%26sid%3Dliteratum%253Aachs%26aulast%3DYalkowsky%26aufirst%3DS.%2BH.%26aulast%3DValvani%26aufirst%3DS.%2BC.%26atitle%3DSolubility%2520and%2520Partitioning%2520I%253A%2520Solubility%2520of%2520Nonelectrolytes%2520in%2520Water%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1980%26volume%3D69%26issue%3D8%26spage%3D912%26epage%3D922%26doi%3D10.1002%2Fjps.2600690814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coveney, P. V.</span></span> <span> </span><span class="NLM_article-title">Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00780</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00780" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVyrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=897-909&issue=4&author=S.+Wanauthor=A.+P.+Bhatiauthor=S.+Skerrattauthor=K.+Omotoauthor=V.+Shanmugasundaramauthor=S.+K.+Bagalauthor=P.+V.+Coveney&title=Evaluation+and+Characterization+of+Trk+Kinase+Inhibitors+for+the+Treatment+of+Pain%3A+Reliable+Binding+Affinity+Predictions+from+Theory+and+Computation&doi=10.1021%2Facs.jcim.6b00780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation</span></div><div class="casAuthors">Wan, Shunzhou; Bhati, Agastya P.; Skerratt, Sarah; Omoto, Kiyoyuki; Shanmugasundaram, Veerabahu; Bagal, Sharan K.; Coveney, Peter V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-909</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of ligand binding affinity to the target protein of interest is a primary objective in small-mol. drug discovery.  Until now, the prediction of binding affinities by computational methods has not been widely applied in the drug discovery process, mainly due to its lack of accuracy and reproducibility, as well as the long turnaround times required to obtain results.  Herein, the authors report on a collaborative study that compares tropomyosin receptor kinase A (TrkA) binding affinity predictions using two recently formulated fast computational approaches - namely ESMACS (Enhanced Sampling of Mol. dynamics with Approxn. of Continuum Solvent) and TIES (Thermodn. Integration with Enhanced Sampling) - to exptl. derived TrkA binding affinities for a set of Pfizer pan-Trk compds.  ESMACS gives precise and reproducible results and is applicable to highly diverse sets of compds.  It also provides detailed chem. insight into the nature of ligand-protein binding.  TIES can predict and thus optimize more subtle changes in binding affinities between compds. of similar structure.  Individual binding affinities were calcd. in a few hours, exhibiting good correlations with the exptl. data of 0.79 and 0.88 from ESMACS and TIES approaches resp.  The speed, level of accuracy and precision of the calcns. are such that the affinity predictions can be used to rapidly explain the effects of compd. modifications on TrkA binding affinity.  The methods could therefore be used as tools to guide lead optimization efforts across multiple prospective structurally-enabled programs in the drug discovery setting for a wide range of compds. and targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounHo5S0rFTrVg90H21EOLACvtfcHk0liQxC5ffRi1RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVyrurc%253D&md5=2e366f56c1ee8c2f2b2760b9098e2030</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00780%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DS.%26aulast%3DBhati%26aufirst%3DA.%2BP.%26aulast%3DSkerratt%26aufirst%3DS.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DCoveney%26aufirst%3DP.%2BV.%26atitle%3DEvaluation%2520and%2520Characterization%2520of%2520Trk%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Pain%253A%2520Reliable%2520Binding%2520Affinity%2520Predictions%2520from%2520Theory%2520and%2520Computation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26issue%3D4%26spage%3D897%26epage%3D909%26doi%3D10.1021%2Facs.jcim.6b00780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">On Achieving High Accuracy and Reliability in the Calculation of Relative Protein–Ligand Binding Affinities</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1073/pnas.1114017109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1073%2Fpnas.1114017109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=1937-1942&issue=6&author=L.+Wangauthor=B.+J.+Berneauthor=R.+A.+Friesner&title=On+Achieving+High+Accuracy+and+Reliability+in+the+Calculation+of+Relative+Protein%E2%80%93Ligand+Binding+Affinities&doi=10.1073%2Fpnas.1114017109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1114017109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1114017109%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DOn%2520Achieving%2520High%2520Accuracy%2520and%2520Reliability%2520in%2520the%2520Calculation%2520of%2520Relative%2520Protein%25E2%2580%2593Ligand%2520Binding%2520Affinities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D6%26spage%3D1937%26epage%3D1942%26doi%3D10.1073%2Fpnas.1114017109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, B. J.</span></span> <span> </span><span class="NLM_article-title">Replica Exchange with Solute Scaling: A More Efficient Version of Replica Exchange with Solute Tempering (REST2)</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">9431</span>– <span class="NLM_lpage">9438</span>, <span class="refDoi"> DOI: 10.1021/jp204407d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp204407d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFymurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2011&pages=9431-9438&issue=30&author=L.+Wangauthor=R.+A.+Friesnerauthor=B.+J.+Berne&title=Replica+Exchange+with+Solute+Scaling%3A+A+More+Efficient+Version+of+Replica+Exchange+with+Solute+Tempering+%28REST2%29&doi=10.1021%2Fjp204407d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Replica Exchange with Solute Scaling: A More Efficient Version of Replica Exchange with Solute Tempering (REST2)</span></div><div class="casAuthors">Wang, Lingle; Friesner, Richard A.; Berne, B. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">9431-9438</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small change in the Hamiltonian scaling in Replica Exchange with Solute Tempering (REST) is found to improve its sampling efficiency greatly, esp. for the sampling of aq. protein solns. in which there are large-scale solute conformation changes.  Like the original REST (REST1), the new version (which the authors call REST2) also bypasses the poor scaling with system size of the std. Temp. Replica Exchange Method (TREM), reducing the no. of replicas (parallel processes) from what must be used in TREM.  This redn. is accomplished by deforming the Hamiltonian function for each replica in such a way that the acceptance probability for the exchange of replica configurations does not depend on the no. of explicit water mols. in the system.  For proof of concept, REST2 is compared with TREM and with REST1 for the folding of the trpcage and β-hairpin in water.  The comparisons confirm that REST2 greatly reduces the no. of CPUs required by regular replica exchange and greatly increases the sampling efficiency over REST1.  This method reduces the CPU time required for calcg. thermodn. avs. and for the ab initio folding of proteins in explicit water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYjGgEHE_cMbVg90H21EOLACvtfcHk0liQxC5ffRi1RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFymurs%253D&md5=8acb0d670bcb70eacfc30e32d5dfb6dd</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjp204407d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp204407d%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBerne%26aufirst%3DB.%2BJ.%26atitle%3DReplica%2520Exchange%2520with%2520Solute%2520Scaling%253A%2520A%2520More%2520Efficient%2520Version%2520of%2520Replica%2520Exchange%2520with%2520Solute%2520Tempering%2520%2528REST2%2529%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2011%26volume%3D115%26issue%3D30%26spage%3D9431%26epage%3D9438%26doi%3D10.1021%2Fjp204407d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darout, E.</span>; <span class="NLM_string-name">Guimaraes, C.</span>; <span class="NLM_string-name">Mascitti, V.</span>; <span class="NLM_string-name">McClure, K. F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyridinyl Pyrimidinyl Piperidine Compounds as GPR119 Modulators for Therapy</span>. <span class="NLM_patent">WO2013011402A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=E.+Darout&author=C.+Guimaraes&author=V.+Mascitti&author=K.+F.+McClure&title=Preparation+of+Pyridinyl+Pyrimidinyl+Piperidine+Compounds+as+GPR119+Modulators+for+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDarout%26aufirst%3DE.%26atitle%3DPreparation%2520of%2520Pyridinyl%2520Pyrimidinyl%2520Piperidine%2520Compounds%2520as%2520GPR119%2520Modulators%2520for%2520Therapy%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Funk, L. A.</span>; <span class="NLM_string-name">Jia, L.</span>; <span class="NLM_string-name">Kung, P.-P.</span>; <span class="NLM_string-name">Meng, J. J.</span>; <span class="NLM_string-name">Nambu, M. D.</span>; <span class="NLM_string-name">Pairish, M. A.</span>; <span class="NLM_string-name">Shen, H.</span>; <span class="NLM_string-name">Tran-Dube, M. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Aminoheteroaryl Compounds as C-Met Tyrosine Kinase Inhibitors</span>. <span class="NLM_patent">WO2006021886A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=J.+J.+Cui&author=L.+A.+Funk&author=L.+Jia&author=P.-P.+Kung&author=J.+J.+Meng&author=M.+D.+Nambu&author=M.+A.+Pairish&author=H.+Shen&author=M.+B.+Tran-Dube&title=Preparation+of+Aminoheteroaryl+Compounds+as+C-Met+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26atitle%3DPreparation%2520of%2520Aminoheteroaryl%2520Compounds%2520as%2520C-Met%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span>; <span class="NLM_string-name">Richardson, P. F.</span>; <span class="NLM_string-name">Collins, M. R.</span>; <span class="NLM_string-name">Richter, D. T.</span>; <span class="NLM_string-name">Burke, B. J.</span>; <span class="NLM_string-name">Gajiwala, K.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Linton, M. A.</span>; <span class="NLM_string-name">Le, P.
T. Q.</span>; <span class="NLM_string-name">Hoffman, J. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives and Triazoles as Axl Inhibitors</span>. <span class="NLM_patent">WO2016097918</span> <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+W.+Johnson&author=P.+F.+Richardson&author=M.+R.+Collins&author=D.+T.+Richter&author=B.+J.+Burke&author=K.+Gajiwala&author=S.+Ninkovic&author=M.+A.+Linton&author=P.%0AT.+Q.+Le&author=J.+E.+Hoffman&title=Preparation+of+Pyrimidine+Derivatives+and+Triazoles+as+Axl+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520and%2520Triazoles%2520as%2520Axl%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelesky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-Methyl-2-Phenyloxazol-4-Yl)Ethoxy)Phenyl)Propanoic Acid (PF-407288) in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=10.1124%2Fdmd.108.024489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=19225039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=946-955&author=L.+Zhouauthor=K.+Schmidtauthor=F.+R.+Nelsonauthor=V.+Zeleskyauthor=M.+D.+Troutmanauthor=B.+Feng&title=The+Effect+of+Breast+Cancer+Resistance+Protein+and+P-Glycoprotein+on+the+Brain+Penetration+of+Flavopiridol%2C+Imatinib+Mesylate+%28Gleevec%29%2C+Prazosin%2C+and+2-Methoxy-3-%284-%282-%285-Methyl-2-Phenyloxazol-4-Yl%29Ethoxy%29Phenyl%29Propanoic+Acid+%28PF-407288%29+in+Mice&doi=10.1124%2Fdmd.108.024489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice</span></div><div class="casAuthors">Zhou, Lin; Schmidt, Kari; Nelson, Frederick R.; Zelesky, Veronica; Troutman, Matthew D.; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">946-955</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of breast cancer resistance protein (Bcrp) and the combined activities of Bcrp and P-glycoprotein (P-gp, Mdr1a/1b) in limiting the brain penetration of drugs at the blood-brain barrier (BBB) were investigated using wild-type FVB, Mdr1a/1b(-/-), (-/-), Bcrp(-/-), and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice.  Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were detd.  Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport assocd. with Bcrp.  The brain/plasma (B/P) ratios at 0.5 and 2 h in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice were 1- to 2-fold for both compds., whereas the ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 5-fold of those obsd. in FVB mice.  For imatinib, a better substrate of P-gp than Bcrp, the B/P ratios in Bcrp(-/-) were comparable to those in FVB mice, whereas the B/P ratios in Mdr1a/1b(-/-), (-/-) and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 4- and 28-fold of those in FVB mice at both time points, resp.  Finally, the Bcrp-specific substrate PF-407288 exhibited comparable B/P ratios in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice and slightly but significantly increased B/P ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in FVB mice.  The B/P ratios of compds. in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in Mdr1a/1b(-/-), (-/-) mice clearly demonstrate that Bcrp impairs the brain penetration of its substrates.  Moreover, P-gp and Bcrp at BBB function synergistically to limit the brain penetration of shared substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvZVpc58zzbVg90H21EOLACvtfcHk0lhJm2kCEaaqZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D&md5=422881b70fa04474e0242a9c3a095093</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024489%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DZelesky%26aufirst%3DV.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DThe%2520Effect%2520of%2520Breast%2520Cancer%2520Resistance%2520Protein%2520and%2520P-Glycoprotein%2520on%2520the%2520Brain%2520Penetration%2520of%2520Flavopiridol%252C%2520Imatinib%2520Mesylate%2520%2528Gleevec%2529%252C%2520Prazosin%252C%2520and%25202-Methoxy-3-%25284-%25282-%25285-Methyl-2-Phenyloxazol-4-Yl%2529Ethoxy%2529Phenyl%2529Propanoic%2520Acid%2520%2528PF-407288%2529%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D946%26epage%3D955%26doi%3D10.1124%2Fdmd.108.024489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKW','PDB','6DKW'); return false;">PDB: 6DKW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKB','PDB','6DKB'); return false;">PDB: 6DKB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKG','PDB','6DKG'); return false;">PDB: 6DKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DKI','PDB','6DKI'); return false;">PDB: 6DKI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00633">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14173"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00633">10.1021/acs.jmedchem.8b00633</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings are provided along with surface plasmon resonance data for ligands <b>10b</b>, <b>13b</b>, and <b>19</b>; Trk cell-based assay protocols; metabolite identification data for compounds <b>10b</b>, <b>13b</b>, and <b>19</b>; kinase selectivity data for compounds <b>10b, 13b</b>, and <b>19</b>; ultraviolet irradiation-induced thermal hyperalgesia data in rats for <b>10b</b>, <b>13b</b>, and <b>19</b>; measurement of CNS penetration in rats; solubility determination method; chemical abbreviations; general experimental conditions; commercial starting materials; NMR and LCMS spectra of <b>10b</b>, <b>13b</b>, and <b>19</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Excel spreadsheet of compound names and abbreviations (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_001.pdf">jm8b00633_si_001.pdf (1.32 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00633/suppl_file/jm8b00633_si_002.csv">jm8b00633_si_002.csv (5.47 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are 6DKW for compound <b>3</b>, 6DKB for compound <b>10b</b>, 6DKG for compound <b>13b</b>, and 6DKI for compound <b>19</b>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00633&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00633%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-15%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00633" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995e490a5e3cac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
